Field cancerisation in colorectal cancer by Patel, Abhilasha
 warwick.ac.uk/lib-publications  
 
 
 
 
 
 
A Thesis Submitted for the Degree of PhD at the University of Warwick 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/87284 
 
Copyright and reuse:                     
This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to cite it. 
Our policy information is available from the repository home page.  
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1 | P a g e  
 
Field cancerisation in colorectal 
cancer  
 
 
 
 
By Abhilasha Patel  
MA (Hons) Cantab, MB BChir, MMedEd, MRCS 
 
 
 
A thesis submitted in partial fulfilment of the requirements for the 
degree of Doctor of Medicine 
 
Division of Translational and Systems Medicine, Warwick Medical 
School, University of Warwick 
 
 
December 2015 
2 | P a g e  
 
 
 
 
 
 
 
 
For my boys: Taran and Tilak 
 
 
 
 
 
 
 
 
 
 
3 | P a g e  
 
Table of Contents 
Abbreviations………………………………………………….. 12 
List of figures………………………………………………….. 19 
List of tables…………………………………………………… 21 
Acknowledgements……………………………………………. 22 
Declaration…………………………………………………….. 23 
List of publications……………………………………………. 23 
Abstract………………………………………………………... 24 
Section 1. Introduction………………………………………... 25 
1.1. Colorectal cancer epidemiology…………………………………………….... 26 
1.2 Anatomy of the colon…………………………………………………………. 27 
1.2.1. The colonic wall…………………………………………………… 27 
1.2.2. The stem cell compartment……………………………………… 28 
1.2.3 Blood supply of the colon………………………………………….. 29 
1.3. Staging and prognosis of colorectal cancer…………………………………... 30 
1.4 Risk factors for colorectal cancer……………………………………………... 33 
1.4.1 Genetic predisposition to CRC……………………………………... 33 
1.4.1.1. FAP……………………………………………………... 34 
1.4.1.2. HNPCC…………………………………………………. 36 
1.4.2. Environmental risk factors………………………………………… 38 
4 | P a g e  
 
1.4.2.1. Diet……………………………………………………… 38 
1.4.2.2. Physical activity and obesity…………………………… 39 
1.4.2.3. Cigarette smoking and alcohol consumption…………… 39 
1.4.3. Inflammatory bowel disease……………………………………….. 40 
1.4.4. Previous colorectal cancer…………………………………………. 40 
1.5. Pathogenesis of colorectal cancer……………………………………………. 41 
1.5.1. Evidence to support polyps as precursors to colorectal cancer…… 42 
1.5.2. The adenoma-carcinoma sequence ................................................... 43 
1.5.3. Chromosomal instability…………………………………………… 47 
1.5.4. DNA mismatch repair defects……………………………………... 48 
1.5.5. CpG island methylator subtype…………………………………… 50 
1.5.6. Newer emerging theories…………………………………………... 50 
1.6. Screening and treatment of colorectal cancer………………………………… 52 
1.6.1. FOBT……………………………………………………………… 52 
1.6.2. Flexible sigmoidoscopy…………………………………………… 53 
1.6.3. Colonoscopy……………………………………………………… 54 
1.6.4. Emerging screening modalities…………………………………… 54 
1.7. Cancer biology………………………………………………………………... 55 
1.7.1. Multi-hit Hypothesis of cancer…………………………………….. 56 
1.7.2. The stem cell theory………………………………………………... 58 
1.7.3. Top down or bottom up histogenesis……………………………… 61 
1.7.4. Other cancer theories……………………………………………… 62 
5 | P a g e  
 
1.7.4.1 Tissue Organisation theory………………………………. 62 
1.7.4.2 Chromosomal theory…………………………………….. 62 
1.7.4.3. Metabolic theory………………………………………… 63 
1.8. The role of the tumour microenvironment and supporting stroma…………… 63 
1.8.1. Tumour infiltrating cells…………………………………………… 64 
1.8.2. Angiogenesis……………………………………………………… 66 
1.8.3. Extracellular matrix………………………………………………... 66 
1.8.4. Growth Factors…………………………………………………….. 68 
1.8.4.1. Epidermal growth factor (EGF) ………………………… 68 
1.8.4.2. Vascular endothelial growth factor (VEGF)……………. 69 
1.8.4.3. Transforming growth factor β (TGF- β)………………… 69 
1.8.4.4. Insulin like growth factors……………………………… 70 
1.8.4.5. Fibroblast growth factors………………………………... 70 
1.9 Genetic profiling in CRC……………………………………………………… 77 
1.9.1. Techniques for genetic profiling …………………………………... 77 
1.9.2. Micro-array analysis……………………………………………….. 78 
1.10. Field cancerisation…………………………………………………………... 80 
1.10.1 Field defect in inflammatory bowel disease……………………… 81 
1.10.2. Mechanism for field cancerisation ……………………………… 82 
1.10.3. Field cancerisation in CRC……………………………………… 85 
1.11. Summary…………………………………………………………………… 85 
1.12. Research hypothesis, aims and objectives…………………………………... 86 
 1.12.1. Research hypothesis……………………………………………… 86 
6 | P a g e  
 
 1.12.2. Research aims…………………………………………………… 86 
 1.12.3. Research objectives……………………………………………… 86 
Section 2: Materials and methods…………………………… 88 
2.1. Ethical approval………………………………………………………………. 89 
2.2. Setting and participants………………………………………………………. 89 
 2.2.1. At endoscopy………………………………………………………. 89 
 2.2.2. At surgery………………………………………………………….. 90 
 2.2.3. Sample processing………………………………………………… 91 
 2.2.4. Collection of blood samples……………………………………… 91 
 2.2.5. Study design………………………………………………………. 91 
2.3. Micro-array methods…………………………………………………………. 92 
 2.3.1. Participants……………………………………………………....... 92 
 2.3.2. Experimental design……………………………………………….. 93 
 2.3.3. Isolation, purification and quantification of RNA…………………. 94 
 2.3.4. Genechip micro-array assay method………………………………. 94 
 2.3.5. Micro-array data analysis…………………………………………. 95 
2.4 Gene expression………………………………………………………………. 97 
 2.4.1. RNA extraction and processing…………………………………… 97 
 2.4.2. Complimentary DNA (cDNA) synthesis…………………………. 98 
 2.4.3. Quantitative real time polymerase chain reaction (qRT-PCR)……. 98 
2.5. Protein expression……………………………………………………………. 99 
 2.5.1. Protein extraction…………………………………………………. 99 
7 | P a g e  
 
 2.5.2. Western blot analysis………………………………………………. 100 
2.6. Serum analysis……………………………………………………………….. 100 
2.7. Statistical analysis……………………………………………………………. 101 
Section 3: Colonic polyps are biomarkers of field  
cancerisation in colorectal cancer…………………………… 102 
3.1. Introduction, aims and objectives…………………………………………..... 103 
 3.1.1. Introduction………………………………………………………... 103 
 3.1.2. Aims and objectives……………………………………………….. 105 
3.2. Materials and methods………………………………………………………... 105 
3.2.1. Data collection…………………………………………………….. 107 
3.2.2. Statistical data analysis……………………………………………. 107 
3.3. Results………………………………………………………………………… 108 
3.3.1. Characteristics of patients with synchronous polyps at  
presentation ………………………………………………………………. 111 
3.3.2. Presence of synchronous adenomas indicates future risk of  
metachronous adenomas…………………………………………………. 114 
3.3.3. Local recurrence is not affected by presence of adenomas ………..116 
            3.3.4. Overall and disease free survival do not differ with adenomas…….. 117 
3.4 Discussion…………………………………………………………………...... 119 
3.5. Summary and conclusions……………………………………………………. 123 
Chapter 4: Characterisation of the gene expression  
profile of the mucosal field around colorectal cancer and 
polyps………………………………………………………….. 124 
8 | P a g e  
 
4.1. Introduction………………………………………………………………...... 125 
 4.1.1. Gene expression profiling in colorectal cancer……………………. 125 
 4.1.2. Aims and objectives……………………………………………….. 127 
4.2. Materials and methods………………………………………………………. 128 
 4.2.1. Setting and participants 
 4.2.2. Data Analysis 
4.3. Results………………………………………………………………………… 130 
4.3.1. The global gene expression profile of patients with adenomas  
and colorectal cancer differs…………………………………………….. 130 
4.3.2. Multiple signalling pathways are dysregulated in the colonic  
field (DAVID analysis)………………………………………………… 131 
 4.3.2.1. Cancer versus control…………………………………… 131 
 4.3.2.2. Polyps versus control…………………………………… 131 
 4.3.2.3. Polyp versus cancer…………………………………….. 131 
 4.3.2.4. Selection of genes for validation and further enquiry…. 133 
4.3.3. Multiple differences in cellular component, molecular function  
and biological processes in the colonic field (PANTHER analysis)…….. 135 
 4.3.3.1. Intersect genes………………………………………….. 135 
 4.3.3.2. PANTHER analysis of union genes…………………….. 139 
 4.3.3.3. Cancer versus control…………………………………… 139 
 4.3.3.4. Polyp versus control……………………………………. 142 
 4.3.3.5. Polyp versus cancer…………………………………….. 146 
9 | P a g e  
 
 4.3.3.6. Several cellular processes are dysregulated in the  
colonic field…………………………………………………… 
  4.3.3.6.1. Immune response……………………………. 151 
  4.3.3.6.2. Metabolism………………………………… 151 
  4.3.3.6.3. Cell-cell interaction………………………… 152 
  4.3.3.6.4. RNA transcription……………………………. 153 
4.4 Discussion……………………………………………………………………... 154 
4.4.1. Immune response………………………………………………... 155 
4.4.2. Metabolic process…………………………………………………. 156 
4.4.3 Epithelial-mesenchymal transition…………………………………. 157 
4.4.4. Cell proliferation…………………………………………………… 158 
4.4.5. Field cancerisation ………………………………………………… 159 
4.4.6. Limitations……………………………………………………….... 160 
4.5. Summary and conclusions…………………………………………… ………. 161 
Chapter 5: Differences in gene expression in the colonic  
field around colorectal cancer and polyps ………………...... 162 
5.1 Introduction, aims and objectives…………………………………………….. 163 
 5.1.1. Introduction……………………………………………………….. 163 
 5.1.2. Aims and objectives………………………………………………. 167 
5.2. Materials and Methods………………………………………………………. 168 
5.2.1 Setting and participants…………………………………………. 168 
5.2.2. Experimental methods……………………………………………. 170 
5.2.3. Statistical analysis………………………………………………… 170 
10 | P a g e  
 
5.3. Results……………………………………………………………………….. 172 
5.3.1. Mucin expression is altered in colorectal cancer but GADD45B  
expression is no different ………………………………………………. 172 
5.3.2. CXCL2, S100P and FUT2 are dysregulated in colorectal cancer…. 176 
5.3.3 There is a gradient in gene expression along the colon  
comparing caecum to rectum…………………………………………….. 180 
5.3.4. Serum CXCL2 levels do not differ between the three groups…….. 181 
5.4 Discussion…………………………………………………………………….. 182 
5.5. Summary and conclusions……………………………………………………. 187 
Chapter 6: The role of fibroblast growth factors  
in field cancerisation in colorectal cancer…………………… 189 
6.1. Introduction, aims and objectives…………………………………………. 190 
 6.1.1. Introduction……………………………………………………… 190 
 6.1.2. Aims and objectives…………………………………………….. 192 
6.2. Materials and methods…………………………………………………….. 193 
6.2.1. Setting and participants…………………………………………. 193 
6.2.2. Experimental methods………………………………………….. 195 
6.2.3. Statistical analysis ………………………………………………. 196 
6.3. Results………………………………………………………………………. 197 
 6.3.1. FGF7 is upregulated in the colonic field……………………….. 197 
 6.3.2. The FGF7-FGFR2 signalling axis is dysregulated in tumour  
tissue…………………………………………………………………….. 198 
 6.3.3. FGF7 and FGFR2 gene expression are no different in patients  
11 | P a g e  
 
with polyps………………………………………………………………... 199 
 6.3.4. The FGF7-FGFR2 signalling axis is dampened in colorectal  
cancer tissue……………………………………………………………… 200 
 6.3.5. FGF7 serum concentration does not differ between cancer and  
control subjects…………………………………………………………… 201 
 6.3.6. FGF19 is expressed at low levels in colonic tissue……………….. 202 
6.3.7. FGF19 serum levels are lower in colorectal cancer patients  
with right sided tumours………………………………………………… 202 
6.4. Discussion…………………………………………………………………. 204 
6.5. Summary and conclusions………………………………………………... 209 
Chapter 7: Discussion………………………………………… 210 
7.1. Introduction………………………………………………………………… 211 
7.2. Field cancerisation in colorectal cancer – parallels between inflammatory  
bowel disease and sporadic colorectal cancer…………………………………. 211 
7.3. Existing scientific evidence to support field cancerisation………………. 212 
7.4. A candidate free approach to identify novel genes………………………. 213  
7.5. Implications of the findings of this thesis………………………………… 214 
7.6. Limitations…………………………………………………………………. 216 
7.7. Future directions…………………………………………………………… 217 
7.8. Final conclusion……………………………………………………………. 219 
Bibliography…………………………………………………. 220 
Appendices……………………………………………………... 282 
12 | P a g e  
 
Abbreviations 
dCT  Delta threshold cycle 
mL  millilitres 
µg  micrograms 
μm  Micrometres 
ng  nanograms 
nm  nanometres 
V  Volt 
AAPC  Attenuated Adenomatosis Polyposis Coli 
ACF  Aberrant crypt focus 
AJCC  American Joint Committee on Cancer 
Akt   Protein kinase B 
APC  Adenomatous Polyposis Coli 
AXIN2  Axis inhibitory protein 2 
β-actin  Beta-actin 
BCL2  B-cell lymphoma 2 
BMP3  Bone morphogenetic protein 3 
BRAF  B-raf proto-oncogene 
CAF  Cancer associated fibroblasts 
CCL2  (C-C motif) ligand 2 
CD8  Cluster of differentiation 
CDKN2A  Cyclin-dependent kinase inhibitor 2A 
13 | P a g e  
 
CEA  Carcinoembryonic antigen 
CGH  Comparative genomic hybridisation 
CIMP  CpG island methylator phenotype 
CpG  Cysteine-phosphate-guanine 
CRC  Colorectal cancer 
CSC  Cancer stem cell 
CT  Computed tomography 
CXCL2  Growth related oncogene β (GRO- β) 
CXCL12 C-X-C motif ligand 12 
CYP7A1 Cholesterol 7 alpha-hydroxylase 
DACH1 Dachshund Family Transcription Factor 1 
DALMs  Dysplasia associated lesion or mass 
DCC  Deleted in colon cancer 
DEG  Differentially expressed gene 
DFS  Disease free survival 
DNA  Deoxyribonucleic acid 
ECM  Extracellular matrix 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
EMT  Epithelial Mesenchymal Transition 
Eps8  Epidermal growth factor receptor substrate 8 
Erk 1/2  Extracellular signal-regulated kinase 
14 | P a g e  
 
FaMISHED Food and Fermentation using Metagenomics in Health and Disease 
FAP  Familial Adenomatous Polyposis 
FGF  Fibroblast growth factor 
FGF2  Fibroblast growth factor 2 
FGF7  Fibroblast growth factor 7 
FGF15  Fibroblast growth factor 15 
FGF19  Fibroblast growth factor 19 
FGF21  Fibroblast growth factor 21 
FGF23  Fibroblast growth factor 23 
FGFR  Fibroblast growth factor receptor 
FGFR2  Fibroblast growth factor receptor 2 
FGFR4  Fibroblast growth factor receptor 4 
FISH  Fluorescence in situ hybridisation 
FOBT  Faecal occult blood test 
FRS2α   Fibroblast receptor substrate 2α  
FUT2  Fucosyltransferase 2  
GADD45B Growth arrest DNA damage inducible 45, subunit B 
GM-CSF Granulocyte macrophage stimulating factor 
HCC  Hepatocellular carcinoma 
HIF-1α  Hypoxia-inducible factor 1α  
hMLH1 MutL homolog 1 
hMSH2  MutS homolog 2 
hMSH6  MutS homolog 6 
15 | P a g e  
 
HNPCC Hereditary Non-Polyposis Colorectal Cancer 
HOXB9 Homeobox B9 
HS  Heparan sulfate 
IBD  Inflammatory bowel disease 
IBD-CRC Colorectal cancer associated with inflammatory bowel disease 
IGF  Insulin like growth factor 
IL-1β  Interleukin 1β 
IL-4  Interleukin 4 
IL-7  Interleukin 7 
IL-13  Interleukin 13 
IRF-1  Interferon regulatory factor 1 
IRF-2  Interferon regulatory factor 2 
KGF  Keratinocyte growth factor 
KRAS  Kirsten rat sarcoma virus 
LIMMA LmFT function (Bioconductor R package) 
LOH  Loss of heterozygosity 
LR  Local recurrence 
MA  Metachronous adenoma 
MAP  MYH-associated polyposis 
MAPK  Mitogen activated protein kinase 
MDT  Multidisciplinary team 
ME1  Malic enzyme 1 
16 | P a g e  
 
ME2  Malic enzyme 2 
MGMT  O-6-Methylguanine-DNA Methyltransferase 
MIP2  Macrophage inhibitory protein 2 
MMP  Matrix Metalloproteinase 
MNM   Macroscopically normal mucosa 
MP  Metachronous polyp 
MSI  Microsatelite instability 
MSI-H  Microsatelite stability - high 
MSI-L  Microsatelite stability – low 
MUC2  Mucin 2 
MUC5AC Mucin 5, subunit AC 
NF-Kappa B   Nuclear factor kappa B 
OS  Overall survival 
PCR  Polymerase chain reaction 
PDGF  Platelet derived growth factor 
PET-CT Positron emission tomography – computed tomography 
PGE2  Prostaglandin E2 
PGF  Placenta growth factor 
PI3K  Phosphatidylinositol 3-kinase 
PLS3  Plastin 3 
PSCA  Prostate stem cell antigen 
qRT-PCR Quantitative real time polymerase chain reaction 
17 | P a g e  
 
RAF  Rapidly accelerated fibrosarcoma 
RAGE  Receptor for advanced glycation end products 
RAS  Rat sarcoma virus 
RIPA  Radioimmunoprecipitation 
RNA  Ribonucleic acid  
ROS  Reactive oxygen species 
RR  Robust regression function (Bioconductor R package) 
S100P  S100 calcium binding protein P 
SA   Synchronous adenoma 
SDF-1  Stroma derived factor 1  
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SIR  Standardised incidence ratio 
siRNA  Synthetic RNA duplex 
SLC46A1  Solute carrier family 46, folate transporter, member 1 
SMAD2 SMAD family member 2  
SMAD4 SMAD family member 4 
SP  Synchronous polyp 
SR   Standardised incidence rate 
STAT  Signal transducers and activators of transcription 
STAT6  Signal Transducer And Activator Of Transcription 6 
TAF  Tumour associated fibroblasts 
TAN  Tumour associated neutrophils 
18 | P a g e  
 
TCA  Tricarboxylic acid cycle 
TCF/LEF T-cell factor/lymphoid enhancer factor 
TGF  Transforming growth factor 
Th1  T helper cell response 1 
TH2  T helper cell response 2 
TIMP  Tissue Inhibitors of Metalloproteinases 
TNF-α  Tumour necrosis factor alpha 
TNM  Tumour Nodes Metastasis 
TP53/p53 Tumour suppressor p53 
TPPP  Tubulin Polymerization Promoting Protein 
TPPP3  Tubulin Polymerization Promoting Protein 3 
WNT  Wingless-type mouse mammary tumour virus integration site 
UHCW  University Hospitals of Coventry and Warwickshire NHS Trust 
UK  United Kingdom 
USA  United States of America 
UV  Ultraviolet 
VEGF  Vascular endothelial growth factor 
ZEB  Zinc finger E-box-binding homeobox 1 
 
 
 
 
19 | P a g e  
 
List of figures 
1.2. Crypt of Lieberkuhn 
1.3. Staging of colon cancer 
1.4. Diagnostic criteria used for HNPCC 
1.5. The adenoma-carcinoma sequence 
1.7. The stem cell theory 
1.8.1. Signalling cascade involved in FGF-FGFR interaction 
1.8.2. The physiological roles of FGF19 
1.10. Schematic representation of proposed mechanisms for formation of field defect 
2.2. Sampling sites from specimen 
2.3. Two channel micro-array experiment 
2.4. Analysis of micro-array data 
3.1. Flowchart showing how patients were selected from the MDT database 
3.2. Flowchart of patients included in the analysis 
3.3. Kaplan-Meier survival analysis demonstrating overall survival in SA and non-SA 
patients  
3.4. Kaplan-Meier survival analysis demonstrating disease free survival in SA and non-SA 
patients 
4.1. Principal components analysis of the global gene expression profile  
4.2. DAVID analysis 
4.3. PANTHER analysis 
4.4. PANTHER analysis of DEGs found between cancer and control 
4.5. PANTHER analysis of DEGs found between polyp and control 
20 | P a g e  
 
4.6. PANTHER analysis of DEGs found between polyp and cancer 
4.7. Proposed cellular alterations in the colonic field 
5.1.1. MUC2 expression in control subjects compared to tumour samples, MNM adjacent to 
tumour and at resection margin from colectomy specimen 
5.1.2. MUC5AC expression in control subjects compared to tumour samples, MNM adjacent 
to tumour and at resection margin from colectomy specimen 
5.1.3. GADD45B expression in control subjects compared to tumour samples, MNM 
adjacent to tumour and at resection margin from colectomy specimen 
5.1.4. MUC2 expression levels in control subjects compared to right colonic, left colonic and 
adjacent MNM taken in patients with polyps 
5.1.5. MUC5AC expression levels in control subjects compared to right colonic, left colonic 
and adjacent MNM taken in patients with polyps 
5.1.6. GADD45B expression levels in control subjects compared to right colonic, left 
colonic and adjacent MNM taken in patients with polyps 
5.2.1. Expression levels of CXCL2, FUT2, S100P and SLC46A1 in control subjects 
compared to patients with cancer 
5.2.2. Expression levels of CXCL2, FUT2, S100P and SLC46A1 in control subjects 
compared to patients with polyps 
6.1. Mean gene expression level of FGF7 and FGFR2 
6.2. FGF7 and FGFR2 correlation 
6.3. FGF7 and FGFR2 gene expression in patients with polyps 
6.4. Protein expression of FRS2α and pFRS2α 
6.5. Protein expression of pErk, Erk, pAkt and Akt 
 
21 | P a g e  
 
List of tables 
1.4. Genetic syndromes 
1.5. Different molecular types of colorectal cancer 
2.3. Demographic and clinical details of patients that were included in the micro-array study 
3.1. Clinical, operative and pathological details of patients who met the inclusion criteria 
3.2. Clinical, operative and pathological details of SA and non-SA patients 
3.3. Univariate and multivariate factors that predict the development of MAs in colorectal 
cancer patients 0-24 months after surgery 
3.4. Univariate and multivariate factors that predict the development of MAs in colorectal 
cancer patients 0-60 months after surgery 
3.5. Univariate and multivariate factors that predict development of local recurrence at site 
of previous resection 
4.1. Candidate genes for further validation 
4.2. Potential genes for qRT-PCR validation 
4.3. Statistical over representation test for cancer versus control 
4.4. Statistical over representation test for polyp versus control 
4.5. Statistical over representation test for polyp versus cancer 
5.1. Micro-array genes 
5.2. Clinical and pathological details of patients included in the analysis 
6.1. Clinical and pathological details of all participants in the study 
6.2. Serum FGF19 concentration and correlation with clinical factors 
 
22 | P a g e  
 
Acknowledgements 
This thesis was possible through the continued support and funding provided by 
several people whom I would like to acknowledge –  
Dr Ramesh Arasaradnam, Mr Nigel Williams and Dr Gyanendra Tripathi for giving 
me the opportunity to undertake this research and providing excellent support and 
supervision  
Dr Philip McTernan for his help and advice, which was invaluable in ensuring timely 
completion of this work 
Sean James for his assistance in sample collection and immunohistochemistry  
Dr Kishore Gopalakrishnan for his support in collection of tissue samples from 
colectomy specimens 
The FAMISHED research team (Catherine Bailey, Nicola O’Connell and Subie 
Wuriatu). 
My colleagues who provided help and support in learning molecular biological 
laboratory techniques (Philip Voyias, Warunee Kumsaiyai, Alice Murphy, Sahar 
Azharian, Adaikala Antonysunil, Nithya Sukumar, Ciara McCarthy, Milan Piya and Lucia 
Martinez de la Escalera Clapp).  
The Department of Systems Biology, University of Warwick, particularly Yi-Fang Wang 
and Jonathan Moore for their assistance in analysing the micro-array data. 
Oxford Gene Technology for performing the micro-array chip hybridisation 
The Bowel Disease Research Foundation (BDRF) and Colorectal Cancer Research Fund 
(UHCW) for providing some of the funding that contributed to this research. 
Finally, my family for their everlasting concern, support and inspiration.  
23 | P a g e  
 
Declaration 
This thesis is submitted to the University of Warwick in support of my application for the 
degree of Doctor of Philosophy. I, Abhilasha Patel, declare that it has been composed by 
myself and has not been submitted in any previous application for any degree and all the 
research has been undertaken in accordance with University safety policy and Guidelines on 
Ethical Practice.  
The presented work, including data generation and data analysis, was carried out by the 
author except in the cases outlined below: 
 The micro-array chip hybridisation was commercially performed by Oxford Gene 
Technology 
 The micro-array results were analysed in collaboration with the Department of 
Systems Biology, University of Warwick 
 
List of publications 
Patel A, Tripathi G, Gopalakrishnan K, Williams N, Arasaradnam R. (2015). Field 
cancerisation in colorectal cancer: A new frontier or pastures past? World J Gastroenterol. 
2015 Apr 7; 21(13): 3763–3772 
 
 
 
 
 
 
24 | P a g e  
 
Abstract 
Colorectal cancer (CRC) continues to cause significant global health burden, despite 
advances in our understanding of tumour biology, the development of screening programs 
and increasing public awareness about the disease. Previous studies investigating CRC 
pathogenesis have been criticised for focussing on the tumour tissue itself. Investigators 
have proposed that if early biomarkers of disease are to be identified, efforts need to be 
undertaken in examining pre-neoplastic tissue prior to malignant transformation. Based on 
the field cancerisation concept, the research hypothesis was that the macroscopically normal 
mucosa (MNM) around colorectal cancer and polyps is biologically altered. The aims of the 
study were to determine if the presence of colorectal adenomas at time of cancer diagnosis 
was predictive of future risk of colonic neoplasia and to characterise the global gene 
expression profile of MNM adjacent to CRC and adenomas. A retrospective cohort study of 
CRC patients demonstrated that synchronous adenomas were associated with a higher risk of 
future adenomas at short term follow up but were not predictive of local recurrence. Thus, 
other more reliable biological markers of field effect need to be identified. Global gene 
expression profiles of MNM around cancer, polyps and in control subjects were significantly 
different when evaluated with micro-array. The differentially expressed genes were involved 
in immunity, metabolism, epithelial-mesenchymal transition and RNA transcription. CXCL2 
and FGF7 were identified as being upregulated in MNM adjacent to CRC suggesting that 
they could be utilised as markers of field cancerisation in the colon. Further investigation 
demonstrated that the FGF7-FGFR2 axis was disrupted only at the tumour site with 
downregulation of some of its downstream targets emphasising the potential role of this 
signalling axis in CRC formation. Collectively, these findings support the field cancerisation 
concept in CRC and highlight the importance of signals released by stromal cells in 
facilitating epithelial growth. These genes may be utilised to develop early biomarkers of 
disease or could be targeted with pharmacotherapy to modulate future CRC risk.  
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Chapter 1: Introduction 
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1.1. Colorectal cancer epidemiology 
Colorectal cancer is the fourth most common cancer in the UK affecting 1 in 17 people in 
the UK (CRUK) and more than a million people worldwide (Ferlay J et al., 2013). The 
highest rates of cancer are found in Australia/New Zealand and the lowest in Western 
Africa. In Europe, it is the second most common cancer with just under half a million cases 
diagnosed in 2012. The incidence rate in the UK is 20th highest in males in Europe and 17th 
highest in females (Ferlay J et al., 2013). Overall, CRC occurs more frequently in men 
compared to women with an overall male:female ratio of 13:10 (CRUK). Most cancers 
occur in the colon with just over a third (34%) in the rectum. Incidence is related to age with 
the majority (95%) of cancers being diagnosed in those aged above 50 yrs.  
 
Within the UK, a north-south divide has been observed for men with the highest incidence 
being recorded in Scotland, Northern Ireland and north of England (Quinn et al., 2005; 
NCIN). In comparison, the overall incidence for women does not demarcate as clearly with 
areas in the east and southwest also experiencing high rates of CRC.  
 
The European age standardised incidence rates (SR) have increased by 29 % and 7 % for 
men and women respectively between 1975-1977 and 2009-2011 (CRUK). Some of the 
increase in the last decade has been the result of better screening which has detected cancers 
at an early stage (Jones et al., 2009).  
 
There has been a gradual improvement in CRC survival over time. The one year age 
standardised survival rate has increased from 46.2 % to 75.7 % between 1971-1972 and 
2010-2011 (CRUK). However, despite improvements in screening and diagnosis, prognosis 
after CRC in the UK remains poor, particularly compared to the rest of Europe (Sant et al., 
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2009). The age standardised 5-year survival rate in the UK is 53.6 % compared to 65.9 % 
and 62.6 % in Australia and Sweden respectively (Coleman et al., 2011). Some of these 
inter-country differences have been attributed to later presentation (Woodman et al., 2001) 
and delay in treatment, however, there may be other differences in ethnicity, dietary and 
lifestyle factors that could account for variation in survival.  
 
1.2 Anatomy of the colon 
The last part of the aerodigestive tract is referred to as the colon or large intestine. It consists 
of four sections; the ascending colon, transverse colon, descending colon and sigmoid colon. 
Based on its embryological origin, the right colon refers to the caecum, ascending colon and 
2/3 proximal transverse colon originating from the midgut. The rest of the transverse colon, 
descending colon and sigmoid colon are derived from the hindgut and are collectively 
described as the left colon.  
 
1.2.1. The colonic wall 
The wall of the colon can be divided into four layers: 
i) The innermost mucosa which consists of an epithelial layer, the lamina propria 
which is a connective tissue layer that contains blood vessels, nerves, lymphoid 
tissue to support the mucosa and the muscularis mucosa which is a layer of 
smooth muscle that contracts to change the shape of the lumen 
ii) The submucosal region contains fat, fibrous connective tissue and larger blood 
vessels and nerves 
iii) The muscularis externa comprises an inner circular and outer longitudinal layer 
of smooth muscle fibres responsible for peristaltic activity driving digestion  
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iv) The serosa formed by fat and another layer of epithelial cells called 
mesothelium. 
 
1.2.2. The stem cell compartment 
The epithelial layer consists of a single sheet of columnar epithelial cells folded into finger 
like vaginations that form the functional unit of the intestine called crypts of Lieberkuhn. In 
the adult human colon, around 14,000 crypts per square centimeter are found and it is 
estimated that over 6 times 1014 colonocytes are produced every 5 days (Potten et al., 1992; 
Cheng et al., 1984). Each colonic crypt is shaped like a test tube and consists of 2500-5000 
cells (Nooteboom et al., 2010), 85-106 cells in length and 29-43 cells in circumference 
(Bernstein et al., 2010). At the base, there are 10-20 cells designated the stem cell niche 
(Nicolas et al., 2007; Willis et al., 2008) which are pluripotent stem cells that undergo self-
renewal through asymmetric division and generate a population of transit amplifying cells 
(Radtke & Clevers, 2005) (See figure 1.2.1). These cells proliferate and differentiate as they 
migrate upward along the crypt giving rise to the terminally differentiated epithelial cells 
found at the top of the crypt. Each stem cell can give rise to one of three differentiated 
epithelial cell types that include colonocytes (responsible for absorption), mucus secreting 
goblet cells and enteroendocrine cells.  
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Figure 1.2. Crypt of Lieberkuhn showing stem cells at base with progressive upward 
differentiation of cells. 
 
 
 
 
 
 
 
Proliferation, life span and cell death are regulated to ensure that the stem cell compartment 
in the crypt remains constant despite this cycling process. This is achieved through Wnt 
signaling ligands that are produced by the mesenchymal cells of the myofibroblast lineage 
and are closely applied to the basal lamina that surround the crypt (Fevr et al., 2007). Other 
factors that have been found to contribute to stem cell behavior include bone morphogenetic 
protein, antagonists gremlin 1 and gremlin 2 (Kosinski et al., 2007), Notch signaling 
pathways, ephin-B1 and its receptors (Eph-B2, Eph-B3) (Batlle et al., 2002; van Es & 
Clevers, 2005; Crosnier et al., 2006).  
 
1.2.3 Blood supply of the colon 
Based on its embryological origin, the blood supply to the right colon is from the superior 
mesenteric artery and to the left colon is from the inferior mesenteric artery. Curative CRC 
surgery will aim to remove the draining lymph nodes of the tumour and therefore will 
require resection of the entire segment of colon that is supplied by that particular artery. 
Hence, a tumour of the sigmoid will require resection of the descending colon and sigmoid 
up to the recto-sigmoid junction with ligation of the inferior mesenteric artery at its origin. 
Transient amplifying cells 
Stem cells 
Differentiated cells 
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This will ensure that the entire lymphatic basin draining the tumour, which could potentially 
harbour metastasis, is removed. 
  
1.3. Staging and prognosis of colorectal cancer 
The pathological stage of CRC describes the disease extent both locally at the colonic site 
and distal spread into lymph nodes or distant organs such as the liver. In 1950, Cuthbert 
Dukes first described the relationship between pathological stage and rectal cancer survival 
(DUKES, 1950). He described 4 distinct stages of CRC based on depth of local invasion and 
subsequent spread into lymph nodes or distant organs. The more recent Astler-Coller 
(ASTLER & COLLER, 1954) and TNM staging system (Edge SB et al., 2010) are based 
upon similar principles to that of Dukes staging, namely, description of local and distant 
tumour spread. TNM staging relies on 3 pieces of information –  
i) T (tumour)-– spread of the tumour in terms of the different layers of the colonic 
wall 
ii) N (nodes) – spread to local or systemic lymph nodes 
iii) M (metastasis) – systemic spread of tumour outside of the colon (does not 
include organs that are adjacent to the tumour and are directly invaded). 
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Figure 1.3: Staging of colon cancer. Three different staging systems that have been 
described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Duke's staging
Dukes' A: Invasion into but not through the bowel wall
Dukes' B: Invasion through the bowel wall penetrating the 
muscle layer but not involving lymph nodes
Dukes' C: Involvement of lymph nodes
Dukes' D: Widespread metastases
Astler-Coller
Stage A: Limited to mucosa
Stage B1: Extending into muscularis propria but not 
penetrating through it; nodes not involved
Stage B2: Penetrating through muscularis propria; nodes 
not involved
Stage C1: Extending into muscularis propria but not 
penetrating through it. Nodes involved
Stage C2: Penetrating through muscularis propria. Nodes 
involved
Stage D: Distant metastatic spread
TNM staging
Stage 0 - Tumour confined to mucosa (Tis)
Stage I - tumour confined to submucosa (T1) or muscularis 
propria (T2)
Stage II - tumour invades subserosa (T3) or adjacent 
organs (T4)
Stage III - any T stage with lymph node involvement
Stage IV - metastatic involvement of distant organs
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Staging of CRC is not only important for planning adjuvant therapy but determines 
prognosis. Early stage colorectal cancer confined to the colon is associated with a 5-year 
survival of 93.2 % for T1-T2 lesions and 77 % for T3-T4 lesions (NCIN). In comparison, 
cancer that has spread to the lymph nodes or distant organs only has a 5-year survival of 
47.7 % and 6.6 % respectively (NCIN). At present, only 13 % patients present with early 
stage disease and more than a quarter (32.8 %) have either nodal or distant metastases at 
time of diagnosis. Patients with liver or lung metastases that are amenable to surgical 
resection have a five-year survival of approximately 25% (Cady & Stone, 1991; Fong et al., 
1999; Kanemitsu et al., 2004; Vogelsang et al., 2004; Choti, 2009).  
Other prognostic factors that have been described by AJCC (7th edition) (Edge SB et al., 
2010) include–  
i) Presence of tumour deposits – these are discrete foci of tumour that are 
found in the pericolic, perirectal or mesenteric fat, in the absence of 
residual lymph node tissue but within the lymph drainage area of the 
primary tumour.  
ii) Residual tumour at the radial or excision margin 
iii) Presence of perineural invasion 
iv) Microsatellite instability (MSI) – recorded as stable, MSI-low, MSI-
high and not registered 
v) Tumour regression grade – this describes the change in rectal tumour 
following neoadjuvant therapy as either no tumour viable cells present 
to extensive residual tumour present 
vi) K-ras gene analysis as mutated K-ras is associated with poor response to 
anti-EGFR therapy which is given to patients with metastatic CRC 
vii) 18q loss of heterozygosity (LOH) assay – this is used to determine if 
patients with stage II CRC require neoadjuvant therapy or not. 
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1.4 Risk factors for colorectal cancer 
Most cases of CRC are sporadic, however, 5 % cases are associated with familial syndromes 
(CRUK). Risk factors for sporadic colorectal cancer include increasing age, male sex, 
previous colonic polyps/cancer and environmental factors such as red meat, high fat diet, 
low fibre intake, obesity and a sedentary lifestyle. 
 
Familial syndromes associated with colorectal cancer include Lynch syndrome (also known 
as hereditary non-polyposis colorectal cancer, HNPCC), familial adenomatous polyposis 
(FAP) and MYH-associated polyposis (MAP). They are characterised by the presence of 
specific mutations (mutation in the gene APC in FAP and mutations in DNA mismatch 
repair genes in Lynch syndrome) that lead to earlier onset of cancer and higher risk of 
further lesions. Lynch syndrome and FAP are both autosomal dominant whereas MYH-
associated polyposis is autosomal recessive. Aside from these syndromes, in 20 % sporadic 
cases there is a higher risk based on number of first-degree relatives with cancer and the 
underlying aetiology for this is unknown (Butterworth et al., 2006; Johns & Houlston, 
2001).  
 
The other risk factor for CRC is inflammatory bowel disease.  Both Ulcerative Colitis and 
Crohn’s disease have been linked with an increased risk of CRC, particularly with increasing 
duration or severity of disease activity (Eaden et al., 2001; Bernstein et al., 2001; Canavan et 
al., 2006; von Roon et al., 2007; Laukoetter et al., 2011).   
 
1.4.1 Genetic predisposition to CRC 
FAP and HNPCC account for around 5 % of all CRC (Hampel et al., 2008; Bülow et al., 
1996) with the hamartomatous syndromes such as Peutz-Jeghers, familial juvenile polyposis 
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and Cowden’s syndrome being associated with a further 1 % CRC. The genes that have been 
linked with these syndromes are shown below (Fearnhead et al., 2002). 
 
Table 1.4.: Genetic syndromes with increased colorectal cancer risk and underlying genetic 
defect responsible 
 
Syndrome Genes responsible 
FAP APC (dominant), MYH (recessive) 
HNPCC hMLH1, hMSH2, hMSH6, PMS1, PMS2, 
hMLH3, EXOI 
Peutz-Jeghers syndrome STK1 
Juvenile polyposis SMAD4/MADh4 or BMPR1A 
Cowden disease PTEN/MMAC1 
Li-Fraumeni syndrome p53 
Modified from Arnold et al, 2005 
 
1.4.1.1. FAP 
FAP has an incidence at birth of around 1 in 8619 (Evans et al., 2010). It occurs equally in 
both sexes and is characterised by multiple polyps (>100) in the colon and rectum. If 
untreated, there is 100% chance of malignancy, usually before the age of 40 years (Half et 
al., 2009). There are three forms of FAP: classic FAP, attenuated adenomatous polyposis 
coli (AAPC) and MYH-associated polyposis (MAP). Classic FAP and AAPC are both 
autosomal dominant and are associated with a mutation in the Adenomatous Polyposis Coli 
gene on chromosome 5q21. In AAPC, however, the gene is partly functional which leads to 
fewer colonic polyps that develop at a later stage, predominantly affect the proximal colon 
(Knudsen et al., 2003; Grover et al., 2012) and confer a 70 % lifetime risk of CRC. 
Although FAP is usually diagnosed based on prior family history, up to 16 % cases are 
35 | P a g e  
 
associated with a de novo mutation in the APC gene (Evans et al., 2010). The APC gene is a 
tumour suppressor gene that promotes apoptosis in colonic cells. It phosphorylates beta 
catenin leading to its ubiquitination and degradation through the proteasome pathway (Oving 
& Clevers, 2002). Loss of the APC protein leads to increased levels of nuclear B-catenin 
which is able to stimulate cell proliferation and transcriptional activation of c-myc, cyclin 
D1 and PPAR-delta. Interestingly, the phenotype of FAP patients depends upon the site of 
the truncating mutation in the APC gene (Brensinger et al., 1998).  
 
FAP is also associated with extra-intestinal manifestations such as osteomas, dental 
abnormalities (unerupted teeth, congenital absence of one or more teeth, supernumerary 
teeth, dentigerous cysts and odontomas), congenital hypertrophy of the retinal pigment 
epithelium (CHRPE), desmoid tumours, and extracolonic cancers (thyroid, liver, bile ducts 
and central nervous system) (Half et al., 2009).  
 
MYH-associated polyposis syndrome is an autosomal recessive condition characterised by a 
germline inactivation of a base excision repair gene called mutY homologue (Al-Tassan et 
al., 2002; Kastrinos & Syngal, 2007). This gene is responsible for excising the 8-oxoguanine 
product of oxidative damage to guanine. As it is recessive, two inactive germline MYH 
alleles need to be inherited to develop the disease which confers an almost 100 % risk of 
CRC by 60 years of age (Kastrinos & Syngal, 2007). One third of individuals with more 
than 15 colorectal adenomas will test positive for the two common mutations Y165C and 
G382D. Somatic inactivation of MYH allele has not been detected in sporadic cancer.  
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1.4.1.2. HNPCC 
HNPCC or Lynch syndrome is an autosomal dominant condition associated with defective 
DNA mismatch repair leading to microsatellite instability (Lynch et al., 2009). HNPCC 
sufferers have an 80 % lifetime risk of CRC. The majority (2/3) of these cancers occur in the 
proximal to the splenic flexure and CRC usually occurs at an earlier age (44 yrs.) compared 
to the general population (63 yrs.). Accelerated carcinogenesis is seen in the colon whereby 
small adenomas become malignant over 2-3 years in comparison to the usual 8-10 years 
(Rijcken et al., 2002; Rijcken et al., 2008). The colorectal tumours that are encountered 
amongst HNPCC individuals tend to be poorly differentiated, are mucinous and associated 
with a lymphocytic infiltrate often described as a ‘Crohn’s like reaction. There is an 
increased risk of metachronous CRC if the initial operation was not a subtotal colectomy 
(Parry et al., 2011). These individuals are also at increased risk of developing cancer of the 
endometrium (40-60 % lifetime risk), ovary (12-15%), stomach, urinary tract, pancreas, 
small bowel and brain (Watson et al., 2008; Barrow et al., 2009).   
 
The most commonly affected genes are hMLH1 (Bronner et al., 1994; Papadopoulos et al., 
1994) and hMSH2 (Fishel et al., 1993; Leach et al., 1993) which together account for 90 % 
of all gene mutations found in HNPCC. Other genes that have been implicated include 
hPMS2 (Nicolaides et al., 1994) and hMSH6 (Hendriks et al., 2004). These genes are 
involved in DNA mismatch repair and defective function usually results in microsatellite 
instability (Thibodeau et al., 1993; de la Chapelle, 2003). Mutations in hMSH6 result in 
partial deficiency of mismatch repair with tumours often displaying lower levels of 
microsatellite instability. Clinically, this mutation is associated with an attenuated form of 
HNPCC with later age of onset (around 70 yrs.), however, there is a particularly elevated 
risk of endometrial cancer (Senter et al., 2008).  
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Patients with HNPCC can be identified based upon the Amsterdam II criteria (Vasen et al., 
1999) which detail clinical aspects of the disease. However, the Revised Bethesda guidelines 
(Umar et al., 2004), based upon pathological criteria, have been found to be more effective 
at discriminating HNPCC sufferers (Piñol et al., 2005).  
 
 
 
Figure 1.4: Diagnostic criteria used for HNPCC 
 
 
Amsterdam criteria
•3 or more relatives with an associated cancer (colorectal cancer, or cancer 
of the endometrium, small intestine, ureter or renal pelvis);
•2 or more successive generations affected;
•1 or more relatives diagnosed before the age of 50 years;
•1 should be a first-degree relative of the other two;
•Familial adenomatous polyposis (FAP) should be excluded in cases of 
colorectal carcinoma;
•Tumors should be verified by pathologic examination.[4]
Bethseda guidelines
•1. Patients aged less than 50 years with a diagnosis of colorectal cancer. 
•2. Patients with synchronous or metachronous colorectal or other 
syndrome-associated tumours, regardless of age. 
•3. Patients aged less than 60 years with colorectal cancer with histology 
suggestive of microsatellite instability (presence of tumour infiltrating 
lymphocytes, Crohns disease–like lymphocytic reaction, mucinous or 
signet-ring differentiation, or medullary growth pattern). 
•4. Patients with at least one first-degree relative with a diagnosis of 
colorectal cancer or a syndrome-associated tumour under age 50 years.
•5. Colorectal cancer or syndrome associated tumour diagnosed at any age 
in two first or second degree relatives
38 | P a g e  
 
1.4.2. Environmental risk factors 
A western diet and lifestyle have been associated with an increased risk of CRC based on the 
geographical worldwide distribution of CRC. Furthermore, countries such as Japan, 
Singapore and Eastern European countries that have recently made a transition from a low-
income to high-income demonstrate rising rates of CRC (Coleman et al., 2011; Boyle & 
Langman, 2000). Migrants that move from a low risk to high risk country acquire CRC at a 
rate that is similar to the population of the host country (Boyle & Langman, 2000; Johnson 
& Lund, 2007). This has been observed in the offspring of the Japanese population that 
migrated to United States who have 3-4 times higher CRC incidence compared to the native 
Japanese. 
 
1.4.2.1. Diet 
A high fat, low fibre diet with high red meat consumption has been implicated in CRC 
(Bingham et al., 2002; Liang & Binns, 2009). High fat content is associated with the 
development of bacterial flora that degrade bile salts into potentially carcinogenic N-nitroso 
compounds (Larsson & Wolk, 2006). A systematic review showed that high red meat 
consumption increased the relative risk of colonic but not rectal cancer (Magalhães et al., 
2012). The heme iron found in red meat and production of carcinogenic agents such as 
heterocyclic amines and polycyclic aromatic hydrocarbons have been proposed to be 
causative factors (Santarelli et al., 2008; Sinha, 2002). Similarly, differences in dietary fibre 
intake are also associated with differing risk of CRC. A high fibre intake, particularly 
comprising cereal grains and wholegrains was found to be strongly associated with a 
reduced risk of CRC across several studies (Aune et al., 2011).  
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1.4.2.2. Physical activity and obesity 
Higher levels of physical activity have been linked to a reduced risk of CRC (Lee et al., 
2007; de Jong et al., 2005). However, in several studies, this association appears only to 
exist with colonic cancers and not rectal cancers (Bazensky et al., 2007; Harriss et al., 
2009a). The underlying mechanism behind this association is being elucidated. Moderate 
physical activity increases the metabolic rate, increases oxygen uptake, reduces blood 
pressure, reduces insulin resistance and increases gut motility (Lee et al., 2007) which are 
believed to protect against cancer formation. Increased physical activity also protects against 
obesity which has also been linked to increased CRC risk (Harriss et al., 2009b).  
 
1.4.2.3. Cigarette smoking and alcohol consumption 
Smoking has been linked to both formation of adenomas (Botteri et al., 2008) and higher 
incidence of CRC (Zisman et al., 2006). A review of the literature demonstrated that several 
parameters of cigarette smoking including quantity of cigarettes smoked, duration of 
smoking and number of pack years were quantitatively linked with relative risk of CRC 
(Liang et al., 2009). This effect was more pronounced for rectal cancer in studies which 
examined risk according to segment of colon affected. An earlier age of onset of CRC has 
also been found in individuals who smoke (Zisman et al., 2006; Tsong et al., 2007).  
 
Several studies have also linked increased alcohol consumption to CRC risk (Zisman et al., 
2006; Tsong et al., 2007). Reactive metabolites that are produced in response to alcohol 
consumption such as acetaldehyde have been shown to be carcinogenic (Seitz & Mueller, 
2015) and these effects may be potentiated by the presence of tobacco (Zisman et al., 2006).  
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1.4.3. Inflammatory bowel disease 
Inflammatory bowel disease comprises Ulcerative Colitis and Crohn’s disease, both of 
which are associated with significant increase in risk of colorectal cancer compared to the 
normal population. In a meta-analysis of the incidence of CRC in UC (Eaden et al., 2001), 
the risk of cancer was 2% after 10 years, 8 % after 20 years and 18 % after 30 years. Similar 
studies on the incidence of colorectal cancer in Crohn’s disease show a similar risk (Maykel 
et al., 2006; Friedman et al., 2008; Seitz & Mueller, 2015), however, do not report length of 
duration of the disease. A subsequent meta-analysis which did adjust for duration of disease 
found that the SIR (standardised incidence ratio) was 2.5 and the relative risk was 4.5 (von 
Roon et al., 2007). Therefore both Crohn’s disease and UC are subject to surveillance 
programs when patients have had the disease for more than 10 years (Gillen et al., 1994). 
The risk of cancer is also related to the age of onset of the disease and its extent; the greatest 
risk being found in patients with colitis affecting colon up to or more proximal to the hepatic 
flexure (Sugita et al., 1991).  
 
1.4.4. Previous colorectal cancer 
Patients with CRC are at higher risk of developing cancers elsewhere in the colon. The SIR 
of a second cancer was higher at 1.5 compared to the general population risk (Levi et al., 
2013) and was related to age. The SIR was 7.5 for those below the age of 50 and declines 
thereafter to reach 1.0 at the age of 80 years and above. Several other studies have found 
similar findings (Mulder et al., 2012; Liu et al., 2013a). In the long-term, CRC survivors 
older than 50 years, elevated risk was only observed for the proximal colon with no 
detectable differences for rectal cancer. Amongst the patient and tumour factors that have 
been investigated, presence of synchronous neoplastic lesion at time of diagnosis (Ballesté et 
al., 2007) and a proximal location of the first tumour (Gervaz et al., 2005) have found to be 
predictive for development of subsequent metachronous lesions. 
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1.5. Pathogenesis of colorectal cancer 
A large body of epidemiologic, clinical and pathological evidence exists to support the 
notion that colorectal cancer develops from precursor lesions called polyps. Histologically, 
there are two types of polyps: hyperplastic polyps, which contain increased number of 
glandular cells with decreased cytoplasmic mucus but preserved cell architecture and 
adenomatous polyps, which have disordered cell architecture consisting of cells that are 
enlarged, hyperchromatic, cigar-shaped and crowded together to form a palisade pattern. 
Malignant transformation involves these cells becoming invasive and migrating beyond the 
basement membrane. Adenomas are classified into tubular adenomas where there are 
branched tubules and villous adenomas that contain finger-like villi arranged in a frond. 
Tubulovillous adenomas contain elements of both. Increased colorectal cancer risk has 
previously only been associated with the presence of adenomas, however, there is emerging 
evidence to suggest that hyperplastic polyps in a certain setting are also pre-malignant 
(Jeevaratnam et al., 1996; Rashid et al., 2000). Risk factors that are associated with 
increased CRC risk in hyperplastic polyps include large polyp size (>1 cm diameter), 
location in the right colon, focus of adenoma within the hyperplastic polyp, presence of 
more than 20 hyperplastic polyps and a family history of hyperplastic polyposis syndrome 
(Jass, 2001). Serrated polyps may appear similar to hyperplastic polyps but have a 
significant associated risk of CRC as they tend to be large, are usually found in the right 
colon and the colonocytes in these polyps frequently contain BRAF mutations and DNA 
methylation (Montgomery, 2004; Wynter et al., 2004).  
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1.5.1. Evidence to support polyps as precursors to colorectal cancer 
The following clinical observations support the concept that adenomas are precursor lesions 
for CRC –  
i) The prevalence and anatomical distribution of adenomas and CRC is similar 
(Morson, 1974; Muto et al., 1975) 
ii) Patients who have colorectal adenomas are at higher risk of developing CRC 
(Neugut et al., 1993; Winawer et al., 1993) 
iii) Synchronous adenomas are found in up to one third of CRC colectomy resection 
specimens (Day DW & BC., 1978) 
iv) Adenomatous tissue is found contiguous with CRC (Day DW & BC., 1978) 
v) The risk of CRC increases with number and size of polyps (Heald & Bussey, 
1975).  
vi) Patients who refuse polypectomy develop CRC at a rate of 4 % after 5 years and 
14 % after 10 years (Stryker et al., 1987).  
vii) Following curative resection, adenomas develop in 30 % patients who have 
CRC (McFall et al., 2003; Mattar et al., 2005; Moon et al., 2010). 
viii) Removal of adenomas results in reduced CRC incidence (Müller & Sonnenberg, 
1995; O'brien et al., 2004a). 
The earliest lesions that lead to the development of adenomas are aberrant crypt foci (ACF) 
(Bird, 1987; Bird et al., 1989). These consist of abnormal tube like glands, which contain 
cells that are resistant to apoptosis. Previous studies have utilised ACFs as a surrogate 
endpoint biomarker in chemoprevention trials (Raju, 2008; Corpet & Taché, 2002; Cho et 
al., 2008), however, the relevance of ACFs in this setting remains controversial (Lance & 
Hamilton, 2008). Not all ACFs lead to CRC and it is unclear which attributes of ACFs 
predispose to further growth and development of adenomas, therefore, the use of chemical 
agents to reduce ACF number or size is of questionable importance.  
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1.5.2. The adenoma-carcinoma sequence  
Based upon the body of evidence outlined above, the adenoma-carcinoma sequence was 
proposed. This refers to the process whereby normal mucosa becomes altered forming 
aberrant crypt foci, followed by adenoma of varying dysplasia and subsequently culminating 
in invasive CRC. The molecular changes that underpin this process were described by 
Vogelstein in the late 1980’s (Vogelstein et al., 1988). It is now well recognised that 
multiple genes and molecular pathways are dysregulated during CRC formation. The 
original description of the adenoma-carcinoma sequence refers to cancers with chromosomal 
instability, which includes around 80 % of all cancers (see figure below).  
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Figure 1.5. The adenoma-carcinoma sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APC 
KRAS 
SMAD2/SMAD4/DCC 
TP53 
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Chromosomal instability is characterised by numerical and structural changes in 
chromosomes collectively referred to as aneuploidy (Muleris et al., 1990; Bardi et al., 1995; 
Thiagalingam et al., 2001). In contrast, cancers with DNA mismatch repair defects (15 % of 
all tumours) retain a near-diploid karyotype and show normal rates of gross chromosomal 
aberrations (Parsons et al., 1993; Eshleman et al., 1998). These tumours exhibit 
microsatellite instability (MSI) and have distinct histological features with frameshift 
mutations and base pair substitutions in short tandemly repeated nucleotide sequences called 
microsatellites. They are similar to the tumours encountered in HNPCC but usually result 
from silencing of the hMLH1 gene through CpG promoter hypermethylation rather than a 
germline mutation. The other molecular pathway that can lead to CRC formation is CIMP 
(CpG island methylator phenotype) whereby tumour suppressor genes are silenced through 
epigenetic modification rather than gene mutation. It appears that chromosomal instability 
and MSI are mutually exclusive (Lengauer et al., 1998). However, a subgroup of colorectal 
cancers with near diploid chromosomes and stable microsatellites have also been described 
suggesting an alternative pathway to genetic instability (Chan et al., 2001).  
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Table 1.5: Different molecular types of colorectal cancer with underlying gene defects 
 
Type of genetic instability Type of 
defect 
Genes involved Phenotype 
Chromosomal instability 
(loss of heterozygosity at 
multiple site) 
Somatic Loss of 
heterozygosity 
at 
APC, TP53, 
SMAD4 
Characteristic of 80 to 85% 
of sporadic colorectal 
cancers, depending on stage 
DNA mismatch repair 
defects 
 
HNPCC 
 
 
 
 
 
Sporadic CRC 
 
 
 
Germline 
 
 
 
 
 
Somatic 
 
 
 
MLH1, MSH2, 
MSH6 germ-
line gene 
mutations 
 
 
 
MLH1 somatic 
methylation 
 
 
 
 
Multiple primary colorectal 
cancers, accelerated 
tumour progression, and 
increased risk of endometrial, 
gastric, and urothelial 
tumours 
 
Colorectal cancer with 
increased risk of 
poor differentiation, more 
commonly located in right 
colon, less aggressive clinical 
behaviour than tumours 
without mismatch-repair 
deficiency 
CpG island methylator 
phenotype 
Somatic Target loci 
MLH1, 
MINT1,MINT2
, MINT3 
Characteristic of 15% of 
colorectal cancers, 
with most showing mismatch 
repair deficiency from loss of 
tumour MLH1 expression 
Base excision repair defect Germline MYH Development of 15 or more 
colorectal adenomas with 
increased risk of colorectal 
cancer 
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1.5.3. Chromosomal instability 
Most sporadic cases have chromosomal instability characterised by an allelic imbalance at 
several chromosomal loci (5q, 8p, 17p and 18q) which leads to loss of tumour suppressor 
genes such as APC, p53 and SMAD4. There are also rare inactivating mutations of genes 
that are involved in maintaining chromosomal stability (Barber et al., 2008). In contrast to 
most other cancers, amplification of gene number (Leary et al., 2008) or gene rearrangement 
through translocation are rarely found in colorectal cancer.  
 
The majority (around 70-80 %) of FAP and sporadic CRCs are characterised by loss of 
heterozygosity and bi-allelic mutations in APC (Miyoshi et al., 2002; Lammi et al., 2004). 
APC forms a ‘destruction complex’ in association with beta catenin, GSK-3beta and CKI 
kinases which triggers the phosphorylation of beta catenin in the absence of the WNT 
ligand. This leads to proteolytic degradation of beta catenin. In the presence of WNT, this 
destruction complex is inhibited which prevents beta catenin degradation, enabling it to 
translocate to the nucleus and activate downstream target genes through interaction with the 
TCF/LEF family of transcription factors (Polakis et al., 1999). Constitutive activation of the 
WNT pathway occurs most commonly due to mutations in the APC or beta catenin genes. 
However, mutations in other members such as AXIN 2 have also been detected (Lammi et 
al., 2004). 
 
Up to 50 % of all CRCs contain an activating mutation in the KRAS2 oncogene (Bos et al., 
1987; Vogelstein et al., 1988; Andreyev et al., 2001). In its absence, 20 % of CRCs contain 
mutations in BRAF (Davies et al., 2002; Rajagopalan et al., 2002). Both play a role in the 
RAS-RAF-MAPK signalling pathway that modulates cell growth and survival. Although 
both mutations are associated with adenoma growth and progression (Vogelstein et al., 
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1988; Rajagopalan et al., 2002), there is some evidence to suggest that they may develop 
earlier in aberrant crypt foci (Takayama et al., 2001).  
 
Alterations in the TGFβ signal transduction pathway are associated with the progression to 
late adenoma/early adenocarcinoma. Most CRCs contain mutations in a component of this 
pathway such as TGFβ receptor 2 (Markowitz et al., 1995) or SMAD2 and SMAD4 genes 
(Takagi et al., 1996; Takagi et al., 1998; Thiagalingam et al., 1996) which affects 
angiogenesis, cell proliferation and differentiation.  
 
The next step in the adenoma carcinoma sequence is marked by the malignant 
transformation from adenoma to carcinoma which is accompanied by loss of TP53, found in 
at least 45 % CRCs (Baker et al., 1989; Delattre et al., 1989; Purdie et al., 1991; Iacopetta, 
2003). This is a tumour suppressor gene that inhibits cell growth and stimulates cell death 
hence; its inactivation has far reaching consequences on the genome integrity of intestinal 
cells. 
 
Additional pathways that have been implicated in CRC include those involving P13K, 
receptor tyrosine kinases and phosphatases (Wang et al., 2004c; Samuels et al., 2004; 
Parsons et al., 2005; Bardelli et al., 2003).  
 
1.5.4. DNA mismatch repair defects 
In hereditary syndromes such as HNPCC, there are mutations in DNA mismatch repair 
genes such as hMLH1, hMSH2 or hMSH6. These genes are responsible for recognising 
frameshift mutations and base pair substitutions that occur in short tandemly repeated 
nucleotide sequences called microsatellites during DNA replication. Loss of function of 
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these genes is characterised by accumulation of single nucleotide mutations and length 
alterations in repetitive microsatellite nucleotide sequences. Germ line defects in mismatch 
repair genes confer a lifetime risk of colorectal cancer of 80 % in individuals with HNPCC 
(Leach et al., 1993; Papadopoulos et al., 1994; Fishel et al., 1994; Bronner et al., 1994) and 
are associated with an accelerated course of development of colorectal cancer with invasive 
cancer emerging within 36 months of a normal colonoscopy.  
 
In sporadic colorectal cancer, loss of one of the DNA repair genes, hMLH1 occurs through 
hypermethylation of its CpG islands, which silences the genes and leads to microsatellite 
instability. Defective mismatch repair function leads to the development of tumours that 
have a proximal location, mucinous histology, poor differentiation and lymphocytic 
infiltration. In sporadic cases, they are associated with older age and female sex. Genes that 
contain mononucleotide or dinucleotide repeat sequences such as that for TGFβ receptor 2 or 
BCL2-associated X protein can become inactive in individuals with mismatch repair 
deficiency contributing to the carcinogenesis process.  
 
The level of microsatellite instability is usually assessed using a standard panel of five 
markers (BAT25, BAT26, D5S346, D2S123 and D17S250) defined by the National Cancer 
Institute in 1998 (Boland et al., 1998). MSI-H (MSI high) is defined when two of the five 
markers are mutated or unstable. MSI –L (MSI low) is present when only one of the five 
markers is unstable. When none of the five markers are mutated, the tumour is described as 
MSS (microsatellite stable).  
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1.5.5. CpG island methylator subtype. 
Loss of gene function can occur through aberrant DNA methylation, which leads to 
epigenetic silencing of genes. Cytosines within CpG dinucleotides are modified by DNA 
methylases that attach a methyl group to carbon 5 of cytosine. Under normal circumstances, 
cytosine methylation only occurs in areas of repetitive DNA sequences outside of exons 
being excluded from the CpG islands in the promoter regions of half of all genes (Issa, 2004; 
Tahara et al., 2014). In colorectal cancer, there is an overall reduction in cytosine 
methylation, however, there is an increase in aberrant methylation within certain promoter 
associated CpG islands responsible for epigenetic gene silencing. In sporadic CRC, 
hypermethylation of MLH1 is responsible for loss of function of this DNA mismatch repair 
gene. Hypermethylation of other genes usually occurs as a collective group that has led to 
the term CpG island methylator phenotype (CIMP). However, the molecular mechanism that 
underlies CIMP or the effects of epigenetic silencing of genes other than MLH1 remain to be 
elucidated. There are three patterns of methylation: CIMP-high where a subgroup of genes 
become hypermethylated, CIMP-low with an intermediate level of hypermethylation and 
aberrant methylation of exon 1 of the gene encoding vimentin. The latter is not usually 
expressed by colonic mucosa but aberrant methylation is found in 53-83 % of patients with 
colorectal cancer in a pattern that is independent of CIMP (Chen et al., 2005; Zou et al., 
2007).  
 
1.5.6. Newer emerging theories 
A number of different pathways have recently emerged that explain a higher risk of CRC in 
patients with particular types of adenoma.  
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Serrated polyposis refers to a condition whereby serrated polyps confer a high risk of CRC 
that develops along a different pathway to the traditional adenoma-carcinoma sequence. The 
current criteria for diagnosis (Snover et al., 2010) include – 
1. at least five serrated polyps proximal to the sigmoid colon with two or more of these 
being >10 mm 
2. any number of serrated polyps proximal to the sigmoid colon in an individual who 
has a first-degree relative with serrated polyposis 
3. >20 serrated polyps of any size, but distributed throughout the colon. The implied 
meaning of this last criterion is that the polyps are not all present in the rectum  
It is associated with a five-fold increase in the risk of CRC to first degree relatives (Boparai 
et al., 2010). Most cancers that arise in these patients are proximal (Yeoman et al., 2007), 
however, in young onset (<50 years) individuals they are more likely to be distal (Buchanan 
et al., 2010; Young & Jass, 2006).  Somatic molecular alterations that have been associated 
with serrated polyposis syndrome include BRAF (V600E) mutation, KRAS (codons 12 and 
13) mutations, hMLH1 methylation, MGMT methylation, and CpG island methylator 
phenotype (CIMP) (Rashid et al., 2000; O'Brien et al., 2006; Chan et al., 2003; O'Brien et 
al., 2004b; Beach et al., 2005). The prevalence of each mutation varies with the subtype of 
serrated polyp, however, in most instances, a somatic mutation in BRAF is the earliest event 
detected in aberrant crypt foci (Rosenberg et al., 2007). The other characteristic of serrated 
polyposis is widespread hypermethylation of gene promoters (CIMP) (Chan et al., 2002) 
with or without MSI (Hawkins et al., 2000; Jass et al., 2000). This is evident even in normal 
mucosa of young individuals suggesting that there is a widespread epigenetic regulatory 
defect that leads to premature ageing of the mucosa and confers a higher risk of developing 
CRC (Minoo et al., 2006; Wynter et al., 2004). At present, clinical management of patients 
with these lesions is unclear and regular surveillance colonoscopy is advised.  
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1.6. Screening and treatment of colorectal cancer 
At present, most patients with CRC are diagnosed when they become symptomatic with a 
change in bowel habit, blood in the stool, abdominal mass or iron deficiency anaemia. 
Hence, the condition is often detected at a later pathological stage when chances of cure are 
less, resulting in the low observed survival rates. Consequently, population based screening 
programs have been introduced that aim to detect CRC in asymptomatic patients at the 
preneoplastic stage (adenomatous polyps) or early cancer stage. Current screening 
modalities rely on detecting and removing adenomas from which 80 % of CRCs are believed 
to arise. However, only a small proportion of these adenomas will eventually develop into a 
cancer, hence, screening often results in overtreatment of patients and can cause 
considerable morbidity to the patient.   
 
1.6.1. Faecal occult blood test (FOBT) 
In the UK, population based CRC screening commenced in 2006. The current protocol is 
based on the guaiac based Faecal Occult Blood Test (gFOBT) with biennial testing of 
individuals aged 60-74. In a systematic review, FOBT screening reduced CRC related 
mortality by 16 % (Hewitson et al., 2007; Hewitson et al., 2008). If found to be positive, 
individuals are offered a colonoscopy to establish a diagnosis. Results from the UK cancer 
screening program have shown that only 52 % of individuals invited to participate 
completed a FOBT and only around 50 % of those with a positive result underwent a 
colonoscopy. Of those attending colonoscopy, only one in 10 were diagnosed with cancer. 
Half of these patients had no abnormality and the remaining 40 % had polyps (Logan et al., 
2012). This suggests that the vast majority of those investigated by invasive tests such as 
colonoscopy did not have cancer. Other tests that are currently being examined include the 
immunochemical faecal occult blood test that has superior sensitivity with fewer samples 
required and less interference from animal blood in the diet (Whitlock et al., 2008; 
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Castiglione et al., 2002). However, the optimum threshold for testing is currently unknown 
and is being evaluated in several studies. In the UK, this test will be introduced into clinical 
practice in 2016.  
 
1.6.2. Flexible sigmoidoscopy 
Other approaches to CRC screening rely on more invasive tests such as flexible 
sigmoidoscopy or colonoscopy. As more than 60 % of cancers arise in the sigmoid colon 
and rectum (Lieberman et al., 2000), they can be detected with a 60 cm flexible 
sigmoidoscope.  Three large randomised trials of once only flexible sigmoidoscopy have 
been conducted in the UK (Atkin et al., 2002), Italy (Segnan et al., 2002) and Norway 
(Gondal et al., 2003). Based on intention to treat analysis, the UK trial demonstrated a 23% 
reduction in CRC incidence and 31 % reduction in mortality in the intervention group (Atkin 
et al., 2010). In the first year of follow up after sigmoidoscopy, the incidence of distal 
cancers is 4 % of expected which remains at 18 % expected at 4 years. In comparison to 
FOBT, flexible sigmoidoscopy is able to detect three times as many adenomas (Brevinge et 
al., 1997; Segnan et al., 2005). However, there are disadvantages with flexible 
sigmoidoscopy screening. Referral rates for colonoscopy are higher at around 5-19 % 
compared to the 1.2-2.1 % referral rates seen in FOBT trials. Similarly, compliance is lower 
than that for FOBT screening, probably as these tests are invasive and require attendance at 
hospital compared to FOBT tests, which can be performed at home. The overall compliance 
rate in the UK trial was 39 % (Atkin et al., 2002) compared to the 54 % compliance rate 
recorded in the first round of the FOBT trial.  
 
At present, flexible sigmoidoscopy screening is being offered in six regions in the UK that 
are piloting the test to determine its feasibility and cost effectiveness. There are plans to 
offer the test on a more universal basis across UK by 2016.  
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1.6.3. Colonoscopy 
In the USA, the most common method of screening is colonoscopy every 10 years (Rex et 
al., 2000; Rex & Trustees, 2004) which has been shown to have little effect on reducing 
rates of proximal cancers (Lakoff et al., 2008; Baxter et al., 2009) and can result in 
considerable more morbidity to the patient than flexible sigmoidoscopy as it requires full 
bowel preparation and sedation. There are no randomised controlled trials that demonstrate a 
reduction in CRC related mortality if colonoscopy is utilised for screening. Most of the 
evidence to support colonoscopy based screening has been extrapolated from case control 
studies of sigmoidoscopy. These have demonstrated an 80 % risk reduction in death from 
CRC in individuals who have undergone a flexible sigmoidoscopy compared to those that 
have not (Newcomb et al., 1992; Selby et al., 1993). Similarly, there is a 70 % risk reduction 
for CRC following negative colonoscopy which drops to 55 % at years and 28 % at 10 years 
(Singh et al., 2006). This suggests that the benefits from a negative examination are long 
lasting. However, as the detection rate for advanced adenomas in the younger age group (40-
49) drops to 3.5 %, screening below 50 years is not recommended in the USA (Imperiale et 
al., 2002). The other disadvantage of colonoscopy is that up to 6 % of lesions, including 
polyps < 10mm can sometimes be missed. In one study, 2 % of asymptomatic patients 
undergoing screening had a missed polyp. Almost one quarter of these missed lesions were 
found within 10 cm of the anal verge and the rest were on a fold in the colon (Pickhardt et 
al., 2004). Given the huge demand on resources, colonoscopy based screening has not been 
deemed cost effective in the UK and is therefore unlikely to be utilised in the future.  
 
1.6.4. Emerging screening modalities 
Current research into population based screening methods has therefore focussed on the 
development of non-invasive tests. Several studies have investigated DNA based tests of 
blood or stool (Link et al., 2010; Ahlquist et al., 2012; Summers et al., 2013). Cologuard has 
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recently been developed and is being used in USA. It is a stool based test that measures 
KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, plus a haemoglobin 
immunoassay. Early studies have shown that it has a sensitivity of 92 % and specificity of 87 
% (Imperiale et al., 2014). Its feasibility, cost effectiveness and long term impact needs to be 
investigated further before it can be widely adopted.  
 
Others have used novel strategies such as evaluation of metabolomic profile of urine or 
faeces and breath with mass spectrometry or electronic devices that detect emitted volatile 
gases such as the electronic nose (Arasaradnam et al., 2014; Westenbrink et al., 2015). Pilot 
studies suggest that these technologies offer promise for the future development of more 
accurate screening tests. 
 
1.7. Cancer biology 
Despite considerable advances in our understanding of how CRC develops, there are a 
number of theoretical aspects of cancer formation that require consideration. Many different 
theories of carcinogenesis have been proposed which have influenced the way in which CRC 
pathogenesis has been explored. The fundamental concept that has been explored in greatest 
depth and has dominated CRC research is the somatic mutation theory (Curtis, 1965; Hahn 
& Weinberg, 2002) which proposes that cancer is a clonal, cell-based disease where 
quiescence is the default state of the cell (Soto & Sonnenschein, 2004). Consequently, 
investigators have focussed on characterising the genetic changes that take place in CRC in 
order to identify both causative agents and methods for improved diagnosis and treatment. 
Others have questioned this approach by challenging the very theoretical assumptions it is 
based on and have proposed alternative hypotheses such as the tissue organisation theory 
(Soto & Sonnenschein, 2011) or metabolic theory of cancer (WARBURG, 1956).  
1.7.1. Multi-hit Hypothesis of cancer 
56 | P a g e  
 
The multi hit hypothesis of cancer was first described by Nordling (NORDLING, 1953) and 
later popularised by Knudson (Knudson, 1971). A simple mutation is not sufficient to cause 
cancer and it is the progressive accumulation of mutations in the cell’s DNA that result in 
malignant growth. A three step process was described consisting of initiation, promotion and 
progression. Initiation refers to the process where DNA is damaged through the action of 
carcinogenic agents such as UV light, ionising radiation, thermal disruption or chemical 
sources (de Gruijl et al., 2001). There are also endogenous carcinogens that cause cancer. In 
CRC, the colonic epithelium is exposed to numerous toxins and microbial agents found in 
food. Bile acids produced at high levels in individuals who have a high fat diet, damage 
DNA and have been identified as initiators in CRC formation (Bernstein et al., 2011). 
Similarly, presence of macrophages and neutrophils found in inflamed colonic mucosa are a 
source of reactive oxygen species, which is also capable of damaging DNA (Katsurano et 
al., 2012). There are five main types of DNA damage comprising oxidation of bases, 
alkylation of bases, hydrolysis of bases, bulky adduct formation and mismatch of bases 
during DNA replication. In the promotion phase, a promoter agent induces clonal expansion 
of the cell generating a group of cells that harbour mutated genes. Further mutation and 
genetic instability or epigenetic modulation contributes to drive the cells towards malignant 
transformation in the progression phases. It has been estimated that at least seven mutations 
are necessary for development of cancer (NORDLING, 1953). Only so called ‘driver’ 
mutations that confer selective growth advantage contribute to carcinogenesis; the remaining 
vast majority of mutations found in malignant cells are actually innocent bystander 
‘passenger’ mutations that occur because of genomic dysregulation. In CRC, 15 ‘driver’ and 
60 ‘passenger’ mutations have been described (Wood et al., 2007).  
 
The multi-hit hypothesis of cancer has developed further in the last decade. Hanahan and 
Weinberg described 6 attributes of cancer cells in their seminal paper on ‘Hallmarks of 
cancer’ (Hanahan & Weinberg, 2000): 
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i) Self –sufficiency of growth which leads to uncontrolled growth 
ii) Evading growth suppressors 
iii) Activating invasion and metastasis 
iv) Replicative immortality (absence of senescence) 
v) Induce angiogenesis 
vi) Resist cell death 
Consequently, tumours have been described as complex tissues of multiple cell types which 
interact with each other rather than collections of proliferating cells (Centelles, 2012). Cells 
need to acquire other attributes besides replicative ability to form a tumour and there are 
multiple signalling pathways that are disrupted in cancer formation.  
 
Several investigators have recently challenged Knudson’s two hit hypothesis. A number of 
experimental approaches have demonstrated haploinsufficiency in cancers whereby 
inactivation of one allele of a tumour suppressor gene is sufficient to cause tumour 
formation (Fodde & Smits, 2002). Furthermore, the dominant negative effect describes how 
one mutated copy of a tumour suppressor gene renders the other, wild-type copy non-
functional (Willis et al., 2004). Therefore, it appears that under certain circumstances, loss 
of function of tumour suppressor genes can arise through mutational loss or epigenetic 
marking of a single allele.  
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1.7.2. The stem cell theory 
Fundamental to the concept that cancer arises from DNA damage and accumulation of 
mutations is the concept of the cancer stem cell theory. This proposes that the different cells 
found in a tumour originate from a single group of cells called cancer stem cells (CSCs) (see 
figure 1.7.).  
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Figure 1.7. Stem cell theory of colorectal cancer formation demonstrating how a mutation 
in the stem cells at the base of the crypt is acquired by daughter cells as they migrate 
upwards along the crypt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stem cells at base of crypt 
acquire genetic mutation 
Mutation is inherited by all cells 
in the crypt 
Several crypts acquire mutation 
through crypt fission resulting in 
patch of dysplastic mucosa 
Mutated cells undergo further 
mutations developing the ability 
to invade and metastasize 
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CSCs are pluripotent cells capable of self-renewal that divide and give rise to the cells found 
in tumours. They may arise from transformation of normal adult stem cells or differentiated 
cells. Evidence that they arise from normal adult stem cells is the following -   
i) there is a positive correlation between the risk of developing a cancer and the 
number of normal stem cell divisions taking place in the same tissue – this was 
tested across 31 cancer types and extended across 5 orders of magnitude 
(Tomasetti & Vogelstein, 2015). 
ii) The increased incidence of cancer with age suggests that most cancers occur 
because cells accumulate damage. DNA is the only cellular component that can 
accumulate damage with age and stem cells are the only cells that can transmit 
DNA from the zygote to the cells we have when we die (López-Lázaro, 2015). 
The mutant cells compete for space and resources. The clonal evolution theory suggests that 
only cells with mutations that give them a selective advantage over the other cells will 
survive, similar to Darwinian evolution (Nowell, 1976; Cahill et al., 1999; Greaves & 
Maley, 2012).  
Both the cancer stem cell theory and the clonal evolution theory have been applied to CRC. 
It has been proposed that stem cells at the bottom of a crypt acquire mutations. As these cells 
divide and give rise to terminally differentiated cells, the daughter cells acquire the 
mutations. Only cells that have a growth advantage over other cells survive and eventually 
the crypt contains only mutated cells. These crypts divide by crypt fission resulting in a 
tumour mass with cells that harbour the original mutations. It is also conceivable that due to 
defective DNA repair mechanisms, the cells also develop different passenger mutations, 
which gives rise to genetically heterogeneous populations of cells within the tumour that 
share similarity in the driver mutations that they have acquired. This process has also been 
termed bottom up histogenesis (Wright, 2000) whereby cells at the bottom of the crypt are 
those that are responsible in giving rise to the malignancy.  
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1.7.3. Top down or bottom up histogenesis 
Early studies where histological examination of pre-neoplastic lesions of the colon was 
performed contradicted the bottom up histogenesis theory (Wright, 2000). These lesions 
only contained dysplastic cells at the orifices and luminal surfaces of the crypts. If the 
epithelial cells of the crypt were traced, there was an abrupt change to dysplastic cells 
midway down the crypt axis (COLE & MCKALEN, 1963; Wiebecke et al., 1974; Nakamura 
& Kino, 1984). Furthermore, cells at the base of these crypts exhibited normal proliferation 
patterns whereas cells at the orifices had a similar proliferation pattern to neoplastic cells 
(Lipkin, 1974; Maskens, 1979; Polyak et al., 1996). Several authors therefore proposed 
alternative theories. The stem cells that give rise to cancer cells may reside in intercryptal 
zones that lie between crypt orifices rather than at the base of the crypt (COLE & 
MCKALEN, 1963). Others suggested that the cells at the base of the crypts were genetically 
transformed but that the dysplastic appearance was only visible as cells migrate and become 
terminally differentiated (LANE & LEV, 1963; Maskens, 1979).  These historical studies 
have led authors to investigate this phenomenon further, which has led some authors to 
propose a top down morphogenesis model. This was based on the observation that dysplastic 
cells at the top of the crypt contain genetic alterations in APC and have a neoplastic genetic 
expression profile (Shih et al., 2001). Similar changes were not seen in the cells at the base 
of the crypt nor was there any evidence to suggest that these cells have a common clonal 
origin. The top down morphogenesis model implies that genetically altered cells are only 
found in the superficial portions of the mucosa and not at the base. These abnormal cells 
spread laterally and downward to form new crypts which connect to pre-existing crypts and 
eventually replace them (Shih et al., 2001). Others have argued that crypt fission, as seen in 
monocryptal adenomas (the earliest precursor lesion to adenomas) is the main mode of 
adenoma progression, certainly in FAP (Chang & Whitener, 1989; Wasan et al., 1998) but 
possibly in sporadic adenomas (Wong et al., 1999). Others have suggested that these two 
theories may not be mutually exclusive whereby crypt fission occurs early in adenoma 
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formation and lateral, downward spread via the surface is a later phenomenon resulting in 
cancer formation.  
 
1.7.4. Other cancer theories 
1.7.4.1 Tissue Organisation theory 
Several other cancer theories have been proposed that question the somatic mutation theory 
and cancer stem cell theory. Based on this premise, cancers are derived from a single 
somatic cell which acquire multiple mutations in genes that control cell proliferation and 
regulate the cell cycle (Alberts B et al., 2004). Thus, cancer is an irreversible process that 
takes place at the DNA- level and the default state of the cell is assumed to be quiescent. In 
comparison, the proponents of the tissue organisation theory state that cancer arises through 
disruption of normal tissue architecture by carcinogenic agents resulting in alteration of cell-
to-cell signalling and genomic instability (Soto & Sonnenschein, 2005; Soto & 
Sonnenschein, 2011). Hence, genetic mutations are the result rather than the cause for cancer 
formation. This theory also assumes that the default state of the cell is proliferation and that 
carcinogenesis is a reversible, curable process (Soto & Sonnenschein, 2005). Although both 
theories appear to have a different philosophical stance, there have been attempts to ally 
them by the proposition that neither process on its own is sufficient to cause a cancer to form 
(Rosenfeld, 2013).  
 
1.7.4.2 Chromosomal theory 
In 2011, an alternative theory was proposed to explain the genomic instability observed in 
cancers (Stephens et al., 2011). Instead of the slow accumulation of genetic mutations, 
cancers arise after a single catastrophic event during which the chromosome or 
chromosomal region shatters into tens to hundreds of pieces. The DNA repair machinery 
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stitches these fragments into a mosaic pattern, giving rise to genomic instability. Cells that 
have acquired such genetic alteration usually undergo apoptosis, however, such remodelling 
is expected to give the cell a survival advantage enabling the cells to proliferate and become 
malignant.  
 
1.7.4.3. Metabolic theory 
Others have suggested that cancers arise due to metabolic dysfunction. Malignant, rapidly 
dividing cells have glycolytic rates that can be up to 200 times higher than those of normal 
tissues, despite the presence of oxygen (Gatenby & Gillies, 2004; Ferreira et al., 2012). This 
has been termed the Warburg effect: there is a switch from energy needs being met by 
oxidative phosphorylation to aerobic glycolysis followed by lactic acid fermentation in the 
cytosol (Vander Heiden et al., 2009). This is necessary for cancer cells to meet the energy 
demands when undergoing rapid rates of cell division. However, it leads to the generation 
and accumulation of reactive oxygen species, which induces DNA damage and contributes 
to cancer formation. The Warburg hypothesis stipulates that these metabolic changes are the 
fundamental cause for cancer formation which is also referred to as the metabolic theory of 
cancer (WARBURG, 1956). Others have argued that the Warburg effect is simply a 
consequence of the mutations that have accumulated in cancer cells rather than being a 
driving force for cancer formation itself (Senyilmaz & Teleman, 2015).  
 
1.8. The role of the tumour microenvironment and supporting stroma 
Several studies highlight the importance of the tumour microenvironment and the reciprocal 
relationship between stromal cells and epithelial cells in driving cancer formation. Chronic 
inflammation has been referred to as the seventh trait acquired by tumour cells (Mantovani 
et al., 2008; Colotta et al., 2009; Hanahan & Weinberg, 2011). The tumour 
microenvironment consists of tumour infiltrating cells (cells associated with inflammation 
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and immunity), vasculature, extracellular matrix and matrix-associated molecules. 
Transformed epithelial cells attract pro-neoplastic stromal cells that will support cell growth 
and help evasion of host defences enabling these cells to survive in hostile conditions.  
 
1.8.1. Tumour infiltrating cells 
Inflammation and release of soluble chemoattractants by the epithelial cells attract a number 
of different cells to the tumour site (Tokunaga et al., 1998; Jedinak et al., 2010; Zins et al., 
2007; Wang et al., 2006b). The role of these cells in carcinogenesis appears to be dynamic. 
Initially they are involved in protecting against tumour formation, however, with time, the 
epithelial cells are able to modulate their activity to promote tumour cell proliferation, 
survival and metastasis (de Visser et al., 2006). Some of the induced changes are reversible, 
however, there have been studies showing loss of heterozygosity and microsatellite 
instability in stromal cells suggesting that irreversible changes also occur (Ishiguro et al., 
2006).  
 
Tumour associated macrophages (TAMs) have multiple roles that support tumour growth 
including promoting angiogenesis through release of VEGF (Barbera-Guillem et al., 2002; 
Pollard, 2004; Sickert et al., 2005), epithelial-mesenchymal transition through interaction 
with TGFβ (Bates et al., 2004) and immunosuppression through release of cytokines that 
inhibit T cell activation and proliferation (Mantovani et al., 1992; Baier et al., 2005). In 
comparison, the role of neutrophils in CRC formation remains controversial. Some authors 
suggest that they support angiogenesis by releasing factors such as oncostatin M which 
stimulates production of VEGF by tumour cells (Queen et al., 2005). Others have proposed 
that release of ROS, proteases and cytokines such as TNF-alpha and IL-1beta can kill 
tumour cells directly (Di Carlo et al., 2001a; di Carlo et al., 2001b).  
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Macrophages are highly plastic and can adopt a different state depending upon the micro-
environment: either M1 (anti-tumour) or M2 (pro-tumour) polarisation states (Sica et al., 
2006; Mantovani et al., 2007; Mantovani et al., 2004; Van Ginderachter et al., 2008). In 
tumours, the M2 polarisation state predominates (Mantovani et al., 2008; Coussens & Werb, 
2002) which is usually induced by IL-4, IL-13, immunoglobulin complexes and Toll-like 
receptor ligands. They are involved in scavenging debris, promoting angiogenesis, tissue 
remodelling and repair. In comparison, M1 macrophages participate in the Th1 response 
against intracellular pathogens including tumour cells. Similarly, a dual role for neutrophils 
may also explain the opposing results seen across studies. N1-TANs have an anti-tumour 
role by expressing higher levels of proinflammatory cytokines and are more cytotoxic to T 
cells (Scapini et al., 2000). In contrast, N2-TANs do not produce pro-inflammatory 
cytokines but instead produce large amounts of arginase that actually inactivates T cell 
effector functions, disabling the host defences against tumour formation (Fridlender et al., 
2009).  
 
The type, density and location of T cells is a better prognostic indicator in CRC compared to 
conventional histopathological factors. Although, some CD8 T cells are reactive against 
tumour antigens, the tumour microenvironment contains inhibitory cytokines that prevent T 
cell activation thus contributing to evasion of the host immune response (Waldner et al., 
2006).  
 
Despite being the main cellular constituent of the reactive stroma around CRC (Kalluri & 
Zeisberg, 2006; Ostman & Augsten, 2009), cancer associated fibroblasts (CAFs) are poorly 
understood. Generally, they are believed to arise from local tissue fibroblasts or fibroblast 
precursors that have been stimulated by PDGF and TGFβ. In vitro studies have shown that 
they are able to enhance tumour cell proliferation (Nakagawa et al., 2004) and in vivo, high 
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levels of stromal CAFs have been linked with greater potential to develop metastasis or 
recurrence (Henry et al., 2007). CAFs have also been shown to release VEGF, FGF and 
CXCL12 that are pro-angiogenic thereby supporting neovascularisation. Furthermore, CAFs 
activate Wnt signalling through the Wnt ligands PDGF and PGE2 which leads to EMT and 
maintenance of the cancer stem cell phenotype (Wang et al., 2004a; Wang et al., 2004b; 
Eisinger et al., 2006; Eisinger et al., 2007).  
 
1.8.2. Angiogenesis 
Neovascularisation is a prerequisite for tumour growth and survival. Hypoxia of the tumour 
leads to activation of hypoxia-induced factor 1, which increases expression of angiogenic 
factors such as VEGF, bFGF and PDGF by the tumour cells. This is usually an early event in 
carcinogenesis and may explain how microvascular density is a predictor of survival in CRC 
patients (Choi et al., 1998).  
 
1.8.3. Extracellular matrix  
The extracellular matrix (ECM) is a highly complex, 3-dimensional structure that not only 
maintains tissue integrity but regulates other cellular processes such as cell migration, 
differentiation and proliferation, acting as a reservoir for cytokines and growth factors. There 
are two components to the ECM: the basement membrane and the interstitial or stromal 
matrix. The basement membrane consists of thin sheets of specialised ECM that surrounds 
epithelial cells and separates it from the interstitial stroma. It is composed of laminin and 
type IV collagen with invasion by malignant cells usually requiring dissolution of the 
basement membrane through a complex process. The stromal matrix contains polysaccharide 
gels, proteoglycans and various fibrous proteins. Several alterations in the ECM constituents 
have been associated with CRC formation. Laminin 332 is commonly lost as a premalignant 
lesion becomes invasive. This parallels inactivation of Smad4 which is a positive 
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transcriptional regulator of all three genes that encode subunits of Laminin 332 (Zapatka et 
al., 2007). Similarly, Syndecan 1 (a transmembrane heparan sulphate proteoglycan) is lost in 
human CRC and its levels have been correlated with several clinicopathological factors in 
CRC including TNM stage, lymph node metastasis and EMT (Hashimoto et al., 2008).  
 
Several molecules of the ECM such as fibronectin, laminin and collagen interact with 
integrins which are cellular receptors. Binding of integrins to these ECM molecules 
influences adhesion, migration and sequestration of growth factors. In CRC, increased 
integrin mediated ECM interactions are found in poorly differentiated cancers with 
disruption of this integrin mediated adhesion resulting in apoptosis and reduced PI3K 
activity.  
 
The ECM is degraded by a number of different proteases including metalloproteases. The 
expression level of several of these metalloproteases (MMP 1, 2, 3, 7, 9 and 13) are 
increased in CRC and correlates with stage of disease (Zucker & Vacirca, 2004). MMP9 
released by neutrophils has been associated with release of VEGF from ECM and is 
increased during the transition from adenoma to adenocarcinoma. MMPs are inhibited by 
another group of molecules called Tissue Inhibitors of metalloproteinases (TIMPs). The 
expression of TIMP-1 has been linked to increased resistance to chemotherapy and shorter 
survival time (Davidsen et al., 2006; Sørensen et al., 2007).  
 
Mucins are glycosylated proteins that have been linked to CRC (Perez et al., 2008).  
 
1.8.4. Growth Factors 
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Communication between the stromal and epithelial cells relies on secreted factors such as 
growth factors and cytokines. Although growth factors are not responsible for tumour 
initiation, progression of the tumour beyond this stage relies upon growth factors, which 
play a pivotal role in clonal expansion, invasion across tissue barriers, angiogenesis and 
colonisation at distant sites. Often, the mutations that develop in cancer cells enable them to 
survive and proliferate in the absence of growth factors. However, there is also evidence to 
suggest that growth factors are involved in chemotherapy drug resistance suggesting that 
treatments where they are targeted could also be of benefit at later stages of CRC.  
 
Several different growth factors have been implicated in CRC formation. They are compact 
polypeptides, which bind to transmembrane receptors with tyrosine kinase activity. Through 
their action on tyrosine kinase receptors, most growth factors share downstream intracellular 
signalling pathways. These include mitogen activated protein kinase (MAPK), the 
phosphatidylinositol 3-kinase (PI3K), phospholipase C-gamma and transcription factors like 
signal transducers and activators of transcription (STATs) or SMAD proteins.  
 
1.8.4.1. Epidermal growth factor (EGF)  
The EGF family consists of 11 growth factors (EGF, Transforming Growth Factor (TGF-α), 
Neuregulin (NRG 1-4), Amphiregulin, Betacellulin, Epiregulin, Heparin binding EGF (HB-
EGF) and Epigen) which share a conserved EGF domain. They bind to a group of four 
receptor tyrosine kinases called ErbB1-4: ErbB-1 is also known as EGFR and ErbB-2 as 
HER-2. Mutations, amplification or dysregulation of at least one of the ErbB family 
members is found in > 20 % solid tumours. EGFR overexpression has been detected in up to 
80 % of CRCs (LeGolvan & Resnick, 2010) and has been correlated with early tumour 
recurrence and extra-hepatic metastatases (Christophi et al., 2008). Consequently, anti-
EGFR agents have been developed and are currently used to treat metastatic cancer. 
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Although the benefit of single anti-EGFR treatments are marginal, when used in 
combination with conventional chemotherapy, there has been a positive impact on survival 
in patients with metastatic disease (Wanebo & Berz, 2010; Tol & Punt, 2010). As some 
authors have shown that this benefit is independent of EGFR expression in the primary 
tumour (Chung et al., 2005), it is possible that EGFR expression in metastatic tissue differs 
from the primary tumour. Despite the use of anti-EGFR agents in clinical practice, the 
precise mechanism of how EGFR signalling contributes to tumour aggressiveness and 
metastatic spread is unknown.  
 
1.8.4.2. Vascular endothelial growth factor (VEGF) 
The VEGF family consists of five glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD and 
PGF (placenta growth factor). Alternative exon splicing results in four isoforms: VEGF 121, 
165, 189 and 206. VEGF 121 and 165 are secreted whereas VEGF189 and 206 bind to cell 
surface heparin like molecules. VEGFs act through one of three receptors, VEGFR 1-3. 
They play a role in tumour cell survival, migration, invasion and angiogenesis. In solid 
tumours, release of hypoxia-inducible factor 1α (HIF-1 α) (Kaur et al., 2005), EGF (Niu et 
al., 2002) and HGF (Dong et al., 2001) leads to increased levels of VEGF. VEGF then 
induces the release of factors such as stroma derived factor 1 (SDF-1) which attracts cancer 
associated fibroblasts (Christophi et al., 2008; Kalluri & Zeisberg, 2006). VEGF is a 
therapeutic target in CRC as anti-VEGF therapy has been found to be effective in the neo-
adjuvant setting for metastatic CRC (Wanebo & Berz, 2010; Tol & Punt, 2010).  
 
1.8.4.3. Transforming growth factor β (TGF- β) 
There are three isoforms of TGF-β (1-3), however, the extended superfamily consists of 
more than 30 additional cytokines, classified into different subfamilies like bone 
morphogenetic proteins, activins etc. Under normal conditions, TGF-β prevents cell cycle 
70 | P a g e  
 
progression, stimulates apoptosis and differentiation. During carcinogenesis, however, 
genetic and epigenetic changes convert TGF-β into a tumour promoter. It activates 
epithelial-mesenchymal transition through activation of the canonical and non-canonical 
pathways. TGF- β is also able to regulate the expression of angiogenic factors such as FGF 
and VEGF. In CRC, the antiproliferative effects of TGF-β are lost through mutations in the 
genes that encode TGF-β, the type II receptor (TGF-β2) or SMAD proteins (Markowitz & 
Bertagnolli, 2009).  
 
1.8.4.4. Insulin like growth factors (IGF) 
The IGF family consists of two ligands (IGF1 and IGF2), two cell surface receptors (IGF1R 
and IGF2R), six high affinity IGF binding proteins and IGFBP degrading enzymes. 
Although IGF 1 activity is not required for malignant transformation, there is evidence to 
suggest that it is essential for survival of transformed cells.  It recruits the PI3K-AKT 
pathway to generate anti-apoptotic signals and is able to have an action on most cells as it is 
expressed in most types of tumour. High IGF-1 serum levels have been linked with high 
IGF-1 receptor (IGF-1R) expression in tumour cells and development of hepatic metastases. 
IGF-1 attracts endothelial cells and stimulates production of VEGF thus leading to increased 
angiogenesis and supporting tumour growth.  
 
1.8.4.5. Fibroblast growth factors 
Fibroblast growth factors (FGFs) consist of a family of 22 structurally related polypeptides 
that share a common core of 140 amino acids. In developmental processes, they are 
responsible for mesoderm induction, anterior-posterior patterning, limb development, neural 
induction and neural development. In mature tissues, FGFs are involved in angiogenesis, 
keratinocyte organisation and wound healing processes that play a key role in proliferation 
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and differentiation of a wide variety of cells and tissues (Ornitz & Itoh, 2015). They interact 
with one of four receptor tyrosine kinases (FGFR1-4) and one kinase deficient receptor, 
FGFR5 (Ornitz & Itoh, 2001; Sleeman et al., 2001; Eswarakumar et al., 2005). Binding of 
FGFs to its receptor results in receptor homodimerisation, autophosphorylation and 
recruitment of cytosolic adaptors such as fibroblast growth factor substrate 2 (FSR2) which 
initiates multiple signalling pathways (Eswarakumar et al., 2005; Beenken & Mohammadi, 
2009) (see figure 1.8.1.below). Dysregulation of this signalling axis has been shown to play 
a significant role in tumour development and progression of several cancers (Sugiyama et 
al., 2010; Frullanti et al., 2011; Miura et al., 2012). 
Figure 1.8.1. Signalling cascades involved in FGF-FGFR interaction 
 
 
 
 
 
 
 
 
 
 
 
 
PLCγ 
Activates 
DAG-PKC and 
IP3 pathways 
FRS2 
SHP2 
GRB2 
FGF 
Receptor 
GAB1 
PI3K 
AKT 
PIP2 
PIP3 
GSK-3β 
SNAIL FOXO 
EMT Cell 
survival 
SOS 
RAS 
RAF 
MAP3K 
MAPK 
Cell different-
iation 
72 | P a g e  
 
Fibroblast growth factor receptors (FGFR) 1-4 consist of three extracellular 
immunoglobulin-type domains (D1-D3), a single span transmembrane domain and an 
intracellular split tyrosine kinase domain. Alternative mRNA splicing gives rise to b and c 
variants of FGFR1-3 therefore there are 8 types of receptor that can be expressed at the cell 
surface (Eswarakumar et al., 2005; Turner & Grose, 2010). FGFs bind to D2/D3domains 
with D3 interaction being responsible for ligand binding specificity. Heparan sulfate (HS) 
binding is conferred through the D2 domain and it is likely that FGFRs are permanently 
complexed with heparan sulfate on the cell surface (Powell et al., 2002). Each FGF binds 
different FGFRs with differing affinity (Ornitz & Itoh, 2015). The specificity of FGFs 
binding to cellular targets will be influenced not only by the type of FGFRs expressed by the 
cell but also by the pattern of heparan sulfate binding that is generated by the cellular 
enzymes.  
 
Most FGFs are only capable of a paracrine action as they are secreted proteins that bind 
heparan sulfates and therefore are usually caught up in the extracellular matrix of tissues that 
contain heparan sulfate proteoglycans (Itoh & Ornitz, 2011). In comparison, members of the 
FGF19 subfamily (FGF15, FGF19, FGF21, and FGF23) have poor affinity with heparan 
sulphate and therefore are able to diffuse through the HS-rich extracellular matrix to enter 
into the bloodstream (Goetz et al., 2007). This enables them to have an endocrine action 
such as is seen with FGF15/19 which is produced by intestinal cells but acts upon FGFR4 
expressed in the liver to downregulate CYP7A1 in the bile acid synthesis pathway (Jones, 
2012). Similarly, FGF23 is produced in the bone but acts upon FGFR1 expressing kidney 
cells to regulate vitamin D synthesis and maintain phosphate homeostasis (Razzaque, 2009).  
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Furthermore, the FGF19 subfamily members have poor affinity for their cognate FGF 
receptors and cannot bind to them and activate them in a solely HS-dependent fashion. 
Therefore, they require members of the Klotho family of proteins for high affinity receptor 
binding (Kurosu & Kuro-O, 2009). There are different types of Klotho proteins that interact 
with FGFs: α-klotho is the cofactor for FGF23, β-klotho for FGF15/19 and FGF21 (Kurosu 
et al., 2006; Kurosu et al., 2007; Urakawa et al., 2006; Ogawa et al., 2007; Wu et al., 
2007b). Despite having widespread tissue distribution, sites of action of the endocrine FGFs 
are limited by the distribution of klotho proteins (Fon Tacer et al., 2010).  
 
Aberrant FGF signalling is found in many different cancers including cancer of the prostate, 
breast, lung, bladder and colon (Brooks et al., 2012; Turner & Grose, 2010). The most 
widely studied FGF in CRC is FGF2 which has a synergistic action with VEGF on 
angiogenesis and has been shown to have prognostic relevance (Elagoz et al., 2006). Other 
fibroblast growth factors that have been implicated in CRC include FGF19 and FGF7. As 
alluded to earlier, FGF19 belongs to the endocrine family of FGFs and usually plays a role 
in bile acid, protein and glucose metabolism (see figure 1.8.2.).  
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Figure 1.8.2. The physiological roles of FGF19 
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is important but that there is concurrent increase in the expression of its receptor and 
cofactor that contribute to HCC formation.  
 
Previous analysis suggests that FGF19 may also play a role in colorectal cancer by acting on 
the wnt signalling pathway. Ectopic expression of FGF19 in transgenic mice results in 
development of HCC and these liver tumours contain neoplastic cells with nuclear 
localisation of beta-catenin indicative of activation. Co-activation of Wnt and FGF 
signalling pathways in tumours leads to a more malignant phenotype and inhibition of beta 
catenin using siRNA completely abolishes FGF19 expression in HCT116 cells suggesting 
that beta-catenin influences FGF19 expression (Katoh, 2006).  
 
Besides the direct action of FGF19 expression on tumour growth, modifications of its 
receptor, FGFR4 have also been linked to carcinogenesis. Reduced expression of FGFR4 
leads to upregulation of E-cadherin and downregulation of other epithelial-mesenchymal 
transition (EMT) mediators such as SNAIL, TWIST and ZEB. E-cadherin loss has been 
recognised as one of the central events in EMT as the study noted that such a change led to 
an accompanied concurrent reduction in tumour growth both in vitro and in vivo models. 
The in vivo tumours that were produced from FGFR4 silenced cells were not only smaller, 
but consisted of a whitish aspect indicative of deficiency in angiogenesis (Peláez-García et 
al., 2013). FGFR4 may also play a role in crosstalk between tumour associated fibroblasts 
(TAF) that govern EMT and the tumour tissue itself. Upregulation of FGFR4 was observed 
in CRC cells that were co-cultured with TAFs (Liu et al., 2013b). This study demonstrated 
that inhibition of FGFR4 reduced TAF-induced signalling cascades including FRS2 and 
ERK phosphorylation. Using both in vitro and in vivo models, suppression of FGFR4 was 
able to reverse TAF-induced migration and invasion of CRC cells. The concept that was 
proposed suggested that TAFs produce CCL2 which induces FGFR4 expression. FGFR4 
overexpression leads to phosphorylation of beta catenin which translocates to the nucleus 
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and initiates expression of SNAIL. This represses expression of E-cadherin, which leads to 
induction of EMT in CRC cells.  
 
In contrast to FGF19, the studies investigating FGF7 and FGFR2b expression in cancer have 
yielded conflicting results. Fibroblast growth factor 7 (FGF7), also known as keratinocyte 
growth factor, is produced by cells of mesenchymal origin (Finch et al., 1989; Rubin et al., 
1989) and acts on epithelial cells through its interaction with a specific isoform of the FGF 
receptor, FGFR2b (Miki et al., 1991). Generally, KGF is not expressed in epithelial cancer 
cell lines (Dahiya et al., 1996; Iida et al., 1994; Knerer et al., 1998) except in a few cell lines 
from pancreatic and breast cancer (Bansal et al., 1997; Siddiqi et al., 1995). In comparison, 
tumour tissue usually expresses KGF. However, there is disagreement across the literature 
with regards to whether KGF expression levels are higher (Siddiqi et al., 1995; Watanabe et 
al., 2000) or lower (Knerer et al., 1998) in tumour tissue compared with paired normal 
mucosa.  Despite these differences, studies where in situ hybridisation is used to locate cells 
expressing KGF have shown that it is usually expressed by stromal cells lying in close 
proximity to cancer cells. Hence, cancer cells probably induce KGF production which 
stimulates further epithelial cell proliferation.  
 
FGFR2b is expressed in cancer cell lines including those of the breast, colon, stomach, 
oesophagus, stomach, pancreas, prostate and oral mucosa. There is similar disagreement in 
the literature with regards to whether expression levels are higher or lower in cancer tissue. 
This is further complicated by the possibility of class switch. Reduced FGFR2b expression 
has been associated with increased FGFR2IIIc expression, which confers a more malignant 
phenotype and has been related to progression of prostate cancer and EMT in bladder cancer 
cells (Carstens et al., 1997; Chaffer et al., 2006; Oltean et al., 2006). Conversely, 
FGFR2IIIb and FGF7 have been shown to increase VEGF-A expression and are associated 
with a poor prognosis in pancreatic cancer (Cho et al., 2007).  Therefore, in certain 
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situations, FGFR2b actually helps to maintain differentiation, inhibit tumour growth and 
tumour invasion and in others, it promotes venous invasion and tumour angiogenesis leading 
to a more malignant form of cancer.  
 
1.9 Genetic profiling in CRC 
Genetic profiling refers to the process whereby a disease state is classified by a set of genetic 
lesions that are consistently found across individuals with similar clinical disease and 
tumour behaviour. It has the potential to identify patients with disease from healthy 
individuals but also sub classify individuals believed to have the same disease based upon 
pathological factors or response to treatment. As a consequence, it can be utilised to screen 
amongst asymptomatic individuals and identify those at most risk of cancer. It can also be 
translated to develop individual targeted molecular therapy where only agents known to act 
upon the specific molecular subtype of cancer are given the therapy. The molecular 
characteristics that are utilised to perform genetic profiling include differences at the -  
i) chromosomal level (karyotype) 
ii) nucleotide level (point mutations or variation of sequences) 
iii) nucleotide-modification level (epigenetic features). 
 
1.9.1. Techniques for genetic profiling  
Multiple techniques have been previously employed to perform genetic profiling. 
Conventionally, genetic analysis of patients with inherited syndromes with linkage analysis 
has been effective at elucidating the genetic alterations that occur in diseases such as CRC 
(Leppert et al., 1990; Lynch & de la Chapelle, 2003). This technique was effective at 
identifying mutations in APC as the causative agent for FAP predisposition and highlighted 
defective DNA mismatch repair genes in HNPCC.  
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Cytogenetics refers to ‘gross’ chromosomal analysis in which large deletions and initial gene 
mapping is performed. This includes techniques such as G-band analysis, fluorescence in 
situ hybridisation (FISH) and comparative genomic hybridisation (CGH). Based on the 
analysis of 17p and 18q loci respectively, this approach discovered p53 and DCC in CRC 
(Baker et al., 1989; Fearon et al., 1990; Jen et al., 1994). Cytogenetic evaluation has 
identified two distinct modes of genetic instability in CRC, namely the microsatellite 
instability pathway and chromosomal instability pathway (Lindblom, 2001).  
 
Classical molecular analysis relies upon identification of mutations in individual genes that 
then have to be associated with a specific disease state, have to satisfy the rules of causality 
(as expressed by Koch) and be attributed to some clinicopathological feature of the disease 
process such as diagnosis, prognosis or response to therapy. These techniques were effective 
at elucidating the molecular changes that underpin the adenoma –carcinoma sequence as 
described by Vogelstein (Vogelstein et al., 1988). The methods used to investigate multiple 
genes in this manner include serial analysis of gene expression, micro-array and polymerase 
chain reaction (PCR).  
 
1.9.2. Micro-array analysis 
Microarray technology has been utilised to investigate several aspects of CRC (Nannini et 
al., 2009). Studies have investigated the carcinogenesis process itself by evaluating the 
differences in gene expression between cancer tissue and control tissue. Genetic profiling 
using micro-array methods has also enabled identification of genes that indicate a better 
prognosis or can be utilised to determine if individuals will respond to chemotherapy agents.   
The identification of genes or pathways in this way can contribute to the development of 
biomarkers that detect disease, predict prognosis or determine outcome following treatment.  
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Previous investigators have demonstrated that it is possible to cluster individuals with 
cancer, polyps and control based on gene expression profile of often a small number of 
genes (Notterman et al., 2001; Kitahara et al., 2001; Grade et al., 2007). Furthermore, 
studies have clearly identified that there is considerable molecular heterogeneity within CRC 
patients that may explain the observed differences in prognosis and response to treatment 
that cannot be justified based on existing clinicopathological features (Groene et al., 2006; 
Perez-Villamil et al., 2012). Common processes that have been found to be dysregulated in 
CRC across the studies include cell adhesion, cell communication, cell cycle regulation, 
cellular and nuclei acid metabolism and cellular response to external stimuli. Although 
microarray methods have been successful in this manner, it is important to realise that there 
are some limitations to this approach.  
 
There is little agreement in the genes that are identified in different studies and often 
inconsistencies in the direction in which the change occurs. The authors of a recent review 
propose that this may be explained by the use of different sample collection techniques or 
different type of omics platform (Chan et al., 2008). There is no standardisation of 
microarrays with some investigators custom making their chip and others using a 
commercially available, though more expensive, chip. Similarly, there is no standardisation 
of analytical techniques that are used for subsequent data analysis leading to variation in the 
conclusions that are reached. Despite some of these shortcomings, microarray profiling has 
led to the development of multiple gene marker panels that identify individuals most likely 
to benefit from adjuvant therapy. Examples include Mammaprint (Agendia, Amsterdam, 
Netherlands) and Oncotype Dx (Genomic Health, Redwood City, California) (Slodkowska 
& Ross, 2009; Gray et al., 2011). 
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1.10. Field cancerisation 
Most of the studies that have been conducted in colorectal cancer have focused on 
describing the molecular changes found in cancer tissue itself and using these to develop 
potential biomarkers for disease detection. Some investigators have argued that if one is 
investigating early biomarkers of disease, the focus should be on the disease process rather 
than the disease itself (Dakubo et al., 2007; Rubin, 2011). Therefore, using molecular 
markers that are known to be mutated in CRC can lead to the identification of potential 
targets that represent late changes in the disease process. Field cancerisation offers a 
different approach to identify pathological changes that occur early on in the cancer process. 
It refers to the concept that the genetic and environmental factors linked with colorectal 
cancer inflict a diffuse field of injury that provides ‘fertile’ background upon which further 
genetic and epigenetic events give rise to cancer. Therefore, the initial genetic or 
environmental insult that preconditioned the colonic mucosa to cancer should not only be 
detectable at the primary tumour site but should also be found throughout the entire colon. 
These early changes do not give rise to a detectable difference in histological appearance of 
the cells and therefore this process has been described as (Dakubo et al., 2007) –  
"the process whereby cells in a particular tissue or organ are transformed, such that 
genetically altered but histologically normal appearing cells predate the development of 
neoplasia or coexist with malignant cells, irrespective of clonality". 
 
The concept of field cancerisation was first introduced by Slaughter in 1953 (SLAUGHTER 
et al., 1953) based upon a number of observations in head and neck squamous cell cancer –  
 
i) Development of cancer in multifocal areas of precancerous change 
ii) Abnormal tissue surrounds cancer 
iii) Persistence of abnormal tissue after surgery may explain the local recurrence of 
tumour at the same site 
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Since then, field cancerisation has been described in the colon as the ‘process whereby 
colonic epithelial cells acquire pro-tumourigenic mutations that are insufficient to cause 
morphological change but which predispose to tumour. It is the clonal expansion of these 
mutant cells that results in large ‘patches’ or fields of tissue that are primed to become 
neoplastic’ (Luo et al., 2014).  
 
The ability to detect the early changes characteristic of field cancerisation could enable risk 
stratification of both asymptomatic patients in the context of screening and aid development 
of more accurate post cancer surveillance programs. Furthermore, at present, 
chemoprevention trials investigating the use of pharmacotherapy in modulating a patient’s 
risk of cancer rely upon the use the incidence of adenoma as a surrogate marker of colorectal 
cancer. Consequently, a long period of follow up, often spanning many years, is required 
reflecting the length of time it can take to form an adenoma. If an early marker of colorectal 
cancer was identified, its use in such trials could considerably shorten the follow up period 
required to determine efficacy.  
 
1.10.1 Field defect in inflammatory bowel disease 
In a similar manner to sporadic CRC, IBD-associated CRC also follows a multistep process 
where inflamed, regenerative epithelium changes to hyperplastic epithelium, flat dysplasia 
and eventually invasive adenocarcinoma (Riddell et al., 1983). Current screening of these 
patients relies upon the identification of dysplastic lesions. Low-grade dysplasia is 
associated with a risk of CRC of around 20 %, which warrants further surveillance 
(Woolrich et al., 1992; Lennard-Jones et al., 1983; Levin et al., 1991). However, the 
presence of high-grade dysplasia is indicative of a higher probability of coexisting cancer 
and progression to carcinoma (around 60 %) which necessitates colectomy (Bernstein et al., 
1994; Connell et al., 1994). IBD associated neoplasia can therefore be used to risk stratify 
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patients and is indicative of colonic mucosa that had been preconditioned to form neoplasia. 
As such, the field cancerisation theory has also been described for IBD as  
 
‘the formation of a histologically indistinguishable area of clonally derived, mutant cells 
within the inflamed segment of intestinal tract in IBD’ (Graham et al., 2011). 
 
Molecular studies have found evidence to support a field defect in IBD. The same mutation 
spectrum in either, TP53 and KRAS is seen in entire neoplastic lesions as well as non-
dysplastic crypts, suggesting that these mutant clones are involved in priming the colon for 
cancer formation (Leedham et al., 2009; Graham et al., 2011). Further characterisation of 
this field defect is necessary to aid risk stratification of these patients. Nevertheless, it 
highlights that once dysplasia is identified in these patients, the entire colon is at risk of 
developing cancer and warrants surgical removal.  
 
1.10.2. Mechanism for field cancerisation  
Several different mechanisms for how field cancerisation occurs in colorectal cancer have 
been proposed (see figure 1.10. below). Based on the stem cell theory, a field defect may 
occur when a epimutation or mutation occur in stem cells giving it reproductive advantage 
so that it generates clonal descendants that outcompete neighbouring stem cells. These stem 
cells replace all the stem cells in the crypt and through crypt fission, a patch of mucosa 
containing several crypts with cells containing mutations is created. As further mutations 
develop, a second patch of altered crypts is created within the first patch (Bernstein et al., 
2013). Eventually, a cell is generated that is capable of invasion and malignant growth. 
Others have postulated that the widespread changes in methylation of genes found at distant 
sites along the colon in cancer patients are explained by dietary exposure to vitamin B and 
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folate which alter the methylation state of macroscopically normal mucosa (Luo et al., 
2014). In contrast, there have been antagonists of field cancerisation who argue that these 
changes occur in response to the tumour itself and do not predate malignant transformation 
(Kuniyasu et al., 2000).  
 
However, it has emerged that ‘more than 80 % of somatic mutations found in the mutator 
phenotype of colorectal cancer occur before the onset of clonal expansion’ (Tsao et al., 
2000) and may be indicative of an underlying field defect. Furthermore, synchronous 
cancers in the same individual have been shown to share similar epigenetic changes (Nosho 
et al., 2009) suggesting that they may arise from the same mutated clone. There are three 
theories that have been proposed to explain the common clonal origin of multiple primary 
tumours (Braakhuis et al., 2003) –  
i) Single cells or small clusters of cells migrate through the submucosa 
ii) Cells are shed in the lumen of an organ at one place and grow at another which 
has been used as a possible theory in oral cancer (Califano et al., 1999) or 
bladder cancer (Bedi et al., 1996). 
iii) There is a large contiguous genetically altered field in the epithelium in which 
multiple clonally related neoplastic lesions develop.  
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Figure 1.10. Schematic representation of proposed mechanisms for formation of field 
defect  
1(a): A mutation or epigenetic alteration in a stem cell (depicted in red) is inherited by all 
cells within the crypt through niche succession. Crypt fission results in several crypts 
becoming biologically altered creating a patch defect. Further mutation within this field of 
altered mucosa leads to malignant transformation.  
1(b): Tumour secretes chemical signals that alter the adjacent mucosa resulting in a field 
defect 
1(c): Malignant cells shed from a tumour travel in the bloodstream and seed in a distant site 
rendering the mucosa susceptible to malignant transformation 
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1.10.3. Field cancerisation in CRC 
There is emerging molecular evidence to suggest that genetic changes seen in cancer tissue 
can be detected in adjacent macroscopically normal appearing mucosa (MNM) of the colon 
(Shen 2005, Chai 2009, Facista 2012, us 2015) lending support to the field cancerisation 
theory. However, clarity regarding which cellular processes and genes are dysregulated in 
the adjacent MNM are lacking. Furthermore, although some of the early studies attempting 
to translate this concept into clinical practice are promising, the utility of field cancerisation 
in a clinical setting needs further evaluation.  
 
1.11. Summary  
Colorectal cancer prognosis remains poor as it is usually diagnosed at a late stage when 
patients present with symptoms. Despite considerable efforts to develop screening programs 
to detect disease at an early stage in asymptomatic individuals, current tests lack specificity, 
are invasive or poorly tolerated by the general population. There have been considerable 
advances in our understanding of colorectal cancer formation, however, there is a relative 
paucity of translation of these findings into the clinical arena. Some have criticised 
investigators on focussing on the tumour tissue itself which has already undergone 
malignant transformation and therefore harbours biological changes that occur relatively late 
in the cancer pathway. Instead, a different perspective is required where the early changes 
that occur prior to malignant transformation are identified. Field cancerisation offers such an 
approach as it eludes that the ‘normal’ mucosa adjacent to cancer contains early biological 
changes that contribute to cancer formation. Characterisation of this field ‘defect’ could thus 
enable better screening tests to be developed and would facilitate more accurate estimation 
of future neoplastic risk compared to existing modalities which rely upon detection of 
polyps. In addition, individuals deemed to be at high risk could undergo targeted 
pharmacotherapy, which would modulate their risk of colorectal cancer prior to the 
development of any histological abnormality in their colon.  
86 | P a g e  
 
1.12. Research hypothesis, aims and objectives. 
1.12.1. Research Hypothesis 
The present research hypothesis is-  
‘The macroscopically normal mucosa adjacent to polyps and cancers differs from that in 
control subjects therefore field cancerisation takes place in the colon.’ 
 
1.12.2. Research aims 
The research aims are –  
i) to determine if colorectal adenomas are reliable markers of field effect in the 
colon 
ii) to characterise the global gene expression profile of macroscopically normal 
mucosa (MNM) adjacent to cancer, adenomas and in control subjects 
iii) to investigate the role of fibroblast growth factors in field cancerisation and 
CRC formation 
 
1.12.3. Research objectives  
Although polyps are well established as a precursor lesion for CRC, evidence to support 
their role in identifying individuals with a field defect are lacking. Thus, the first chapter will 
investigate the utility of polyps as a biomarker of field cancerisation in CRC. The 
assumption being that CRC survivors that develop polyps in the remaining bowel after 
surgery are more likely to have a diffuse field of altered mucosa and therefore are at higher 
risk of both polyp and cancer recurrence. Similarly, those with synchronous polyps at time 
of diagnosis are also more likely to harbour a field defect and therefore would be expected to 
exhibit poorer survival.  
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In the next chapter, the global gene expression profile of the macroscopically normal 
mucosa around cancer or polyp will be compared to that found in control subjects using 
micro-array technology. The findings from this study will help to identify important genes 
that are dysregulated and this will then be validated in the subsequent chapter.  
 
In the final chapter, the role of fibroblast growth factor 7 and 19 will be investigated to 
determine the contribution of stromal elements to field cancerisation. As most of the studies 
investigating field cancerisation have focussed on changes occurring in the epithelial cells 
themselves, it will be important to evaluate how growth factors released by stromal cells 
precondition the mucosa to CRC formation.  
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Section 2: Subjects, 
Materials and Methods 
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2.1. Ethical approval 
This was part of a prospective NIHR observational cohort study (FaMISHED- Food and 
Fermentation using Metagenomics in Health and Disease designed to evaluate the role of 
biomarkers in gastrointestinal diseases, including colorectal cancer. Ethical approval was 
granted by Coventry and Warwick Local Research Ethics Committee (ref MREC ref no 
09/H1211/38) and University Hospital Coventry & Warwickshire Research & Development 
division. Funding was obtained from various sources including the Bowel Disease Research 
Foundation and the Colorectal Cancer Research Fund at University Hospitals of Coventry 
and Warwickshire NHS Trust 
 
All participants provided written informed consent in accordance with the Declaration of 
Helsinki.  
 
2.2. Setting and participants 
Subjects were either recruited at time of endoscopy (both screening and symptomatic) or at 
time of surgery. Written informed consent was gained.  
 
2.2.1. At endoscopy 
Mucosal pinch biopsies were taken from the caecum and rectum in all subjects. Participants 
who were diagnosed with polyps or a cancer also underwent biopsy of macroscopically 
normal mucosa (MNM) within 1 cm of the lesion. This was classified as MNM adjacent to 
polyp/cancer. Although biopsies were taken from cancer tissue itself, this was not possible 
for polyps therefore the values of gene expression given under the name ‘polyp’ refer to 
tissue adjacent to the polyp rather than the polyp tissue itself. Polyps that have been removed 
endoscopically require histopathological analysis to determine there are no cancerous 
elements, hence, it was not possible to use this tissue for research purposes.  
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2.2.2. At surgery 
The colectomy specimen was collected after bowel resection and taken to the pathology 
department. In conjunction with the histopathologist who would be examining the specimen, 
the specimen was opened and mucosal biopsies were taken from the areas outlined in figure 
2.2. The sample taken from the most distant margin to the tumour was utilised for analysis 
as the nearer margin may contain altered mucosa through a field defect. In a subset of 
patients, serial biopsies were taken at 3cm, 5 cm and 10 cm from the tumour edge. Patients 
who had undergone neoadjuvant chemoradiotherapy were excluded from the study as this 
has been shown to alter tumour biology and subsequent clinical outcome (Rödel et al., 
2005).  
Figure 2.2. Sampling sites. Photo of right hemicolectomy specimen showing site of 
sampling marked with crosses (white – tumour, blue – adjacent MNM, green- 3 cm distal to 
tumour, black – 5 cm distal to tumour and yellow – distal resection margin.  
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2.2.3. Sample processing 
Tissue samples were taken for three purposes; for RNA analysis, for protein analysis and for 
immunohistochemistry. Hence, each biopsy was divided into three parts and stored in RNA 
later (Fisher Scientific, UK), formalin or snap frozen using liquid nitrogen. All samples were 
stored at -80 oC for long term storage.  
 
2.2.4. Collection of blood samples 
Blood samples were taken at time of endoscopy or on the day of surgery. In a subset of 
patients, samples were collected after overnight fast on the morning of surgery/endoscopy 
for the measurement of FGF19 which has both a diurnal variation and responds to oral 
intake (Lundåsen et al., 2006; Reiche et al., 2010). Samples were collected in 
ethylenediaminetetraacetic acid (EDTA) tubes and thrombin based clot serum separator 
tubes (serum collection). Samples were spun at 25000 g for 15 mins and the supernatant was 
aliquoted for serum and plasma analysis. These samples were stored at -80 oC for long term 
storage. 
 
2.2.5. Study design 
For the purposes of gene expression analysis, patients with cancer were age and sex matched 
with control subjects. Cancer patients with right sided tumours or polyps (caecum to mid 
transverse) were matched to caecal samples taken from control subjects and patients with 
left sided tumours/polyps (distal to mid transverse) were matched with rectal samples from 
control subjects. This is because initial analysis revealed differences in the genes being 
measured in the right colon compared to the left colon. 
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2.3. Micro-array methods 
2.3.1 Participants 
Subjects (n=16) were recruited into the study from December 2010 to April 2011. Informed 
consent was obtained from all patients. Mucosal pinch biopsies were taken at time of 
endoscopy from macroscopically normal mucosa within 1 cm of polyp (n=6) or cancer 
(n=5).  In healthy controls (n=5), biopsies were taken from the caecum and rectum. 
Diagnosis was confirmed by histology and patients were divided into three groups: control, 
polyp and cancer. The clinico-pathological characteristics of these patients are given in table 
2.3.  All tissue specimens were taken and immediately placed in Qiazol prior to being frozen 
and stored at -80 deg C.  
 
Table 2.3: Demographic and clinical details of patients that were included in the microarray 
study. The reference numbers refer to each individual patient in the three groups. Patient 
(Adc-5) did not undergo surgical resection therefore there is no TNM staging available for 
this patient.  
 
Sample 
type 
Reference 
Number 
Gender Age Indication/clinical details Histology 
Control C1 M 82 Change in bowel habit Normal 
 C2 M 80 Acute diarrhoea Normal 
 C3 M 75 Change in bowel habit Normal 
 C4 F 67 Abdo pain, PR bleeding Not done 
 C5 F 83 Microcytic anaemia Not done 
Polyp Pol-1 F 60 4 mm sigmoid sessile TVA + LGD 
 Pol-2 M 79 3 mm sigmoid sessile TA + LGD 
 Pol-3 F 71 4 mm sigmoid sessile TVA + LGD 
 Pol-4 M 61 3 mm transverse sessile Hyperplastic 
 Pol-5 M 53 Small rectal polyp TA + LGD 
 Pol-6 F 77 5 mm splenic pedunculated TA + LGD 
Cancer Adc-1 M 53 Rectal T3N0M0 
 Adc-2 M 62 Rectal T2N0M0 
 Adc-3 M 66 Polyp cancer sigmoid T1 
 Adc-4 M 72 Hepatic flexure T3N0M0 
 Adc-5 F 81 Rectal Poorly diff cancer 
Abdo pain=abdominal pain, TVA – tubulovillous adenoma, TA – tubular adenoma, LGD – low grade dysplasia, Poorly diff = 
poorly differentiated cancer. TNM staging used for cancers.  
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2.3.2. Experimental design 
The SurePrint G3 Human Gene Expression 8x60K Gene Expression array was utilized. This 
consists of 62, 976 probes of which 42, 405 are unique. Agilent have developed an inkjet 
method which prints oligonucleotides onto the surface of a glass slide similar to a colour 
printer where the four ink colours are replaced with the nucleotides ATCG. Based on 
oligonucleotides of 60 bases in length, differences in gene expression between samples were 
assessed in a 2 channel micro-array experiment (see fig 2.3.). 
 
Figure 2.3. Two channel microarray experiment 
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2.3.3. Isolation, purification and quantification of RNA 
RNA was extracted from the mucosal biopsy tissue (approximately 0.2 mg) using Qiazol 
(Qiagen, UK) and total RNA was extracted using a spin column (RNeasy Mini Tissue Kit: 
Qiagen, UK) according to manufacturer’s instructions. Quantification was performed using a 
spectrophotometer (Nanodrop ND-1000, Labtech, UK) by measuring absorbance at 260 nm 
wavelength.  
 
2.3.4. Genechip micro-array assay method 
All experiments were performed in triplicate. Total RNA samples were quality checked on 
an Agilent Bioanalyser 1200 (Agilent Technologies Inc, Santa Clara, CA, USA) and only 
RNA Integrity numbers between 6.5 and 9.8 were selected.  The RNA concentrations were 
normalised to 100ng in 1.5µL and the Low Input QuickAmp Labelling Kit Protocol (Agilent 
Technologies) was followed according to manufacturer’s instructions. This uses a T7 RNA 
Polymerase to simultaneously amplify target material and incorporate cyanine 3 or cyanine 5 
labelled CTP. A universal RNA reference was labelled with Cyanine 5-CTP. The samples 
were labelled in randomised batches with Cyanine 3-CTP and yields and specific activities 
were tested to ensure they were in the recommended ranges.  The labelled cRNAs were 
hybridised to SurePrint G3 Human Gene Expression 8x60K Gene Expression arrays 
(AMADID 028004; Agilent Technologies) according to manufacturer’s instructions.  The 
arrays were washed in Gene Expression Wash Buffer 1 and Gene Expression Wash Buffer 2 
and immediately scanned in an Agilent GA2565CA scanner at 2µm resolution.  The data 
were extracted using Feature Extraction v10.7.3.1 with default settings appropriate to the 
array design. 
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2.3.5. Micro-array data analysis 
Bioinformatic software was used to convert the output images into data for further analysis. 
Data normalisation was performed both within array (Lowess) and between array 
(Aquantile) using the Agilent microarray scanner. Summarisation was performed as despite 
more than 62,000 probes, only 42, 405 probes were unique. The Bioconductor R package 
was used for statistical analysis. In the lmFit function, either ‘ls’ (LIMMA) or ‘robust’ (RR) 
were used for the two different types of data analysis to identify differentially expressed 
genes (DEGs). Previous studies have utilised a similar approach with multiple statistical 
methods to reduce the likelihood of false positives (Xu et al., 2013). For the functional 
analysis, genes found with either statistical method were used as a larger pool of genes 
would more likely represent the cellular processes that were dysregulated. Furthermore, two 
different types of analysis were undertaken (Figure 1). In the first analysis, functional 
analysis was performed using DAVID software (Huang et al., 2009a). Using DAVID 
software, the genes were classified into biological functional terms. The enrichment ratio of 
genes in each category was calculated as a means of determining how prevalent these genes 
were compared to the background levels of expression. An enrichment ratio of greater than 
1.33 was considered to be significant.  
 
In the second analysis, functional analysis was undertaken using PANTHER software (Mi et 
al., 2013). Three separate analyses were undertaken; cellular components, molecular 
function and biological process. A statistical overrepresentation test was performed using the 
DEGs in each category to identify biological processes that were overrepresented in the 
DEGs list compared to the background level of gene expression. A p value of <0.05 was 
considered significant.  
 
Although both methods compare DEGs with background levels of gene expression, the way 
in which the genes are clustered differs. The first analysis clusters genes according to 
biological process only whereas the second analysis used molecular function and cellular 
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component. This enhanced the understanding of which cellular compartments were affected 
along the adenoma-carcinoma sequence and enabled linkage of this to molecular/biological 
function.  
 
Figure 2.4: Analysis of micro-array data showing thresholds used for each statistical 
method and details of the functional analysis. FC is fold change difference between the 
groups being examined. 
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2.4. Gene expression 
2.4.1. RNA extraction and processing 
RNA was extracted from mucosal biopsy tissue stored in RNA later (approximately 0.2 mg). 
This was homogenised in 1 mL Qiazol (Qiagen, UK) and total RNA was extracted using a 
column based isolation method (RNeasy Mini Tissue Kit: Qiagen, UK) according to 
manufacturer’s instructions. This gave 30 µL of RNA. A DNase I Kit (Sigma) was utilised 
to remove possible genomic DNA. 3.5 µL (1000 U/mL) DNase I digestion enzyme and 3.5 
µL reaction buffer were added for 15 minutes at room temperature followed by 3.5 µL stop 
solution (50mM EDTA). The solution was centrifuged for 8 seconds and heated to 70oC for 
10 minutes then chilled on ice. Quantification was performed using a spectrophotometer 
(Nanodrop, Labtech) at absorbance of 260 nm using 1.5 µL sample in duplicates. The ratio 
between absorbance at 260/280 nm and at 260/230 nm were measured to determine RNA 
purity. RNA with a value between 1.8 and 2.1 was deemed appropriate for use.  
 
RNA integrity was also evaluated using agarose gel electrophoresis with ethidium bromide. 
A 1.5 % agarose gel was made by adding 1.5 g agarose to 150 mL 1x TAE (Tris base, acetic 
acid and EDTA). The agarose was dissolved by heating for 60 seconds in a 900-watt 
microwave. The solution was cooled before adding 4 µL 1 µg/ml ethidium bromide. After 
the gel had set, eight lanes with 2 µL RNA were loaded. 1x TAE was used as a buffer during 
the 60-minute electrophoresis at 100 V. The gel was viewed under UV light to show 
ethidium bromide incorporated DNA and images were taken (ChemiGenius). If there were 
two sharp distinct bands representing 18S and 28S, the RNA was considered to be of 
acceptable integrity for use.   
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2.4.2. Complimentary DNA (cDNA) synthesis 
cDNA was synthesised using a Bioline kit (#BIO-65026). Based on quantification as 
outlined above, 250 ng RNA per sample was used to make complimentary DNA (cDNA). 
The following were added to a 200 µL sterile micro centrifuge tube –  
 RNA (250 ng) 
 1 µL random hexamers 50-250 ng (Bioline, UK) 
 1 µL 10 mM dNTP mix (Invitrogen, UK). 
 RNase free water  
 to a total volume of 10 µL.  
 
Samples were vortexed, spun briefly and heated to 70 oC for 5 minutes and chilled on ice for 
2 minutes. Samples were mixed with 10 µL reverse transcription master mix (4µL of 5X 
reaction buffer, 1µL RNase inhibitor, 0.5 µL reverse transcriptase (200u/μL) made up to 
10µL by adding RNase free water) giving a total volume of 20 µL. Each sample was mixed 
thoroughly, briefly centrifuged and incubated at room temperature for 5 minutes. The 
samples were transferred to a thermocycler (Biorad, UK). This enabled the samples to be 
heated for 37 oC for 5 mins, 42 oC for 55 minutes and 70 oC for 15 minutes to make cDNA 
which was stored at -20 oC until use.  
 
2.4.3. Quantitative real-time Polymerase Chain Reaction (qRT-PCR).  
This was carried out using an ABI 7500 standard Sequence Detection System (Applied 
Biosystems, UK). Reactions were prepared to 25 µL volumes in a 96 well plate, each 
containing the following –  
 Taqman universal PCR mastermix 12.5 µL (Applied Biosystems, UK) 
 cDNA 1 µL 
 Commercially available TaqmanTM Gene Expression Assay (Applied Biosystems, 
UK). 
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Samples were processed in triplicate and a housekeeping gene 18 S (ribosomal RNA) was be 
used as an endogenous control in each reaction. Reactions were carried out at 50 oC for 2 
minutes, 95 oC for 10 minutes and then 40-44 cycles of 95 oC for 15 seconds, followed by 60 
oC for 1 minute. Pre-designed Taqman primers were used (Applied Biosystems, UK, FGF7 
(Hs00940253_m1); FGF19 (Hs00192780_m1); FGFR2 (Hs01552918_m1); FGFR4 
(Hs01106908_m1); CXCL2 (Hs00601975_m1), FUT2 (Hs00704693_s1), MUC2 
(Hs00894043_g1), MUC5AC (Hs00873651_mH), GADD45B (Hs00169587_m1), S100P 
(Hs00195584_m1), SLC46A1 (Hs00560565_m1) and PSCA (Hs04177224_g1). All 
reactions were multiplexed so that both the target gene primer and housekeeping gene 
primer were included in the same well. Each sample was processed in triplicate. A ΔCt value 
was determined for each well by subtracting the Ct value of the housekeeping gene from that 
of the target gene. The mean ΔCt was calculated for each sample by taking the average of the 
triplicates. All statistical analysis was performed using the inverse of the ΔCt which is a 
measure of level of gene expression. Relative fold change difference in gene expression was 
calculating by 2- ΔΔCt where ΔΔCt is ΔCt (control sample) subtracted from ΔCt (test sample, 
that is cancer or polyp).  
 
 
2.5. Protein expression  
2.5.1. Protein extraction 
Snap frozen colonic samples were homogenised and re-suspended in 1 mL of protein lysis 
buffer. The latter consisted of 5mL of 1x radioimmunoprecipitation (Tripathi et al.) 
(Millipore, UK) with 100µL of dissolved protease and phosphatase inhibitors (2 Roche 
Complete Mini protease inhibitor cocktail tablets with 8 mg sodium fluoride (Fisher 
Scientific) and 20 mg sodium vanadate (Acros Organics) in 2 mL 1x RIPA. Protein 
concentration was measured using Bio-Rad detergent compatible protein assay kit (Bio-Rad 
Laboratories, CA). A standard curve of absorbance against protein concentration was created 
using a series of known dilutions of bovine serum albumin (BSA, fraction V, Sigma, UK) (2 
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µg/µL) in the range 0 to 6 µg/µL.  The absorbance of both samples and standards was 
measured at a wavelength of 595 nm, using a spectrophotometer (Tecan, UK), allowing the 
protein concentration (µg/µL) of samples to be determined. 
 
2.5.2. Western blot analysis 
This was conducted in a manner similar to previously described (Alhusaini, et al., 2010).  
25 – 30 µg of protein was loaded onto a 7.5 – 10% polyacrylamide gel (Geneflow Ltd, 
Fradley, UK), under reducing conditions. Proteins were resolved by SDS-PAGE at 100V for 
60 – 90 minutes and then transferred to Immobilon-P transfer membranes 0.45 μm pore size 
(Fisher Scientific, UK). The membrane was blocked for 60 minutes in 0.2 % I-Block PBS-
tween (PBST) and was then incubated in primary rabbit-derived antibody diluted in 0.2 % I-
Block PBST (FRS2 1:1000, Abcam, UK; pFRS2 – 1:250; pErk 1:2000, Erk 1:2000, pAKT 
1:1000 and AKT 1: 1000; β-actin 1:70,000 (Cell Signalling, UK) at 4ºC overnight. Equal 
protein loading was determined by measuring β-actin expression. Membranes were washed 
three times for ten minutes in PBST and were then incubated in anti-rabbit IgG (whole 
molecule), horseradish peroxidase antibody produced in goat, IgG fraction of antiserum, 
buffered aqueous solution (Sigma #A9169). A chemiluminescent detection system 
ECL/ECL+ (GE Healthcare, UK) enabled visualization following exposure on hyperfilm MP 
(Fisher Scientific, UK). Intensity was determined using densitometry (GeneTool software, 
Syngene, UK) and expression values obtained were normalised against those of β-actin. 
 
 
2.6. Serum analysis 
Serum concentrations of FGF7 and FGF19 were measured using Quantikine ELISA FGF19 
kit (intra-assay CV – 3.6-6.4%) and inter-assay CV – 4.5-5.5%) (R&D systems, UK) and 
Quantikine ELISA FGF7 kit (intra-assay CV – 3-3.5% and inter-assay CV 5.2-7.7%) (R&D 
systems, UK) according to manufacturer’s instructions. A standard curve was created using 
serial dilutions of FGF19 standard or FGF7 standard (R&D systems, UK). 100 µL serum 
101 | P a g e  
 
was utilised in each reaction and the assay was performed in duplicates. The absorbance of 
samples and standards was measured at a wavelength of 570 nm, using a spectrophotometer 
(Tecan, UK) which enabled the concentration (pg/mL) of the samples to be determined by 
comparison with the standard curve.  
 
Serum concentration of CXCL2 was measured using the MIP2 (CXCL2) Human Simple 
Step ELISA kit (intra-assay CV – 2.8 % and inter-assay CV – 3.5 %) (Abcam, UK - 
ab184862). A standard curve was created using serial dilutions of CXCL2 in duplicates. 
Serum samples were diluted at a ratio of 1:16 and 50 µL diluted serum was utilised in each 
reaction. The assay was performed in duplicates and the absorbance was measured at a 
wavelength of 450 nm using a spectrophotometer (Tecan, UK). The serum CXCL2 
concentration was calculated based on the standard curve and dilution ratio.  
 
2.7. Statistical analysis 
Statistical analysis was undertaken using Microsoft Excel and IBM SPSS Statistics 21.0. 
Parametric data were expressed as mean ± SEM and comparisons between groups have been 
made using the unpaired two-tailed Student’s t test and within groups, using the paired 
sample t test. Non-parametric data have been described using median ± interquartile range. 
Multivariate logistic regression was utilised to determine which variables, including level of 
gene expression, were predictive of cancer in subjects. A multivariate linear regression 
model was utilised to determine patient and pathological factors that affect serum 
concentration of the proteins measured. A p value < 0.05 was considered as statistically 
significant and significance levels have been indicated as follows; *P<0.05, **P<0.01, ***P 
<0.001.  
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Chapter 3: Colonic polyps 
are biomarkers of field 
cancerisation in colorectal 
cancer 
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3.1 Introduction, aims and objectives 
3.1.1 Introduction 
A large body of epidemiological, post mortem, clinical and molecular evidence exists to 
support the notion that adenomas are the precursors to colorectal cancer (Muto et al., 1975; 
Stryker et al., 1987; Vogelstein et al., 1988; Winawer et al., 1993; Olsen et al., 1988).  A 
single adenoma develops into a cancer at a rate of approximately 0.25 % to 1 % per year 
(Eide, 1986; Otchy et al., 1996; Morson & Bussey, 1985; Wilson & Lightwood, 2001). The 
exact risk of progression into cancer varies with the number of polyps (Winawer et al., 1993; 
Atkin et al., 1992), size (Muto et al., 1975; Stryker et al., 1987; Eide, 1986), histology (Eide, 
1986; Yang et al., 1998), age and sex (Jensen et al., 1996; van Stolk et al., 1998; Noshirwani 
et al., 2000; Martínez et al., 2001). Strategies aimed at reducing the incidence of adenomas, 
such as screening colonoscopy, have successfully reduced colorectal cancer related mortality 
confirming that removal of adenomas is important in preventing CRC formation (Thiis-
Evensen et al., 1999; Mandel et al., 1999; Scholefield et al., 2002; Atkin et al., 2010; 
Jørgensen et al., 1993).  
 
The role of adenoma detection in CRC survivors is less well understood. Although, 
adenomas have been found to predict a higher rate of synchronous and metachronous cancer 
(Chu et al., 1986; Neugut et al., 1996), the rate of adenoma recurrence in these patients 
varies substantially between 8 % and 46 % across the literature (Khoury et al., 1996; 
Patchett et al., 1993; Barlow & Thompson, 1993; McFall et al., 2003; Kawai et al., 2012), 
depending upon the frequency of surveillance colonoscopy and mode of reporting outcomes. 
If patients who undergo resection for CRC continue to develop polyps in the remaining 
bowel, it suggests that they are at increased risk of developing a metachronous cancer. 
Furthermore, it suggests that the mucosa is preconditioned to develop neoplasia as described 
by the concept of field cancerisation. When field cancerisation was first described by 
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Slaughter (SLAUGHTER et al., 1953) , his theory was based on the observation that higher 
rates of recurrent head and neck squamous cell cancer occurred at the site of previous 
resection. Although there have been several reports investigating the factors that predispose 
to polyp recurrence and metachronous colorectal cancer (Kawai et al., 2012; Huang et al., 
2015; Gervaz et al., 2005; Chu et al., 2003), few have examined the link between the 
incidence of polyps and neoplastic risk, in terms of metachronous lesions and local 
recurrence. Previous reports have found that patients who develop polyps in the remaining 
bowel after CRC resection actually have an improved disease free survival (Kronborg et al., 
1986; Chu et al., 1986). The implications of this are twofold; firstly, polyps may not be an 
early marker of a field defect but represent areas of mucosa that have already become 
neoplastic. In other words, polyps are too far along the neoplastic process to represent field 
change. To clarify this further, studies need to investigate the macroscopically normal 
mucosa (MNM) around a polyp. If this mucosa contains aberrant cellular processes and 
signalling, it would suggest that polyps, like cancer, also develop in fields of altered mucosa. 
Secondly, these studies highlight that detection and removal of polyps is protective against 
cancer development and this may be the reason for the improved survival. The group of 
patients who do not develop polyps cannot benefit from endoscopic examination in the same 
way and may be developing recurrence through alternative CRC pathways such as the 
serrated polyposis pathway. Alternatively, patients with synchronous polyps are more likely 
to have DNA mismatch repair and undetected HNPCC which confers a survival benefit 
(Stigliano et al., 2008). In addition, there are a multitude of other factors that can have an 
effect on survival and these have not been accounted for in the earlier reports. More recent 
studies, however, have also demonstrated similar findings (Mattar et al., 2005). 
Nevertheless, there is a body of literature which links synchronous polyps at time of 
resection with a higher rate of metachronous polyps and cancers highlighting that polyps 
could be marker of a field effect.  
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3.1.2. Aims and objectives  
The objective of this study is to investigate if polyps or adenomas are an indicative marker 
of field cancerisation in CRC. If they represent mucosa at risk of malignant transformation, 
it would follow that presence of polyps or adenomas is associated with higher incidence of 
metachronous neoplastic lesions and local recurrence thus, poorer survival of these patients 
would be expected. 
  
The aim of this study is to investigate the impact of  
i) Synchronous adenomas (SA) (adenomas identified at preoperative colonoscopy) 
ii) Metachronous adenomas (MA) (adenomas identified on surveillance 
colonoscopy) 
on local recurrence, 5 year overall and disease free survival of patients with CRC. 
 
Patients undergoing colonoscopy where a polyp was found and either not removed or not 
retrieved were classified as having no adenomas. Only patients in whom the polyp was 
examined histologically and confirmed to contain adenomatous tissue were included in the 
SA or MA group. Patients with hyperplastic, metaplastic or inflammatory polyps were not 
included in the SA or MA groups.  
 
3.2 Materials and methods 
University Hospitals of Coventry and Warwickshire (UHCW) NHS Trust is a tertiary 
referral centre with a catchment population of half a million. Over the last 12 months, 270 
patients were diagnosed with CRC, of whom, 167 underwent major surgery. UHCW keeps a 
prospective database of all patients diagnosed with CRC whom are discussed at the 
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multidisciplinary team (MDT) meeting. This database was utilised to identify patients with 
CRC between 2006 and 2012. The following inclusion and exclusion criteria were applied –  
Inclusion criteria 
• Patients diagnosed with colorectal adenocarcinoma who have undergone 
surgical resection at UHCW between 2006 and 2012.  
• Any mode of presentation so that both screening and symptomatic patients were 
included. 
Exclusion criteria  
• Patients with stage IV disease at time of diagnosis or at time of resection 
• Patients with cancer confined to an adenoma 
• Patients who have not had a surgical resection  
• Patients that are known to have genetic predisposition to CRC 
• Patients with inflammatory bowel disease 
Hospital electronic records were scrutinised to obtain data on patient demographics, 
operative details, pathological findings, endoscopic observations and survival.  
The local Trust policy regarding follow up of CRC patients involves yearly clinic review 
with routine blood tests including an annual serum carcinoembryogenic antigen (CEA). All 
patients undergo inspection of their anastomosis within one year of surgery with either a 
flexible sigmoidoscopy or colonoscopy depending upon site of surgery. A further 
colonoscopy is performed at 5 years unless there are positive findings in the first 
investigation.  These patients undergo interval colonoscopies as per the polyp surveillance 
guidelines. A CT scan is performed at 3 years and 5 years after surgery. Patients are usually 
discharged after 5 years if they remain disease-free.  
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3.2.1. Data analysis  
Synchronous polyps were defined as either polyps found at index colonoscopy or polyps 
found in the resection specimen by the pathologist. The findings of the pre-operative 
investigation were combined with the pathological details and the cumulative rate of 
synchronous polyps (SP) with polyp and adenoma characteristics have been presented. Any 
polyps that were discovered on subsequent colonoscopy after surgery were classified as 
metachronous polyps (MPs). Short term (0-24 months) and mid-term outcomes (0-60 
months) were calculated based on cumulative colonoscopy findings over this period of time.  
Overall survival (OS) was calculated from the date of surgery to the date when the patient 
was last seen alive in the hospital. Disease free survival (DFS) was calculated between the 
date of surgery and the date when the patient was last seen without disease recurrence in the 
oncology or surgical clinic. In patients with local recurrence or metastasis, the date when 
this was diagnosed on imaging was utilised to calculate disease free survival.  
Local recurrence was defined as either soft tissue growth at the anatomical site of previous 
resection on CT or PET-CT or intraluminal recurrence at the anastomotic site on endoscopy. 
Metastasis was defined as the presence of either of the following –  
i) Peritoneal metastases 
ii) Lymphatic metastases resulting in a nodal mass 
iii) Distant organ spread to either liver, lung, bone or other intra-abdominal organ  
 
3.2.2. Statistical data analysis 
Differences in clinical variables amongst the different groups were tested with chi-squared 
test. A multivariate logistic regression model was built to determine which factors affect 
incidence of metachronous polyps/adenomas and local recurrence in CRC survivors. 
Differences in survival outcome were tested using the log rank test. A multivariate Cox 
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regression model was designed to evaluate how different clinical variables affect overall and 
disease free survival.  
 
3.3 Results 
Over the study period, 2101 patients were identified from the MDT database. Patients 
(n=981) were excluded based on criteria shown in figure 3.1. Hence, 1120 patients were 
identified for potential inclusion. After further investigation using electronic records, 393 
patients were found not to meet the inclusion criteria. Patients who did not have complete 
colonic examination prior to surgery were excluded, hence, 562 patients were included in the 
final analysis. The demographic, operative and pathological details of these patients are 
outlined in table 3.1.  
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Figure 3.1. Flow chart showing how patients were selected from the MDT database. 
Number of patients identified (2006-2012) 
N=2101 
 
 
1273 patients 
 
    
1120 patients identified for potential inclusion 
 
 
 
 
 
 
 
727 patients met inclusion criteria 
 
 
 
562 patients included 
 
 
 
 
Not recorded as cancer (n=155) 
No surgery (n=673) 
Metastases at diagnosis (n=153) 
Other cancers (n=72) 
Non resectional operative procedure 
(n=79) 
TEMS/TART (n=9) 
Metastases at surgery (n=34) 
Metastases in resection specimen 
(n=18) 
Polyp cancers (n=27) 
Primary treatment at a different 
hospital (n=48) 
Post-operative deaths (n=47) 
IBD cancers (n=12) 
Duplicate records (n=47) 
Incomplete colonoscopy (n=6) 
Flexible sigmoidoscopy (n=36) 
No preoperative tests (n=123) 
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Table 3.1. Clinical, Operative and Pathological details of patients who met the inclusion 
criteria (n=562).  
Clinical details Operative details 
Median age 
(IQR) 
Male: Female  
(Right sided tumour) 
(Left sided tumour) 
 
69 yrs. 
(62-77yrs) 
323:239 
105:131 
218:108 
Mode of surgery 
Elective 
Emergency 
Scheduled 
Urgent 
 
335 
9 
173 
45 
Status of referral 
Screening 
2-week wait 
Urgent 
Routine 
Emergency  
Other 
 
81 
303 
202 
87 
36 
19 
 
 
Operative Procedure 
Anterior Resection 
Extended Right Hemicolectomy 
Left Hemicolectomy 
Hartmann’s Procedure 
Right Hemicolectomy 
Sigmoid colectomy 
Transverse colectomy 
Subtotal colectomy 
Panproctocolectomy 
Laparotomy 
Combined procedure 
 
188 
20 
32 
29 
212 
20 
2 
9 
2 
2 
3 
 
 
 
Pathological details 
T-stage 
pTx 
pT0 
pT1 
pT2 
pT3 
pT4 
 
5 
4 
22 
83 
355 
91 
N-stage  
pNx 
pN0 
pN1 
pN2 
 
Median LN yield 
(IQR)  
 
1 
377 
120 
64 
 
19 
(13-26) 
Mucinous 
Non-mucinous 
Small focus 
<50 % mucinous 
>50 % mucinous 
Missing  
 
456 
17 
38 
49 
1 
Extramural vascular invasion 
Absent 
Present 
Missing 
 
415 
145 
2 
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3.3.1. Characteristics of patients with synchronous polyps at presentation  
Patients who had undergone complete colonic investigation with either a pre-operative 
colonoscopy (n=532), CT pneumocolon (n=14) and barium enema (n=16) were included for 
further analysis (see figure 3.2). Based on these preoperative investigations, 181 patients had 
polyps. In the remaining 381 patients, there were 66 patients who had polyps found in the 
resection specimen that were not identified at initial investigation. Thus, 247 patients had 
synchronous polyps (SP) at time of diagnosis, of which, 197 had adenomas. Male gender 
and older age was significantly associated with presence of SAs (p<0.001 and p=0.020 
respectively) (see table 3.2. below). There were no significant differences in other clinical 
and pathological parameters recorded.  
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Figure 3.2. Flow chart of patients included in analysis. SP-synchronous polyps, SA- 
synchronous adenoma, MP- metachronous polyp, MA – metachronous adenoma 
 
 
Colonoscopy – n=532 
CT pneumocolon – n=14 
Barium enema – n=16 
 
 
SP on preoperative investigations (n=181) 
SP on histological examination (n=66) 
 
 
247 SP patients   315 non-SP patients 
197 patients with SA     365 patients with no SAs  
 
 
44 patients with MPs    46 patients with MPs 
29 patients with MAs     24 patients with MAs 
 
 
50 patients with MPs      66 patients with MPs 
31/119 patients with MAs     39/248 patients with MAs 
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Table 3.2. Clinical, operative and pathological details of SA and non-SA patients. 
 SA patients 
(n=197) 
Non-SA 
patients 
(n=365) 
P value Odds ratio  
Age 
<60 years 
>60 years  
 
29 
168 
 
81 
284 
 
0.020* 
 
0.605  
M:F 139:58 184:181 <0.001*** 2.35 (Male) 
Right sided 
tumour 
87/197 149/365 0.249 0.872 
Mode of 
operation 
Elective 
Emergency 
Scheduled 
Urgent 
 
118 
0 
61 
18 
 
217 
9 
112 
27 
 
0.148 
 
T-stage 
pT0 
pT1 
pT2 
pT3 
pT4 
 
 
5 
7 
31 
130 
24 
 
5 
15 
52 
226 
67 
 
0.328 
 
N-stage 
pN0 
pN1 
pN2 
 
135 
40 
22 
 
243 
80 
42 
 
0.886 
 
Mucinous content 
None 
Focus 
<50 % 
>50% 
 
166 
2 
13 
16 
 
290 
15 
25 
33 
 
0.279 
 
Metachronous 
polyps 
0-24 months FU 
0-60 months FU 
 
 
44/105 
50/118 
 
 
46/196 
66/248 
 
 
0.001*** 
0.002** 
 
 
 
Metachronous 
adenomas 
0-24 months FU 
0-60 months FU 
 
 
29/105 
31/118 
 
 
24/196 
39/248 
 
 
0.001*** 
0.014* 
 
 
2.74 
1.91 
Local recurrence 
Present 
 
3/193 
 
26/361 
 
0.002** 
 
4.96 
Overall survival 
(months) 
Mean 
 
 
121 
 
 
92 
 
 
0.442 
 
Disease –free 
survival 
(months) 
Mean 
 
 
 
79 
 
 
 
89 
 
 
 
0.530 
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3.3.2. Presence of synchronous adenomas indicates future risk of metachronous 
adenomas 
By 24 months, 301 patients underwent colonoscopy, of whom, 53 (18%) were found to have 
metachronous adenomas (MAs).  An additional 83 patients had incomplete examination with 
a flexible sigmoidoscopy to inspect the anastomosis rather than for investigation of 
metachronous lesions.  The remainder did not undergo any endoscopic examination in this 
period of time. SA patients were more likely to develop MAs than those without (28 % 
versus 12 % respectively, Odds ratio 2.74, p=0.001).  
 
In the first 5 years after surgery, 70/366 (19 %) patients who underwent colonic examination 
had developed MA. SA patients were more likely to develop MA than non-SA patients (26 
% versus 16 % respectively, Odds ratio 1.91, p=0.014).  
 
In a multivariate logistic regression model, the only independent predictor of MA by 24 
months was SA at presentation (see table 3.3.). In comparison, male gender and right sided 
tumours were independent predictors of risk of developing MA over 60 months (see table 
3.4.). Presence of SA at diagnosis was not an independent predictor of future MA in at 
longer term follow-up. Gender, site of tumour and SA incidence were collinear which may 
explain this result. Men were more likely to have SAs (Odds ratio 2.35) and made up a 
larger proportion of patients with left sided tumours (M: F (right sided tumours): 72:73 
versus M: F (left sided tumours): 153:69, p<0.001).  
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Table 3.3.1 Univariate and multivariate factors that predict the development of MAs in CRC 
patients 0-24 months after surgery (n=301)     
                                                            
Variable MA present Univariate p 
value 
Odds ratio 95 % CI Multivariate 
p value 
Age <60 yrs-
13/74 
>60 yrs-
40/227 
0.573 0.830 0.399-1.728 0.619 
 
Sex 39/189 M 
14/112 F 
0.049 0.552 0.272-1.126 0.102 
Site of 
tumour 
29/131 R 
24/170 L 
0.049 0.566 0.294-1.092 0.090 
Mucinous 
content 
39/251 none 
14/50 present 
0.032 2.132 0.995-4.567 0.052 
Synchronous 
adenoma 
24/196 none 
29/105 
present 
0.001 2.735 1.494-5.005 0.003** 
 
Table 3.4. Univariate and multivariate factors that predict the development of MAs in CRC 
patients 0-60 months after surgery (n=366)    
 
Variable MA present Univariate p 
value 
Odds ratio 95 % CI Multivariate 
p value 
Age <60 yrs-
17/94 
>60 yrs-
53/272 
0.448 0.952 0.505-1.794 0.879 
 
Sex 53/224 M 
17/142 F 
0.004 0.400 0.213-0.752 0.004** 
Site of 
tumour 
36/144 R 
34/222 L 
0.016 0.469 0.266-0.829 0.009** 
Mucinous 
content 
56/306 none 
14/60 present 
0.230 1.266 0.626-2.560 0.512 
Synchronous 
adenoma 
39/248 none 
31/118 
present 
0.018 1.910 1.120-3.257 0.104 
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3.3.3. Local recurrence is not affected by presence of adenomas 
On univariate analysis, SA patients were significantly less likely to develop local recurrence 
than non-SA patients (3/193 (1.5%) versus 26/361 (7.2%), p=0.004). However, with 
multivariate logistic regression (see table 3.5), the independent predictors of local recurrence 
included presence of an involved margin after surgery and extramural vascular invasion; the 
presence of synchronous or metachronous adenomas did not affect the incidence of local 
recurrence. There were 38 patients with an involved margin, of whom, 9 patients had a local 
recurrence. If these 9 patients with involved margins were excluded from analysis, SA 
patients had a significantly lower local recurrence rate compared to non-SA patients (2/188 
(1%) versus 18/314 (5 %), p=0.008). In contrast, patients who developed MAs over 5 years 
were more likely to develop recurrence of their cancer compared to those that did not (3/68 
(4.4%) versus 7/279 (2.5%), p=0.309), however, this result did not reach statistical 
significance.  
 
Table 3.5. Univariate and multivariate factors that predict development of local recurrence 
at site of previous resection 
 
Variable Local 
recurrence 
Univariate p 
value 
Odds ratio 95 % CI Multivariate 
p value 
Age <60 yrs- 8/110 
>60yrs 21/452 
0.187 1.878 0.708-4.983 0.205 
Sex 14/323 M 
15/239 F 
0.201 0.977 0.426-2.244 0.957 
T-stage 1/121 T0-T2 
51/605 T3-T4 
0.001 0.252 0.032-1.974 0.189 
N-stage 13/378 N0 
16/168 N1-N2 
0.009 0.762 0.316-1.840 0.546 
Mucinous 20/455 none 
9/107 present 
0.496 0.496 0.193-1.275 0.145 
EMVI 13/415 absent 
15/128 
present 
0.001 0.383 0.155-0.944 0.037* 
Involved 
margin 
9/38 involved 
20/520 not 
<0.001 0.146 0.055-0.383 <0.001** 
Synchronous 
adenoma 
3/197 present 
26/365 absent 
0.002 3.366 0.951-
11.919 
0.060 
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3.3.4. Overall and disease free survival do not differ with adenomas 
After correction for age, sex and pathological T stage, there were no differences observed in 
overall (OS) or disease free survival (DFS) between SA patients and non-SA patients 
(Hazards Ratio 0.926, p=0.687 and Hazards ratio 2.367, p=0.460 respectively). Patients with 
right sided tumours who presented with SAs were likely to survive longer than non-SA 
patients (mean OS 118 months versus 90 months, p=0.587), however, this was non-
significant. In comparison, there was no difference in OS in patients with left sided tumours 
with and without SAs (91 months versus 93 months, p=0.597). Patients who developed MAs 
over the 5-year period after surgery had similar OS compared to those that did not (OS 99 
months versus 102 months, p=0.504).  
 
 
 
Figure 3.3. Kaplan-Meier survival analysis demonstrating overall survival (in months) in 
patients with SAs and non-SAs. 
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Figure 3.4. Kaplan-Meier survival analysis demonstrating disease free survival (in months) 
in patients with SAs and non-SAs. 
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3.4. Discussion 
This study has highlighted that SAs are predictive for development of subsequent 
metachronous lesions in patients who are undergoing surgery for colorectal cancer. 
However, this does not appear to be related to increased risk of local recurrence nor is there 
any difference in overall survival or disease free survival in patients who develop adenomas 
compared to those that do not. This suggests that despite being pre-neoplastic, adenomas are 
not a reliable marker of field cancerisation. Although they indicate which patients will 
develop metachronous adenomas, they do not help to identify which patients will develop 
local recurrence. Based on Slaughter’s field cancerisation concept (SLAUGHTER et al., 
1953), recurrence of cancer occurs in a field of altered mucosa. If adenomas are a marker of 
field cancerisation, one would expect that they would be positively associated with the 
development of local recurrence. In fact, in this study, univariate analysis has demonstrated 
that patients with synchronous adenomas (SAs) were less likely to develop local recurrence 
(LR). However, when multivariate analysis was performed, the only independent predictors 
of local recurrence were an involved margin after surgery or extramural vascular invasion. 
Patients with SAs were less likely to have an involved margin and this confounded the 
relationship seen between SAs and LR.  In order to counteract this, patients with an involved 
margin were excluded from the analysis. SA patients were still significantly less likely to 
develop local recurrence suggesting that other factors besides the presence of an involved 
margin were responsible for this association. There are two possible explanations for this 
observation: either adenomas are not a reliable indicative marker of field cancerisation or 
field cancerisation does not predispose to local recurrence and may be responsible for 
metachronous neoplastic lesions. Although the differences in survival were non-significant, 
patients with right sided tumours and SAs had a longer OS. In comparison, patients with left 
sided tumours did not exhibit such differences. Presence of SAs or subsequent development 
of MAs did not impact upon OS and DFS in patients with CRC which contradicts previous 
reports (Kronborg et al., 1986; Chu et al., 1986; Mattar et al., 2005).   
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The incidence of metachronous adenoma seen in this study (19%) is comparable to other 
reports which quote rates varying between 8 % and 46 % (Khoury et al., 1996; Barlow & 
Thompson, 1993; McFall et al., 2003; Kawai et al., 2012). There is considerable variation in 
the literature because of differences in the surveillance protocols used. Despite the 
publication of several meta-analyses (Rex et al., 2006; Desch et al., 2005; Jeffery et al., 
2007), there is no universally agreed consensus on how CRC patients should be followed up 
(Scheer & Auer, 2009). Furthermore, there is variation introduced on an individual basis as 
invasive tests such as colonoscopy are not offered to frail elderly or medically unfit patients. 
This is reflected in the large proportion of patients that never underwent further endoscopic 
examination after curative resection in the present study. Despite these shortcomings, this 
study has highlighted that synchronous adenomas are more likely to develop in men and 
older patients. Others have reported similar findings with obesity (Scarpa et al., 2014), male 
gender (Mulder et al., 2011), mucinous cancer (Piñol et al., 2004), proximal tumours (Chen 
& Sheen-Chen, 2000; Gervaz et al., 2005) and stage II disease (Piñol et al., 2004) being 
significantly associated with synchronous lesions. Detection of SAs is important as it 
enables identification of patients who are likely to develop metachronous lesions and 
therefore helps to inform surveillance schedules. In a recent study addressing factors that are 
predictive of MAs (Kawai et al., 2015), the only independent predictors identified were age 
and presence of SAs at diagnosis; male gender was initially found to be predictive, however, 
on multivariate analysis, there was no strong relationship. Similarly, in the present study, the 
only predictive marker of MAs at short term follow up (0-24 months), was presence of SAs 
at diagnosis. Others have also reported similar findings (Rajaratnam & Dennett, 2009; 
Neugut et al., 1996). Over a longer period of follow up, male gender and right sided tumours 
were independent predictors of subsequent development of MA. SAs in patients with right 
sided tumours were related to a higher incidence of MA. For left sided tumours, presence of 
SAs at diagnosis did not predict future risk of MA. Others have also reported that a proximal 
location is associated with MA and MC in CRC (Gervaz et al., 2005), however, recent 
reports have suggested that patients with distal tumours are more likely to develop MAs 
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(Borda et al., 2012). Previously, the link between SAs and subsequent development of MAs 
was attributed to underlying undiagnosed HNPCC which is associated with multiple lesions 
(Dykes et al., 2003; Bae et al., 2012; Nosho et al., 2009; Pedroni et al., 1999). However, 
there have also been reports to suggest that risk of MAs is not linked to microsatellite 
instability (MSI) (Ballesté et al., 2007) nor is the incidence of MA in patients with various 
degrees of MSI different (Kang et al., 2010).  Hence, the observed higher incidence of MAs 
in patients with right sided tumours may reflect other differences in tumour biology 
compared to distal tumours.  
 
No SA characteristics were found to be predictive of MA patients in this study. A recent 
report suggested that synchronous tubular adenomas were not predictive of MAs and only 
advanced SAs (more than 1 cm, villous architecture or high grade dysplasia) were associated 
with increased risk of finding MAs (Moon et al., 2010). Others have also shown that a single 
nonadvanced adenoma has a very low risk of forming an advanced adenoma at follow up 
(McFall et al., 2003). However, in this study, presence of any adenoma was associated with 
increased risk of developing subsequent adenomas suggesting that it is the presence of 
adenomas that is important rather than its appearance. 
 
Previous reports have linked presence of SAs with increased incidence of MCs and proposed 
that they can be utilised to identify patients at higher risk of malignant transformation 
(Ballesté et al., 2007; Gervaz et al., 2005). However, incidence of metachronous lesions has 
included both anastomotic recurrence and new cancers in a single category. In this study, no 
relationship was observed between incidence of local recurrence and SAs after multivariate 
analysis which contradicts these earlier reports. It appears that incomplete resection was 
more important in predicting local recurrence than the presence of polyps at a distant site.  
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There were also no differences in overall and disease free survival between the SA patients 
and the non-SA patients. As previously alluded to, there may be little survival benefit in 
removing synchronous and metachronous lesions in the elderly population who undergo 
CRC resection (McFall et al., 2003). Several large scale studies have failed to demonstrate a 
survival benefit with removal of polys in CRC survivors. Also, a recent report has proposed 
that patients with synchronous cancer have worse disease free survival if the primary tumour 
is microsatellite stable (MSS). The presence of synchronous lesions in patients with MSI did 
not affect outcome (Malesci et al., 2014). This implies that adenomas could be a marker of 
neoplastic risk in MSS patients but not in MSI patients. In MSI patients, development of 
adenomas could be a consequence of widespread epigenetic change in the colon rather than 
indicating risk of malignant transformation. It is not possible to confirm nor refute such 
reports based on the findings of the present study as microsatellite stability was not 
examined in all cases. This is one of the limitations of this study. Furthermore, given the 
time taken for a polyp to become cancerous (Eide, 1986; Otchy et al., 1996; Morson & 
Bussey, 1985; Wilson & Lightwood, 2001), a longitudinal study with longer follow up 
would be required to assess the impact of removing MAs in CRC survivors.  
 
The other limitation of this study is that it is retrospective with some missing data that could 
not be retrieved. However, this was less than one per cent and given the number of patients 
included is unlikely to have significantly changed the findings. Those patients undergoing 
CRC resection included in the study have considerable variation in follow up with a large 
proportion never undergoing any endoscopic examination. This could have influenced the 
outcome as patients who underwent colonoscopy and had polyps were more likely to 
undergo further colonoscopy which would increase the number of MAs detected in this 
group. However, the proportion of patients undergoing colonoscopy at 24 months is equal in 
both SA and non-SA groups (around 55 %) and a larger proportion of patients in the non-SA 
group compared to the SA group underwent colonoscopy by 60 months (42% versus 31%). 
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Furthermore, it was not the number of MAs that was utilised in the analysis but rather the 
incidence of MA which is a binary outcome. Thus, it is unlikely that the results could have 
been influenced by the number of procedures.  
 
3.5 Summary and conclusions 
 SA patients were at increased risk of developing MAs after colorectal cancer 
resection at short term (24 months) and long term (60 months) follow up. 
 SA patients were significantly less likely to develop local recurrence, however, the 
only independent predictive markers of local recurrence were an involved margin 
after surgery and extramural vascular involvement 
 No differences in overall or disease free survival were observed in patients who 
develop adenomas compared to those that do not, including presence of SAs or 
MAs.  
 Collectively, the data suggest that adenomas are poor markers of field cancerisation 
and highlight the need for further investigation to identify more reliable biomarkers 
indicative of neoplastic risk.  
 Adenomas are currently used as a surrogate endpoint for CRC chemoprevention 
trials and due to the length of time it takes to develop adenomas, long periods of 
follow up are required in these trials to determine therapeutic benefit. 
 A biomarker based on the field cancerisation concept could enable earlier diagnosis 
and would be more effective as a surrogate marker of colonic mucosa at neoplastic 
risk in chemoprevention trials. 
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Chapter 4: 
Characterisation of the 
gene expression profile of 
the mucosal field around 
colorectal cancer and 
polyps 
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4.1. Introduction 
Advances in molecular medicine have elucidated several different molecular phenotypes of 
colorectal cancer (CRC) (Jass, 2007; Grady & Carethers, 2008; Sinicrope et al., 2015). CRC 
is a complex disease characterised by dysregulation of multiple signalling pathways 
(Sinicrope & Sargent, 2012; Phipps et al., 2015). Epigenetic modification further 
complicates the disease process but has been recognized as an important mode of silencing 
the many genes that protect against carcinogenesis (Ogino et al., 2009). Identification of the 
genetic changes that occur in the tumour tissue has enabled development of targeted 
molecular therapy (De Roock et al., 2010; Lièvre et al., 2008; Peeters et al., 2013; 
Benvenuti et al., 2007). However, CRC prognosis remains poor unless patients are 
diagnosed at an early stage (NCIN). Current screening modalities that are utilised lack 
specificity and often lead to invasive tests being performed in individuals who do not have 
cancer (Burch et al., 2007; Logan et al., 2012). Screening tests that are able to identify early 
molecular changes indicative of CRC are therefore needed to enable more accurate diagnosis 
and prevent unnecessary morbidity. The field cancerisation concept proposes that there are 
genetic changes in the macroscopically normal colonic mucosa (MNM) around a cancer 
(SLAUGHTER et al., 1953).  This renders it premalignant but does not produce 
morphological changes (Luo et al., 2014). Characterisation of these gene expression changes 
could enable identification of the processes that are dysregulated in the early stages of CRC 
formation with clear clinical implications. 
 
4.1.1. Gene expression profiling in CRC 
Previous studies have investigated the global expression profile of cancerous and non-
cancerous tissues comparing tumour tissue with paired normal mucosa (Lin et al., 2002; 
Croner et al., 2005; Kitahara et al., 2001; Bertucci et al., 2004; Birkenkamp-Demtroder et 
al., 2005). The assumption being that the paired ‘normal’ mucosa is in fact not biologically 
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altered. Based on the field cancerisation concept, many authors have shown that the ‘normal’ 
mucosa in cancer patients is biologically altered and this phenomenon is observed at 
considerable distances from the tumour itself (Shen et al., 2005; Polley et al., 2006; Anti et 
al., 2001). Previous studies have failed to identify changes that occur early in CRC 
formation as the comparison is being made between MNM and tumour taken from the same 
patient. If the MNM is altered in these individuals, only genetic changes that take place later 
in the carcinogenesis pathway will be identified; the early genetic changes that take place 
will be found in both the MNM and tumour and therefore will cancel each other out.   
 
Others have adopted a different approach by taking colonic tissue from healthy individuals 
as a control and have successfully demonstrated genetic dysregulation in a number of 
cellular processes (Grade et al., 2007; Bianchini et al., 2006; Alon et al., 1999; Notterman et 
al., 2001). However, it is difficult to ascertain where along the adenoma-carcinoma sequence 
these abnormalities lie. This has been addressed in studies where the gene expression profile 
of adenomas has also been characterised (Notterman et al., 2001; Lin et al., 2002; Lechner et 
al., 2003). In many of these studies, similar genetic changes have been noted in adenomas 
and tumours compared to healthy colonic mucosa. The level of expression of these genes 
often lies in between that found in cancer and that in control subjects (Habermann et al., 
2007; Buckhaults et al., 2001; Galamb et al., 2006; Wang et al., 2005) lending support to the 
adenoma-carcinoma sequence. However, it has been difficult to translate the findings from 
these studies into molecular screening tests. The reason for this is that many adenomas do 
not progress to CRC and some CRCs arise without a recognizable polyp stage. Additional 
information regarding the molecular biology of adenomas is required if they are to be 
utilised for screening. This could come from examination of the MNM as patients with a 
field defect are at higher risk of malignant transformation therefore instead of identifying 
polyps, the molecular makeup of the MNM around polyps and cancer should be examined. 
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This would enable better screening tests to be developed and assist in more accurate risk 
stratification of patients who have already developed polyps or cancer.  
 
Micro-array technology offers the opportunity to examine gene expression profiles in a 
candidate-free approach and has the added benefit of being able to understand network 
pathways through multiple gene analysis. One of the most successful genetic profiling 
studies in CRC has been the discovery of an 18 gene signature that can be used to identify 
patients with a poor prognostic CRC who require adjuvant chemotherapy (Salazar et al., 
2011). This suggests that gene expression profiling can be readily translated into the clinical 
arena and may help elucidate how CRC can behave differently in different individuals. 
Similarly, based on the field cancerisation concept, gene expression profiling could be 
utilized to identify how the MNM around a cancer or a polyp is biologically altered.  This 
would aid our understanding of CRC pathogenesis and could enable more accurate screening 
tools and targeted chemo preventative therapy to be developed. 
 
4.1.2. Aims and objectives 
The aims of this study were as follows –  
i) To investigate field cancerisation in CRC by characterising the key cellular 
processes and genes that are dysregulated in the MNM around cancer and polyp 
compared to that found in control subjects  
ii) To identify individual genes that may contribute to field cancerisation for further 
investigation 
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4.2. Methods 
Subjects (n=16) were recruited and mucosal pinch biopsies were taken at time of endoscopy. 
Biopsies taken from the adjacent macroscopically normal mucosa (MNM) to tumour (n=5) 
and polyp (n=6) were compared with biopsies of MNM in the caecum or rectum from 
control subjects (n=5). A two channel micro-array experiment was performed as outlined in 
section 2.3.  
 
Two different types of statistical analysis referred to as lmFt (LIMMA) and robust 
regression (RR) were performed to improve the reliability of the genes found to be 
differentially expressed (Xu et al., 2013) (see section 2.3 for further details). Based on the 
list of differentially expressed genes (DEGs), two different types of functional analysis were 
conducted, either using DAVID software (Huang et al., 2009a) or the PANTHER database 
(Mi et al., 2013) (see figure 2.4).  
 
The cohort contained a patient with a hyperplastic polyp who was included in the initial 
analysis using the LIMMA method, however, subsequently, was excluded in all other 
analysis. As the aim of the study was to characterise the gene expression profile of 
adenomas, it was felt that inclusion of a hyperplastic polyp in the group would be 
inappropriate and therefore the patient was excluded. The initial analysis had already been 
conducted at this stage therefore it was not possible to exclude this patient at the time.  
 
The second analysis using PANTHER software focused on approaches to combine both 
methods therefore the same threshold was set for both LIMMA and RR to prevent any one 
statistical test identifying a large number of genes and would then be over-represented in the 
analysis.  Genes that were only identified using both statistical analyses, referred to as the 
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‘intersect’ region in the Venn diagrams were used to identify genes for further investigation. 
These genes were ranked based on fold change and a combined rank was calculated by 
averaging the individual ranks. The genes were then reordered based on the combined rank. 
A list of 50 up and down regulated genes in each comparison (cancer versus control, polyp 
versus control and cancer versus polyp) was created. Based on this list, only genes included 
in at least two of the comparison categories were considered potential candidates for 
validation.  
 
In comparison, the ‘union’ DEGs, that is, those that were discovered using either method 
were subject to functional analysis. A larger number of genes were preferred for this analysis 
to ensure that all biological terms of relevance were identified. Three separate analyses were 
performed based on cellular component, molecular function or biological process. The 
statistical overrepresentation test (Mi et al., 2013) was then performed to identify biological 
terms that were more ‘enriched’ in the list of DEGs compared to the background genes 
found on the microarray chip. There are therefore two different types of comparison that 
were made in the analysis. Firstly, differences in gene expression between the groups were 
examined using fold change which is a logarithmic function of the mean difference in raw 
expression values. Thus, it gives an indication of how gene expression of an individual gene 
differs across the clinical groups. In contrast, fold enrichment is a value that indicates 
whether a group of genes belonging to a particular cellular or biological function are over 
expressed or under expressed in the list of DEGs compared to the background expression 
that would be expected. In the DAVID analysis, a fold enrichment value of greater than 1.33 
was considered significant. In the PANTHER analysis, the statistical overrepresentation test 
was utilised to calculate fold enrichment and an associated p value. Fold enrichment greater 
than 2 or a p value <0.05 were considered to be significant. Both fold change and fold 
enrichment are important parameters to include in the analysis as they explain individual 
gene differences and global functional differences respectively.  
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4.3. Results 
4.3.1. The global gene expression profile of patients with adenomas and CRC differs 
Based on the expression level of all probes tested in the micro-array experiment, there 
appeared to be a clear distinction between MNM adjacent to a cancer compared to that next 
to adenoma (see fig 4.1.). It was therefore possible to draw a hypothetical line that can 
separate both groups based on the global gene expression profile of the samples examined. 
In comparison, the global gene expression profile of samples taken from control subjects 
overlaps the other two groups and is not as well demarcated.  
 
Figure 4.1: Principal components analysis of the global gene expression profile of all 16 
patients.  A hypothetical line is able to demarcate the patients with adenomas from CRC. 
C1-5 refers to samples from control subjects, Pol1-6 refers to samples from 6 polyp patients 
and Adc 1-5 refers to samples from 5 cancer patients 
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4.3.2. Multiple signalling pathways are dysregulated in the colonic field (DAVID 
analysis)  
LIMMA and RR methods were used to identify DEGs and biological processes that were 
dysregulated as shown in figure 4.2. The biological processes that were identified were 
ranked based on the enrichment score and are shown in Appendix 1.  
 
4.3.2.1. Cancer versus control 
Using the LIMMA method, only two functions were enriched. These included 
transmembrane signalling and glycosylation; the numbers of genes included in these two 
categories are shown in Appendix 1. No enriched terms were found using the robust method. 
 
4.3.2.2 Polyp versus control 
Using the LIMMA method, there were two terms that were enriched; these included 
extracellular signalling and response to injury. Despite only 90 probes being differentially 
expressed with the robust method, 5 terms were enriched: extracellular signalling, 
coagulation, eye morphogenesis, signalling and cytoskeleton.  
 
4.3.2.3 Polyp versus cancer   
The most striking differences were observed between patients with cancer and polyp. Using 
the LIMMA method, 8 enriched terms were found compared to a staggering 28 enriched 
terms with the RR method. The details of the enriched terms using both methods are given in 
Appendix 3. Key processes that are identified included chromatin organization, protein 
assembly and RNA transport.  
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Figure 4.2. DAVID analysis. Number of DEGs identified using the two different statistical 
methods and subsequent functional analysis with criteria for discrimination of individual 
genes for further enquiry. 
 
LIMMA Cancer 
versus 
control 
Polyp 
versus 
control 
Cancer 
versus 
polyp 
Upregulated genes 220 151 383 
Downregulated 
genes 
127 66 327 
Genes for 
validation 
24 UP   
25 
DOWN 
20 UP  
21 
DOWN 
21 UP  
22 
DOWN 
Genes in pathway 
1 
31 19 11 
Genes in pathway 
2 
25 10 30 
RR Cancer 
versus 
control 
Polyp 
versus 
control 
Cancer 
versus 
polyp 
No of DEGs 84 90 2024 
Upregulated genes 18 38 247 
Downregulated 
genes 
20 8 188 
Genes for 
validation 
16 UP 11 
DOWN 
20 UP 8 
DOWN 
22 UP  20 
DOWN 
Genes in pathway 
1 
13 30 196 
Genes in pathway 
2 
3 3 190 
Adc-Pol 
1914
Pol-C
31
Adc-C
28
Adc-Pol 
447
Pol-C
116
Adc-C
149
Genes for validation chosen based on –  
i) Top 10-15 genes with highest fold change (up and down 
regulated) 
ii) Genes with highest fold change found in top two most 
enriched pathways identified using DAVID 
30 candidate genes identified for 
qRT-PCR validation  
Functional analysis of DEGs 
using DAVID software 
2 
56 53 179 
17 
82 
2 
1 
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4.3.2.4. Selection of genes for validation and further enquiry 
A list of candidate genes for further validation was created based upon the genes recorded 
under the two most enriched terms of the functional analysis and a list of the top 10-15 genes 
with the greatest fold change observed in each category. Based on a literature review to 
explore biological relevance of these genes, 30 potential genes for validation were 
formulated. These genes are shown in table 4.1. and are involved in a number of different 
biological processes. From this list, MUC2, MUC5AC and GADD45B were chosen for 
further validation using quantitative real time polymerase chain reaction (qRT-PCR). The 
results of this are presented in chapter 5. 
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Table 4.1: Candidate genes for further validation with fold change differences, statistical 
significance and biological function displayed. A short synopsis of the literature linking the 
gene to cancer biology and CRC is also given. Numbers in brackets refer to the comparison 
with 1=cancer versus control, 2=polyp versus control and 3=cancer versus polyp. Italicized 
values refer to downregulated genes. 
Gene Gene name Function Fold 
change  
(LIMM
A) 
P value  
(LIMMA) 
Fold 
change  
(RR) 
P value 
(RR) 
MUC2 Mucin 2 Goblet cell 
derived mucin 
1.60 (1) 
1.58 (3) 
0.0007 (1) 
0.0007(3) 
1.61 (3) 0.001(3) 
MUC5AC Mucin 5, 
subunit AC 
Gastric 
foveolar mucin 
1.82 (1) 0.0005(1)   
MUC4 Mucin 4 Integral 
membrane 
glycoprotein 
1.52 (1) 
1.74 (3) 
0.028 (1) 
0.014(3) 
1.95 (3) 0.0003(3) 
GADD45A Growth arrest 
and DNA-
damage-
inducible 
protein 
GADD45 
alpha 
Stress 
response 
1.73 (3)  0.0001 (3) 1.74(3) 0.0003(3) 
GADD45B Growth arrest 
and DNA-
damage-
inducible 
protein 
GADD45 beta 
Stress 
response 
1.79(1) 
1.54 (3) 
0.014(1) 
0.049 (3) 
1.96 (1) 
1.82 (3) 
<0.0001(1) 
<0.0001(3) 
MT1X Metallothionie
n 1X 
Transcription 
co-factor 
2.26 (3) 
1.83 (2) 
0.005 (3) 
0.030 (2) 
  
COL3A1 Collagen, type 
III, alpha 1 
Component of 
type III 
collagen 
1.66 (3) 
1.88 (2) 
0.009 (3) 
0.002(2) 
1.93 (3) 
2.13(2) 
0.0001(3) 
<0.0001(2) 
COL5A2 Collagen, type 
III, alpha 2 
Component of 
fibrillar 
collagen 
1.51 (3) 
1.70 (2) 
<0.0001(3) 
<0.0001(2) 
  
FGL2 Fibrinogen-
like protein 2 
Lymphocyte 
function 
  2.02 (2) <0.0001(2) 
CTSA Cathepsin A Autophagy/pla
telet activation 
  1.74 (2) 
2.27(3) 
<0.001 (2) 
<0.0001(3) 
CTSG Cathepsin G ECM 
degradation 
2.42 (3) 
1.76(2) 
<0.0004(3) 
0.012 (2) 
2.48 (3) 0.0003(3) 
IL-17B Interleukin 17 
B 
Releases 
TNFα and IL-
1-β 
1.93 (3) 0.001 (3) 2.23 (2) 
2.48 (3) 
<0.001 (2) 
<0.001 (3) 
MMP1 Matrix 
metalloprotein
ase 1 
ECM 
degradation 
2.67 (2) 
1.87 (3) 
0.003(2) 
0.045(3) 
  
MMP12 Matrix 
metalloprotein
ase 12 
ECM 
degradation 
and 
aneurysmal 
2.32 (1) 
2.08 (2) 
0.027(1) 
0.042 (2) 
  
135 | P a g e  
 
disease 
FGFBP1 Fibroblast 
growth factor 
binding 
protein 1 
Cell 
proliferation, 
differentiation 
migration, 
growth 
2.24 (2) 
2.28 (3) 
0.024 (2) 
0.022 (3) 
  
GREM1 Gremlin 1 BMP 
antagonist 
2.11 (2) 
1.61 (3) 
0.027 (2) 
0.031 (3) 
3.12 (3) 
 
<0.001 (3) 
SFRP1 Secreted 
frizzled related 
protein 
Modulates 
Wnt signalling 
1.61 (2) 
1.83 (3) 
0.022 (2) 
0.005 (3) 
  
ELANE Neutrophil 
elastase 
Modifies 
natural killer 
cells 
  1.29 (1) <0.001 (1) 
 
4.3.3. Multiple differences in cellular component, molecular function and biological 
processes in the colonic field (PANTHER analysis) 
4.3.3.1. Intersect genes 
Using both LIMMA and RR identified similar number of genes to be upregulated and 
downregulated in all three comparison groups (see figure 4.3.). Genes that were found using 
both statistical tests (intersect genes) were ranked based on the fold change differences. The 
individual rank values were then combined across the three categories of cancer versus 
control, polyp versus control and cancer versus polyp. The top 50 genes identified based on 
the combined rank value were investigated further for their biological relevance in CRC 
formation (see table 4.2. for further details). Candidate genes (n=5) were identified from this 
list using a stratified sampling approach where genes are selected at regular intervals along 
the list.  
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Figure 4.3. PANTHER analysis. Number of DEGs identified using the two different 
statistical methods. Details of subsequent functional analysis using PANTHER software and 
analysis of intersect genes to identify candidate genes for further enquiry is also given.  
 
 
LIMMA Cancer 
versus 
control 
Polyp 
versus 
control 
Cancer 
versus 
polyp 
Upregulated 
genes 
220 151 383 
Downregulated 
genes 
127 66 327 
RR Cancer 
versus 
control 
Polyp 
versus 
control 
Cancer 
versus 
polyp 
Upregulated 
genes 
204 190 442 
Downregulated 
genes 
130 72 380 
LIMMA
55
RR
58
LIMMA
60
RR
86
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132
RR
144
INTERSECT genes – 1130 genes 
UNION genes – 1665 genes 
PANTHER analysis –  
 Cellular component 
 Molecular function 
 Biological process 
Top 50 up and down regulated genes 
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Table 4.2.: Potential candidate genes for qRT-PCR validation. Top 20 genes identified 
based on combined rank displayed with corresponding fold change (FC) differences and 
statistical significance. Combined rank is given under each gene name. Numbers in brackets 
refer to the comparison with 1=cancer versus control, 2=polyp versus control and 3=cancer 
versus polyp. Italicized values refer to downregulated genes. 
Gene 
name 
Combined 
rank 
Gene name FC 
(LIMMA) 
P value 
(LIMMA) 
FC 
(RR) 
p value 
(RR) 
PSCA 
2 
Prostate Stem Cell 
Antigen 
6.62(1) 
7.23(3) 
0.0006(1) 
0.0004(3) 
6.62(1) 
7.35(3) 
 
0.0032(1) 
0.0022(3) 
UGT2B15 
3 
UDP 
glucuronosyltransferase 
2 family, polypeptide 
B15 
5.11(2) 
5.38(3) 
0.0145(2) 
0.0121(3) 
2.66(2) 
2.88(3) 
0.0230(2) 
0.0158(3) 
PYY2 
5 
Peptide YY, 2 
(pseudogene) 
3.00(1) 
2.88(3) 
0.0001(1) 
0.0002(3) 
3.00(1) 
2.82(3) 
0.0018(1) 
0.0030(3) 
 
SLC46A1 
11 
Solute carrier family 46 
(folate transporter) 
Member 1 
2.06 (1) 
2.78(3) 
0.0027(1) 
0.0001(3) 
1.98(1) 
2.87(3) 
0.0065(1) 
0.0002(3) 
 
TMCC2 
13 
Transmembrane and 
coiled coil domain 
family 2 
2.39(1) 
2.38(3) 
0.0036(1) 
0.0039(3) 
2.35(1) 
2.43(3) 
0.0074(1) 
0.0062(3) 
 
JAKMIP3 
13 
Janus kinase and 
microtubule interacting 
protein 3 
2.45(1) 
2.38(3) 
0.0012(1) 
0.0016(3) 
2.30(1) 
2.26(3) 
0.0011(1) 
0.0015(3) 
 
TFF1 
14 
Trefoil factor 1 
 
2.37(2) 
2.29(3) 
0.0146(2) 
0.0182(3) 
2.34(2) 
2.26(3) 
0.0296(2) 
0.0356(3) 
 
SLC1A7 
15 
Solute carrier family 1 
(glutamate transporter), 
membrane 7 
2.06(1) 
2.40(3) 
0.0486(1) 
0.0198(3) 
2.41(1) 
2.55(3) 
0.0036(1) 
0.0030(3) 
 
SDS 
15 
Serine dehydratase 2.85(1) 
2.28(3) 
0.0029(1) 
0.0143(3) 
3.28(1) 
2.83 (3) 
0.0003(1) 
0.0002(3) 
 
FUT2 
16 
Fucosyltransferase 2 2.05(1) 
2.62(3) 
0.0489(1) 
0.0110(3) 
1.78(1) 
3.74(3) 
0.0023(1) 
0.0002(3) 
 
KNG1 
17 
Kininogen 1 2.05(1) 
2.30(2) 
0.0022(1) 
0.0006(2) 
2.22(1) 
2.50(2) 
0.0010(1) 
0.0003(2) 
 
CTSG 
18 
Cathepsin G 1.92(2) 
2.64(3) 
0.0054(2) 
0.0002(3) 
1.91(2) 
2.48(3) 
0.0042(2) 
0.0003(3) 
 
CCL21 
19 
Chemokine (C-C Motif) 
Ligand 21 
2.13(1) 
2.27(3) 
0.00008(1) 
0.0029(3) 
2.13(1) 
2.25(3) 
0.0002(1) 
0.0025(3) 
 
SECTM1 Secreted and 2.15(2) 0.0079(2) 2.28(2) 0.0070(2) 
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20 transmembrane 11 2.29(3) 0.0047(3) 2.42(3) 0.0043(3) 
 
CYP3A4 
20 
Cytochrome 450, family 
3, subfamily A, 
polypeptide 4 
2.01(1) 
2.26(3) 
0.0186(1) 
0.0075(3) 
1.88(1) 
2.11(3) 
0.0044(1) 
0.0012(3) 
 
UGT2B11 
23 
UDP 
Glucuronosyltransferase 
2 family, polypeptide 
B11 
2.21(2) 
2.16(3) 
0.0150(2) 
0.0178(3) 
2.17(2) 
2.23(3) 
0.0120(2) 
0.0107(3) 
 
HSD11B1 
24 
Hydroxysteroid (11-
Beta) Dehydrogenase 
11 
1.82(1) 
2.44(2) 
0.0241(1) 
0.0018(2) 
1.84(1) 
2.27(2) 
0.0168(1) 
0.0026(2) 
 
S100P 
46 
S100 Calcium Binding 
Protein P 
2.05(2) 
1.91(3) 
0.0202(2) 
0.0334(3) 
2.15(2) 
2.01(3) 
0.0159(2) 
0.0254(3) 
 
CXCL2 
48 
Chemokine ligand 
2/GRO-2 
2.06(1) 
1.85(3) 
0.0107(1) 
0.0261(3) 
2.00(1) 
1.80(3) 
0.0203(1) 
0.0449(3) 
 
MUC2 
50 
Mucin 2 1.84(1) 
1.98(3) 
0.0014(1) 
0.0006(3) 
1.84(1) 
2.00(3) 
0.0031(1) 
0.0001(3) 
 
GREM1 
66 
Gremlin 1, DAN family 
BMP antagonist 
1.64(2) 
1.71(3) 
0.0326(2) 
0.0208(3) 
1.76(2) 
1.87(3) 
0.0110(2) 
0.0060(3) 
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4.3.3.2. PANTHER analysis of UNION genes 
In total, 1665 genes were identified for functional analysis when genes identified using 
either LIMMA or RR were combined. These genes were analysed using PANTHER 
software to determine which cellular component the gene belongs to and ascertain its 
biological and molecular function. A number of different biological processes were found to 
be over or underrepresented in the list of DEGs compared to the number of genes found 
under that function in the micro-array chip.   
4.3.3.3. Cancer versus control 
The cellular component analysis showed that the DEGs identified in this category were 
responsible for intracellular and organelle function (see figure 4.4.). Genes involved in 
chemokine and cytokine activity were more enriched compared to the background and there 
was decreased structural molecular and nuclear acid activity (fold enrichment >5, p<0.001 
and fold enrichment 0.5, p<0.001, respectively). In terms of biological processes, genes 
involved in the immune response, antigen processing and natural killer cell activation were 
more enriched (see table 4.3). The other terms that were enriched include glycolysis and 
tricarboxylic acid cycle suggesting that there were changes in metabolic activity (fold 
enrichment >5, p<0.001). Genes that were involved in regulating biological processes and 
involved in mesoderm/ectoderm development were observed at a lower frequency than the 
background level (fold enrichment 0.77, p<0.001 and fold enrichment 0.38. p<0.001 
respectively).  
 
 
 
 
 
140 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. PANTHER analysis of DEGs found between cancer and control (n=389) 
showing which cellular component, molecular function and biological process these genes 
belong to.   
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Table 4.3. Statistical overrepresentation test for cancer versus control. Fold enrichment 
is calculated by taking the ratio of the expected number of genes (based on the genes found 
under that category in the micro-array chip0 to the actual observed number of genes in that 
category.  
Biological 
Process 
Fold 
enric
hme
nt 
P 
value 
No 
of 
gene
s 
Genes 
Immune 
system 
process 
1.74 0.003 
 
28 HLA-DQA1, CCL4, IER3, B2M, LILRB1, 
GADD45B, HLA-DPB1, CCL13, NR4A2, 
CCL19, LILRB5, PLA2G7, CEBPB, MARCH2, 
TSPAN32, KLK3, FPR3, CCL21, CCL23, 
CXCL2, CCL3, CXCL13, NFKBIA, CCL3L1, 
DDTL, LILRB2, GADD45G 
Immune 
response 
2.16 0.008 
 
13 IRF5, CCL4, LILRB1, CCL13, CCL19, 
LILRB5, CEBPB, KLK3, CCL21, CCL23, 
CCL3, CCL3L1, LILRB2 
Antigen 
processing 
and 
presentation 
>5 0.010 3 HLA-DQA1, HLA-DPB1, B2M 
Visual 
perception 
2.67 0.017 7 INPP5J, DHRS4, PCDH11X, HSD11B1, 
LRRC26, RIMS3, TLR3 
Behaviour >5 0.018 2 CXCL2, CXCL13 
Natural 
killer cell 
activation 
3.9 0.020 4 LILRB1, LILRB5, CEBPB, LILRB2 
Tricarboxyli
c acid cycle 
>5 0.024 2 LDHA, LDHC 
Cell growth >5 0.034 1 APOE 
Glycolysis > 5 0.041 2 LDHA, LDHC 
Mesoderm 
development 
0.38 0.040 3 CEBPB, PCDH11X, NYX 
Ectoderm 
development 
0.38 0.045 3 NR4A2, HES5, ABLIM2 
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4.3.3.4. Polyp versus control 
The majority of the DEGs discovered between polyp and control were involved in the 
cytoskeleton, both actin and microtubule components (fold enrichment 2.87, p<0.001). This 
was again seen with the molecular function analysis which identified the following terms to 
be more enriched than background: cytoskeletal protein binding, extracellular matrix (ECM) 
structural constituents and growth factor activity (fold enrichment 3.26, p<0.001; 3.92, 
p<0.001 and >5, p<0.001 respectively). Similar to the cancer versus control category, genes 
involved in nucleic acid binding activity were less enriched amongst the list of DEGs (fold 
enrichment 0.44, p<0.001). A large number of biological processes were found to be more 
enriched including antigen processing, macrophage activation, complement activation, cell-
matrix adhesion and cellular process (see table 4.4.). The biological terms that were 
highlighted could be broadly classified into three categories: cell adhesion, cell morphology 
and cellular process. Genes that were involved in RNA metabolic process, transcription and 
regulation of biological processes were less enriched when compared to the number of genes 
found under these categories in the background.  
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Figure 4.5. PANTHER analysis of DEGs found between polyp and control (n=322) 
showing which cellular component, molecular function and biological process these 
1%
32%
13%
15%
10%
7%
21%
1%
Cellular component
cell junction
cell part
extracellular matrix
extracellular region
macromolecule complex
membrane
organelle
synapse
33%
28%5%
3%
1%
12%
13%
1%
4%
Molecular function
binding
catalytic activity
enzyme regulator activity
nucleic acid binding transcription
factor activity
protein binding transcription factor
activity
receptor activity
structural molecule activity
translation regulator activity
transporter activity
1% 4%
8% 5%
23%
11%7%
7%
0%
20%
6%
1%
7%
Biological Process
apoptotic process
biological adhesion
biological regulation
cellular component organisation
cellular process
developmental process
immune system process
localisation
locomotion
metabolic process
multicellular organismal process
reproduction
response to stimulus
144 | P a g e  
 
Table 4.4. Statistical overrepresentation test for polyp versus control. Fold enrichment is 
calculated by taking the ratio of the expected number of genes based on the genes found 
under that category in the micro-array chip and comparing this to the actual observed 
number of genes in that category. Only biological processes with fold enrichment <0.5 or >2 
have been shown.  
Biological 
Process 
Fold 
enric
hme
nt 
P value No 
of 
gen
es 
Genes 
Anatomical 
structure 
morphogenes
is 
2.29 <0.001 
 
19 COL3A1, GPM6B, COL4A1, 
CALD1,PLS3,LDB3,TPPP,TPPP3, 
CCDC102B,ESPNL,AXIN2,PDLIM3,ACTL8,M
YOC,SYNAPO2,COL5A2,CFL2,TPM2,ACTA2. 
Cellular 
component 
morphogenes
is 
2.42 0.001 
 
16 GPM6B, COL4A1, CALD1, PLS3, LDB3, TPPP, 
TPPP3, ESPNL, PDLIM3, ACTLB, MYOC, 
SYNAPO2, COL5A2, CFL2, TPM2, ACTA2 
Biological 
adhesion 
2.2 0.002 18 LAMA2, COL4A1, LUM, CLEC4A, LEPREL1, 
COL14A1, VCAM1, HAPLN1, FGL2, CTSK, 
TNS1, TIMD4, COL5A2, PCDH18, LRRC66, 
ADAMTS5, EMCN 
Cell adhesion 2.17 0.003 17 LAMA2, COL4A1, LUM, CLEC4A, VCAM1, 
FGL2, CTSK, TNS1, TIMD4, COL5A2, 
PCDH18, LRRC66, CFB, ADAMTS5, EMCN, 
FGF7 
Muscle 
contraction 
3.05 0.003 9 PPP1R14A, VCAM1, EDNRA, LDB3, 
CCDC102B, CCK, PDLIM3, CRYAB, TPM2 
Homeostatic 
process 
2.88 0.007 8 COL3A1, COL4A1, ENRA, CCL23, COL5A2, 
LRRC66, ATP12A, AGR2 
Regulation of 
liquid surface 
tension 
>5 0.008 4 COL3A1, COL4A1, COL5A2, AGR2 
Steroid 
metabolic 
process 
3.09 0.008 7 DHR7SC, CELA3A, CELA3B, CYP3A4, 
HSD11B1, INSIG1, HSD17B6 
Antigen 
processing 
and 
presentation 
>5 0.009 4 HLA-DQA1, HLA-DQA2, HLA-DPA1, HLA-F 
Monosacchar
ide metabolic 
process 
3.27 0.011 6 UGTB11, UGTB10, UGTB15, EDRNRA, PCK1, 
FUT2 
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Complement 
activation 
>5 0.020 3 C4BPB, CFB, SRPX 
Cell-cell 
adhesion 
2.02 0.022 11 LAMA2, COL4A1, LUM, CLEC4A, LEPREL1, 
FGL2, COL5A2, LRRC66, CFB, ADAMTS5 
Macrophage 
activation 
2.64 0.028 6 COL3A1, CLEC4A, S100A14, DMBT1, GPB3, 
PLEKHS1 
Blood 
coagulation 
2.62 0.029 6 CLEC4A, COL14A1, PROCR, C4BPB, CFB, 
SRPX 
Cell-matrix 
adhesion 
3.19 0.038 4 LAMA2, COL14A1, FGL2, ADAMTS5 
Cellular 
defence 
response 
2.21 0.042 7 HLA-DQA1, CLEC4A, BTN3A2, PLEKHS1, 
HLA-DPA1, STAT6, HLA-DQA2 
Nucleobase 
containing 
compound 
metabolic 
process 
0.5 <0.001 23 LUM, RUNXT1, ABCA8, S100A14, COL14A1, 
RGS5, HOXB9, LDB3, APOBEC1, ISL1, 
HIST1H4A, AXIN2, PDLIM3, BHLEH22, 
S100P, PRRX1, TSEN2, MAOB, BMP3, 
APOBEC3B, STAT6 
RNA 
metabolic 
process 
0.43 0.0001 13 LUM, RUNTX1, HOXB9, LDB3, APOBEC1, 
ISL1, PDLIM3, BHLHE22, PRRX1, TSEN2, 
BMP3, APOBEC3B, STAT6 
Transcription 0.4 <0.001 10 LUM, CBFA2T1, HOXB9, LDB3, ISL1, 
PDLIM3, BHLHE22, PRRX1, BMP3, STAT6 
Ion transport 0.21 0.003 2 KCTD12, ATP12A 
Cation 
transport 
0.26 0.017 2 KCTD12, ATP12A 
Organelle 
organisation 
0.38 0.043 3 HIST1H4A, MAOB 
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4.3.3.5. Polyp versus cancer  
In comparison to the changes found between cancer/polyp and control, most of the DEGs in 
this category were associated with membrane structures or the extracellular matrix. 
Similarly, genes that were involved in cell signalling (acetyltransferase activity), protein 
degradation (cysteine type peptidase activity, racemase and epimerase activity) and 
microtubule binding were more enriched (fold enrichment 3.01, p<0.001: 2.66, P<0.001 and 
3.62, p<0.001, respectively). Similar to the previous analyses, genes involved in 
transcription and nucleic acid binding were less enriched compared to the background. The 
biological process analysis revealed enrichment of genes involved in metabolism 
(tricarboxylic acid cycle, monosaccharide metabolic process and glycolysis) and reduced 
enrichment of genes required for regulation of RNA transcription (RNA metabolic process, 
transcription, mRNA process, nitrogen compound metabolic process and biological 
regulation) (see table 4.5).   
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Figure 4.6. PANTHER analysis of DEGs found between polyp and cancer (n=954) 
showing which cellular component, molecular function and biological process these genes 
belong to.   
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Table 4.5. Statistical overrepresentation test for polyp versus cancer. Fold enrichment is 
calculated by taking the ratio of the expected number of genes based on the genes found 
under that category in the micro-array chip and comparing this to the actual observed 
number of genes in that category. Biological processes with fold enrichment ratio >2 or 
<0.66 have been shown.  
 
 
 
 
 
 
Biological 
Process 
Fold 
enric
hme
nt 
P 
value 
No 
of 
gene
s 
Genes 
Chromatin 
organisation 
2.50 <0.001 
 
25 LIN6,HIST1H3A, BRD3, SMC2, NAP1L, 
SMC4,HIST1H4A,HIST1H2BC, HIST1H2AG, 
HIST1H2AB, CARM1, H1FO, HIST2HAA3, 
HIST1H1B, HIST1H2AC, HIST1H1D, TNRC18 
Tricarboxylic 
acid cycle 
>5 0.001 
 
5 LDHB, ACO2, ME1, LDHA, LDHC 
Monosacchar
ide metabolic 
process 
2.17 0.015 11 LDHB, UGTB11, PPARG, PFKL, LDHA, 
UGTB15, LDHC, FUT2, PMM2, INPPL1. 
Glycolysis 4 0.019 4 LDHA, PFKL, LDHB, LDHC 
mRNA 
processing 
0.3 <0.001 3 UPF1, PPP1CB, APOBEC3B 
Nitrogen 
compound 
metabolic 
process 
0.66 0.009 26 BMP5, CDC42EP1, APOA1BP, MLXIP, SPDEF, 
RGS5, PARP1, FOXA2, THNSL2, CYB5R2, 
AXIN2, HIST1H2BC, CARM1, DHX34, 
PPARGC1B, TSEN2, CYC5, MAGOHB, GPT, 
ATP5D, POLR2E, DAB2IP, ABCA7, KIF13B, 
TNRC18, FOXP4 
RNA splicing <0.2 0.038 1 TSEN2 
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4.3.3.6. Several cellular processes are dysregulated in the colonic field 
The findings from the study can be summarized as shown in figure 4.7. The mucosal field 
around a polyp contains cells that have altered cytoskeleton and dysregulated growth factor 
activity. Some of the genes highlighted by the functional analysis were involved in epithelial 
–mesenchymal transition (EMT) suggesting that cell structure and interaction with 
surrounding stromal cells may become modified early on in the carcinogenesis pathway. 
Subsequently, cells acquire the ability to survive in poor nutrient conditions and evade the 
host immune response as seen by the genes that were dysregulated between polyp and 
cancer. In all three categories, there was less enrichment of genes that are involved in 
regulation of RNA replication and transcription suggesting that the cells in the mucosal field 
progressively accumulate disordered nuclear division.  
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Figure 4.7. Proposed cellular alterations in the colonic field during progression along the 
adenoma-carcinoma sequence based upon genes identified in the PANTHER analysis.  
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4.3.3.6.1. Immune response 
Several of the genes that were identified under the immune response category were related to 
macrophage function included LILRB1, CEPB, IRF5 and APOE. LILRB1 is a leukocyte 
immunoglobulin receptor which is found on immune cells where it binds to MHC class I 
molecules on antigen presenting cells. CEBPB is a transcription factor that binds to certain 
DNA regulatory elements on other acute phase and cytokine genes. IRF5 acts as a molecular 
switch determining whether macrophages promote or inhibit inflammation.  
 
The cytokines that were found to be more enriched in cancer versus control included CCL3, 
CCL4, CCL13, CCL19, CCL21 and CCL23. CCL19 and CCL21 have homeostatic function, 
being constitutively expressed in certain tissue and attracting leukocytes as part of normal 
physiological function. In comparison, CCL3 and CCL4 are pro-inflammatory and are only 
expressed under pathological conditions.  
 
4.3.3.6.2. Metabolism 
Enrichment of genes involved in cellular metabolism was found in all three groups, 
however, only two terms were enriched in the polyp versus control comparison: steroid 
metabolic process and monosaccharide metabolic process. UDP glucuronosyltransferase 2 
family, polypeptide B15 (UGTB15) and UDP glucuronosyltransferase 2 family, polypeptide 
B11(UGTB11) were found in both polyp versus control and polyp versus cancer. These 
genes encode enzymes that are important for the conjugation and subsequent elimination of 
potentially toxic xenobiotics and endogenous compounds.  
 
In the cancer versus control and cancer versus polyp comparison, three common processes 
were enriched which included glycolysis, tricarboxylic acid cycle (Hoy et al.) and lipid 
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metabolic process. In terms of glycolysis and TCA, lactate dehydrogenase A (LDHA) and C 
(LDHC) were found in both of these categories whilst lactate dehydrogenase B (LDHB), 
Aconitase 2 (ACO2), Malic enzyme (ME1) and Phosphofructokinase, Liver (PFKL) were 
only found in the cancer versus polyp comparison. 
 
Lipid metabolic process was the other biological term that was found to be enriched in the 
analysis comparing cancer with control or polyp. However, only 8/50 genes found in the 
cancer versus control category were also found in the cancer versus polyp category.  
 
Fucosyltransferase 2 (FUT2) was the only gene that was identified in all three comparisons. 
This gene encodes a protein that is a Golgi stack membrane protein, involved in the creation 
of a precursor of the H antigen in body fluids and intestinal mucosa. The H antigen is an 
oligosaccharide which acts as a carbon source and attachment site for intestinal bacteria. 
 
4.3.3.6.3. Cell-cell interaction 
Most of the genes that were identified under the polyp versus control category contribute to 
cytoskeleton function, microtubule assembly, cell adhesion and cell proliferation. Key genes 
identified included PLS3, TPPP, TPPP3, LAMA2, CLEC4A1, TNS1, HOXB9, STAT6, 
PRRX1 and FGF7. PLS3 encodes an actin-bundling protein that inhibits cofilin mediated 
depolymerisation of actin fibres. LAMA2 encodes the alpha 2 chain of laminin 2 and 4. 
Laminin is an extracellular protein that is a component of the basement membrane and 
interacts with other ECM constituents to mediate migration and attachment of cells. STAT6, 
HOXB9 and PRRX1 are involved in transcription.  
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4.3.3.6.4. RNA transcription 
 In all three categories, the biological processes where genes were less enriched compared to 
the background population included those involved in biological regulation or RNA 
transcription suggesting dysregulation of homeostasis and production of proteins. Only one 
gene which fell under these terms was found in all three categories; HIST1H4A (Histone 
Cluster 1, H4A) which encodes a member of the Histone 4 (H4) family. Histone proteins 
form an octamer around which DNA is wrapped. Despite the similarity in the terms that 
were enriched, only 11/27 and 2/27 of the genes found in the control versus cancer 
comparison were also found in the cancer versus polyp and polyp versus control categories 
respectively. This suggests that different genes with variant cellular and biological functions 
are dysregulated along the adenoma-carcinoma sequence. In the polyp versus control 
category, most of the genes identified had enzymatic activity such as hydrolase activity 
(APOBEC3B), oxidoreductase activity (MAOB), GTPase activity (AXIN2, RGS5). In 
comparison, most of the genes identified in the cancer versus polyp category were 
transcription factors or cofactors suggesting that altered transcription occurs later in the 
cancer process.  
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4.4 Discussion 
This study offers unique opportunity to examine the cellular processes that are altered in the 
MNM and identify genes that may play a role in field cancerisation. Furthermore, it is 
possible to cluster the patients that have polyps and cancers from controls based upon the 
gene expression profile of MNM suggesting a possible role of field cancerisation in 
screening and early diagnosis.  
 
Micro-array analysis is an efficient way to measure gene expression and samples the genome 
in an unbiased fashion enabling a candidate-free approach to identification of putative 
biomarkers. In CRC, most studies have been conducted comparing normal mucosa with 
cancer tissue to determine the molecular pathways that are involved in carcinogenesis (Alon 
et al., 1999; Notterman et al., 2001; Birkenkamp-Demtroder et al., 2005; Grade et al., 2007; 
Croner et al., 2005). Whilst these studies have been successful in clustering normal versus 
tumour samples and to a lesser extent, different progression stages (Frederiksen et al., 2003; 
Groene et al., 2006; Croner et al., 2008), MSI status (Kruhøffer et al., 2005; Banerjea et al., 
2004) and anatomical location (Bertucci et al., 2004; Komuro et al., 2005; Birkenkamp-
Demtroder et al., 2005), there have been few previous reports where the MNM in cancer 
patients has been profiled. Although only a small fraction (approx. 2 %) of the genes used on 
a microarray platform have been found to be differentially expressed between cancer and 
control tissues (Cardoso et al., 2007), a number of common processes have been identified 
across studies. Genes that are dysregulated between cancer and control are usually involved 
in cell adhesion, cell communication, cell cycle regulation, cellular and nucleic acid 
metabolism and the cellular response to external stimuli which includes the immune and 
stress response (Cardoso et al., 2007). However, there are multiple genes that have been 
highlighted in these studies which have no proven role in CRC and require further 
investigation (Nannini et al., 2009).   
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Across the DEGS identified, the gene expression profile of adjacent MNM in cancer and 
polyp patients varied the most. Amongst many of the DEGs found, there was an inverse 
relationship between gene expression in cancer compared to polyp suggesting that either the 
genes involved have a dual function similar to that found with TGFβ (Derynck et al., 2001; 
Wakefield & Roberts, 2002) or that there are dynamic gene expression changes along the 
adenoma-carcinoma pathway. In this setting, genes that play an integral role in polyp 
formation may reach a threshold after which upregulation of the gene is of no further benefit 
to the cell and consequently it is turned off.  
 
A number of cellular processes were found to be dysregulated in the colonic field around 
CRC and adenomas including the immune response, metabolism, epithelial-mesenchymal 
transition (EMT) and cellular proliferation. 
 
 
4.4.1. Immune response 
Several of the genes highlighted under immune system response play a role in macrophage 
function. In some studies, macrophages have been shown to enhance tumour growth and 
progression. They are usually attracted by hypoxic and necrotic tumour cells and release 
pro-inflammatory compounds such as TNF-alpha which activate NF-KB. NF-KB enters the 
nucleus and switches on anti-apoptotic genes and genes that increase cell proliferation or 
inflammation. Tumour growth is further augmented by the macrophages with release of pro-
angiogenic factors such as VEGF, GM-CSF and IL-1/IL-6 (Jedinak et al., 2010).  However a 
more recent study (Ong et al., 2012) has challenged this view and shown that tumour 
associated macrophages in CRC exert a tumour suppressive effect and are pro-inflammatory. 
In another study, it was possible to blunt the innate pro-tumoral effects of macrophages by 
forcing IFN-alpha expression tumour infiltrating macrophages and convert the tumour 
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microenvironment towards more effective dendritic cell activation and immune effector T 
cell cytotoxicity (Escobar et al., 2014).  
The enrichment of genes involved in macrophage function was coupled by enriched genes 
having chemokine/cytokine activity which reflects the requirement to attract 
immune/inflammatory cells. The role of the immune system in carcinogenesis is supported 
by the observation that there is an increased incidence of CRC amongst 
immunocompromised individuals (Sint Nicolaas et al., 2010). Furthermore, an increase in 
the inflammatory/immune component of a tumour has been associated with reduced risk of 
recurrence and improved survival (Pagès et al., 2005; Nosho et al., 2010; deLeeuw et al., 
2012). This suggests that the immune system may be important in counteracting cancer 
growth and if dysregulated, could contribute to invasion and the formation of metastasis. 
This is of further interest as pharmacological manipulation of this immune response could 
aid the host in fighting against cancer and can contribute to chemotherapy induced cell 
death. 
 
 
4.4.2. Metabolic process 
Several of the genes that were dysregulated between cancer and control tissue played a role 
in mitochondrial function and Tricarboxylic acid cycle (Hoy et al.). Several TCA genes have 
been found to be mutated in hereditary and sporadic cancer (Gaude & Frezza, 2014).  Under 
normal physiological conditions, anaerobic respiration only occurs when there is insufficient 
oxygen available. However, in cancer cells, there is increased LDHA activity which enables 
cells to convert pyruvate into lactate even when there is sufficient oxygen. This has been 
termed the Warburg effect (WARBURG, 1956) and explains how the energy demands of 
rapidly dividing cells can be met without relying upon glucose delivery (Vander Heiden et 
al., 2009). Increased lactate levels have been correlated with poor disease free survival and 
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increased incidence of metastases in a number of different cancers (Schwickert et al., 1995; 
Walenta et al., 1997) including rectal cancer (Walenta et al., 2003). 
 
Dysregulation of the TCA also leads to production of higher reactive oxygen species which 
contributes to cancer formation. ME1 is found in the cytoplasm (in contrast to ME2 which is 
mitochondrial) and catalyses the oxidate decarboxylation of malate into pyruvate. Malate 
metabolism has been shown to be compartmentalized (Moreadith & Lehninger, 1984). 
Malate generated in the mitochondrion proceeds through the TCA whereas cytosolic malate 
is converted to pyruvate and then citrate, potentially fuelling fatty acid and cholesterol 
biosynthesis, aiding tumour growth. ME1 and ME2 expression have been shown to be 
regulated by p53 (Jiang et al., 2013) which is one of the key genes to be dysregulated in 
CRC suggesting a potential role of ME1 in colorectal carcinogenesis.  
 
 
4.4.3 Epithelial-mesenchymal transition (EMT) 
Similar to previous reports (Lin et al., 2002), this study demonstrated that there are changes 
in gene expression of genes encoding components of the cytoskeleton and extracellular 
matrix in patients with polyps compared to controls. These changes could contribute to 
epithelial mesenchymal transition (EMT) whereby epithelial cells become spindle shaped, 
motile and develop the ability to invade the basement membrane. Contrary to previous 
studies which have linked EMT with more aggressive, metastatic tumours (Tam & 
Weinberg, 2013) or proposed that it facilitates drug resistance against chemotherapy agents 
(Kim et al., 2015), this study did not find similar enriched terms in the other two 
comparisons. The findings could suggest that EMT may be taking place earlier in the 
colorectal cancer pathway than previously thought. Alternatively, changes in cell 
morphology and adhesion could occur at the polyp stage with the complete process of EMT 
only taking place once key genes, such as TGFβ are activated. A recent study (Yokobori et 
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al., 2013) identified elevated levels of PLS3 in circulating CRC cells and demonstrated that 
it was independently associated with prognosis. The authors postulated that it plays a role in 
driving EMT and therefore cancer cells with high expression have greater malignant 
potential through acquiring a mesenchymal phenotype. A subsequent study (Sugimachi et 
al., 2014) has shown that PLS3 induces EMT via activation of the TGFβ pathway and 
confers the ability to invade. Similarly, TPPP and TPPP3 also bind tubulin and have 
microtubule bundling activity and help maintain the integrity of the microtubule network.  
Several of the other genes that were identified were involved in cell adhesion thus alterations 
in these genes could also contribute to the process of EMT.  
 
 
4.4.4. Cell proliferation 
The other term that was found only to be enriched between polyp and control was ‘cellular 
process’. Multiple different genes were included under this term including transcription 
factors, transcription co factors and supportive growth factors such as FGF7.  STAT6 is 
induced by IL4 and upon phosphorylation, translocates to the nucleus where it induces the 
expression of the anti-apoptotic proteins BCL2L1/BCL-X(L). In one study, CRC cell lines 
where STAT6/IL4 are upregulated displayed increased resistance to apoptosis and increased 
metastatic potential (Li et al., 2008). The authors went onto show that xenograft tumours of 
STAT6 active HT29 cells displayed a predisposition to TH2 cytokines (IL-4 and IL5) and 
were more pro-apoptotic and pro-metastatic (Li et al., 2012). HOXB9 encodes a protein with 
a homeobox DNA-binding domain which acts as a sequence specific transcription factor 
which is involved in cell proliferation and differentiation. HOXB9 expression has been 
shown to correlate with poor survival and higher incidence of metastasis in CRC patients 
(Huang et al., 2014). DACH1 is a chromatin associated protein that interacts with other 
DNA-binding transcription factors to regulated gene expression and determine cell fate. 
Expression of this gene has been shown to be lost in some forms of cancer including breast, 
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endometrial and prostate cancer (Nan et al., 2009; Wu et al., 2006; Wu et al., 2007a; 
Yamada et al., 2008). In a recent study, DACH1 was found to be switched off by promoter 
region hypermethylation in CRC and subsequent reduction in DACH1 expression correlated 
with late tumour stage, poor differentiation grade and increased incidence of lymph node 
metastasis (Yan et al., 2013). Loss of DACH1 expression lead to TGF-β induced EMT 
which contributed to increased cell growth, motility and invasiveness (Wang, 2015). 
 
4.4.5. Field cancerisation 
Most of the previous studies that have investigated field cancerisation in CRC have shown 
differences in cellular proliferation and apoptosis along the colon, at distant sites to the 
primary tumour (Anti et al., 2001; Badvie et al., 2006; Anti et al., 1993). More recently, 
investigators have demonstrated that there are methylation changes in the colonic field 
around a CRC which mirror the epigenetic changes found in the tumour itself (Worthley et 
al., 2010; Belshaw et al., 2008). Others have shown that there is reduced protein expression 
of important DNA repair proteins up to 10 cm away from the tumour in the macroscopically 
normal mucosa around a cancer (Facista et al., 2012). The differences in immune response, 
cellular metabolism and cell-cell interaction that have been reported in this study have 
previously not been investigated in the context of field cancerisation. Thus, a candidate free 
approach was successful at identifying novel cellular processes that are dysregulated in the 
colonic field. Although some of these genes have been implicated in CRC formation 
previously, their role in being a marker of the field defect or driving biological alteration in 
the colonic field has not been evaluated. Further validation of the genes identified could help 
to elucidate if they can act as CRC biomarkers and help to risk stratify individuals based on 
the field cancerisation concept.    
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4.4.6. Limitations 
There are some limitations to this study that require further consideration. Although the 
number of patients investigated may appear small, it is comparable to earlier microarray 
exploratory studies designed to investigate global differences in gene expression (Kitahara et 
al., 2001; Zou et al., 2002; Dai et al., 2012). The other limitation is that no molecular 
subtyping of the CRC was performed. Previous studies investigating field cancerisation have 
highlighted that gene expression changes in the MNM parallel those found in the tumour 
itself suggesting that they may predate or contribute to the malignant process (Worthley et 
al., 2010; Facista et al., 2012). This also implies that there may be differences in the various 
molecular subtypes of CRC with field cancerisation being observed in only specific types. 
However, there is insufficient evidence in the current literature to determine which 
molecular subtypes of CRC are more important when investigating field cancerisation. Thus, 
it was felt that it would be more important to ascertain which cellular processes are 
dysregulated across several molecular subtypes of CRC rather than focusing on any 
individual subtype.  
 
One of the shortcomings of microarray technology has recently been highlighted in a meta-
analysis which found little overlap in the differentially expressed genes reported in different 
studies. Amongst the genes that were reported by multiple studies, there were 
inconsistencies in the direction in which the genes were changed. This may relate to 
differences in sample collection and processing (with some using laser capture 
microdissection), use of different array technology (cDNA versus oligonucleotide array) and 
discrepancies in analysis techniques or definitions of what constitutes differential expression 
(Cardoso et al., 2007). It highlights that individual genes that are identified by these studies 
require validation using different experimental techniques to support the micro-array 
findings.  
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4.5. Summary and conclusions 
 Multiple cellular processes were altered in the MNM around cancer and adenomas 
supporting the field cancerisation concept 
 Several of the genes identified were related to the extracellular matrix, cytoskeletal 
components, cell adhesion and epithelial-mesenchymal transition.  
 The transition to invasive malignancy was accompanied by alterations in immune 
function and metabolism in the MNM around cancer.  
 Across all three groups, genes that regulate RNA transcription were under-
represented suggesting inactivation of these genes which could contribute to the 
genomic instability observed in tumour tissue itself.  
 It is unclear whether these biological processes occur prior to or after the 
development of cancer which requires further investigation 
 It is important to both validate and investigate the differences in global gene 
expression observed in this study as this will facilitate identification of biomarkers 
that can not only aid early diagnosis but could be utilised to risk stratify individuals 
prior to the development of any histological abnormality. 
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5.1. Introduction, aims and objectives 
5.1.1 Introduction 
The concept of field cancerisation, first described by Slaughter (SLAUGHTER et al., 1953), 
has been applied to several different cancers (Wong et al., 2001; Kim et al., 2006; 
Grepmeier et al., 2005; Kakizoe, 2006; Kitago et al., 2004; Jonason et al., 1996) including 
colorectal cancer (CRC). Over the last three decades, there has been a gradual increase in the 
number of reports describing alterations in the macroscopically normal mucosa that could 
potentially hold the clue to the process that underlies field cancerisation (Shen et al., 2005; 
Polley et al., 2006; Badvie et al., 2006; Bernstein et al., 2013). There have been a few 
attempts to translate these findings into the clinical arena enabling early CRC diagnosis 
based upon biological changes detected at a distant site to the tumour (Gomes et al., 2009).  
Despite these advances, the biological processes that underlie field cancerisation remain 
poorly understood. In the previous chapter (chapter 4), a candidate free approach with 
microarray technology was utilised to identify novel cellular processes and genes that were 
dysregulated in the macroscopically normal mucosa (MNM) around CRC and colorectal 
adenomas. A number of genes were identified based on the two different analytical methods 
utilised (see chapter 4) including MUC2, MUC5AC, GADD45B, PSCA, FUT2, CXCL2, 
S100P and SLC46A1 (see table 5.1.).  These genes were chosen based on statistical 
significance and biological relevance as discussed in chapter 4.  
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Table 5.1. Micro-array genes. Genes identified for further investigation based on the 
microarray study findings. Information given regarding the family of genes to which the 
gene belongs, its biological function and role in cancer biology.  
Gene General description Specific description Role in cancer 
MUC2 
Mucin 2 
MUC5AC 
Mucin 5, 
subunit AC 
Family of proteins (MUC1-
MUC21) containing tandem 
repeat structures with high 
proportion of prolines, 
threonines and serines. 
(Timpte et al., 1988; Gendler 
et al., 1987) 
Secreted mucins (MUC2, 
MUC5AC and MUC6) 
produce mucous gel - 
physical barrier. 
MUC2-colorectal 
MUC5AC-bronchial 
Implicated in lung, gallbladder 
and GI tract cancer (López-
Ferrer et al., 2001; Yu et al., 
2005; Briggs et al., 2009). 
Conflicting reports in tumour 
vs control. 
GADD45B 
Growth 
arrest DNA 
damage 
inducible 45, 
subunit B 
Small, conserved proteins 
which act as stress sensors and 
modulate the cellular response 
to genotoxic or physiological 
stress (Liebermann & 
Hoffman, 2002). Interacts 
with other proteins involved in 
the stress response including 
PCNA, p21, Cdc2/Cyclin B1, 
MEKK4 and p38 kinase 
GADD45B acts in co-
ordination with other 
factors to inhibit cell 
growth and promote 
apoptosis 
Implicated in human 
hepatocellular carcinoma and 
pituitary gonadotrope tumours 
(Michaelis et al., 2011; Ou et 
al., 2010; Qiu et al., 2003). 
Role in CRC unclear. 
CXCL-2 
Growth 
related 
oncogene β 
(GRO- β) 
CXC family - group of small 
proteins that modulate 
leukocyte migration to sites of 
inflammation (Charo & 
Ransohoff, 2006) and in 
tumours, induce angiogenesis 
and modify host immune 
response (Balkwill, 2012; 
Koizumi et al., 2007) 
CXCL-2 is an ELR (‘glu-
leu-arg’ ) positive 
chemokine - pro-
angiogenic, able to attract 
& activate neutrophils & 
stimulates endothelial cell 
migration 
(Vandercappellen et al., 
2008; Strieter et al., 2006).  
Possible role in CRC though 
reports are conflicting 
(Friederichs et al., 2005). 
Possible role as a serum 
biomarker of CRC (Zheng et 
al., 2015) 
SLC46A1 
solute carrier 
family 46 
(folate 
transporter), 
member 1 
Proton coupled folate 
transporter (PCFT), involved 
in intestinal absorption of 
dietary folates (Hou & 
Matherly, 2014; Zhao & 
Goldman, 2007) 
More active in the 
stomach and tumour tissue 
as requires a more acidic 
environment  
Linked to longer disease free 
survival in CRC (Odin et al., 
2015) 
S100P 
S100 
calcium 
binding 
protein P 
95 amino acid residue protein, 
member of EF-hand 
superfamily of calcium 
binding proteins which 
mediate calcium dependent 
signalling regulating cellular 
processes such as cell cycle, 
growth, differentiation and 
metabolism (Donato, 
2001)(Donato 2001) 
Interacts with (RAGE) to 
stimulate Erk and (NF)-κB 
activity leading to cell 
growth and migration 
(Tóthová & Gibadulinová, 
2013). Targets E2/EP4 
receptor signalling 
pathway leading to cell 
invasion and motility 
(Chandramouli et al., 
2010)  
 
Implicated in several cancers 
including cancer of the 
pancreas (Dowen et al., 2005), 
breast (Guerreiro Da Silva et 
al., 2000), prostate (Wang et 
al., 2007), lung (Rehbein et 
al., 2008) and colon 
(Birkenkamp-Demtroder et 
al., 2005). 
FUT2 
Fucosyltrans
ferase 
2 
Secretor type of α(1,2) 
fucosyltransferase-regulates  
expression of H antigen 
(Wang et al., 1994a; Wang et 
al., 1994b; Masutani & 
Kimura, 1995) (precursor of 
essential A and B antigens)  
Determine microbial flora 
in colon thus provides link 
between microbiota and 
CRC  
Glycosylation pattern of A/B 
antigens changes during 
malignant transformation 
(Hakomori, 1989). 
PSCA 
Prostate 
stem cell 
antigen 
Member of the LY-6 family of 
surface proteins 
 High in prostate, bladder, 
endometrium, kidney, lung & 
pancreas cancer (Liu et al., 
2010; Cao et al., 2005; 
Elsamman et al., 2006). 
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Early reports addressing the changes in the MNM adjacent to CRC (termed the transitional 
mucosa) identified an increase in the number of goblet cells (Dawson & Filipe, 1976; 
Riddell & Levin, 1977) with changes in sulfation of mucin that was present (Nieuw 
Amerongen et al., 1998; Filipe & Branfoot, 1974). Therefore, it seems plausible that there 
could be changes in mucin content in the adjacent MNM around cancer or polyp that could 
play a role in field cancerisation. Several recent reports have highlighted defective DNA 
repair in the MNM around CRC up to 10 cm from the tumour which could underlie field 
cancerisation (Shen et al., 2005; Facista et al., 2012). Similarly, GADD45B which is usually 
released in response to cellular stress, also helps to maintain genomic integrity by arresting 
cell growth and promoting apoptosis. It has recently been identified in a 12 gene marker 
panel utilised for risk stratification of stage II CRC patients (O'Connell et al., 2010; Gray et 
al., 2011). This implies that it is a marker of risk of recurrence which could occur through 
field cancerisation whereby individuals with a field defect are at higher risk of metachronous 
lesions. Therefore, GADD45B could be an indicative marker of field cancerisation.   
 
The other five genes that were selected for further investigation have previously not been 
linked to field cancerisation, though a few of them have been implicated in CRC formation. 
CXCL2 interacts with its receptor, CXCR2 to activate neutrophils and endothelial cells 
(Strieter et al., 1995; Addison et al., 2000).  There have been a few studies which have 
linked expression of chemokines to increased metastatic potential and poor clinical outcome 
in CRC (Kim et al., 2005; Schimanski et al., 2005; Günther et al., 2005; Kawada et al., 
2007; Kollmar et al., 2006; Yoshitake et al., 2008). However, studies in which CXCL2 
expression in CRC has been examined have yielded conflicting results. Some have proposed 
that it is increased in CRC (Doll et al., 2010), others have failed to demonstrate a difference 
in expression levels (Cuenca et al., 1992; Wen et al., 2006) whilst there have been a few 
reports to imply that it is actually anti-angiogenic (Cao et al., 1995). Further investigation is 
necessary to elucidate the precise role of this chemokine in CRC. 
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SLC46A1 has been linked to improved disease free survival in CRC (Odin et al., 2015) 
whereas S100P has been associated with increased tumourigenic activity and metastatic 
potential in CRC suggesting that it may have a role in promoting carcinogenesis (Jiang et al., 
2011; Wang et al., 2012; Dong et al., 2014). In comparison, despite being linked to 
susceptibility to infections such as Norovirus (Marionneau et al., 2005; Carlsson et al., 
2009) and HIV progression (Kindberg et al., 2006), the role of FUT2 in CRC is poorly 
understood. In the foetus, ABH antigens are expressed equally along the length of the colon 
(Dabelsteen et al., 1988; Szulman, 1987). At birth, ABH antigens are no longer expressed in 
the distal colon which creates a proximal-distal gradient. Several studies have linked 
differences in expression of H antigens to tumour progression in the distal colon and rectum 
(Wiley et al., 1981; Yuan et al., 1985; Schoentag et al., 1987). However, there have also 
been reports suggesting that cell surface fucosylation does not affect development of colon 
tumours in mice (Domino et al., 2007)(Domino et al, 2007) questioning its role in 
carcinogenesis.  
PSCA had the highest fold change in both types of microarray analysis and was therefore 
selected. It is usually overexpressed in prostate cancer, particularly with the more aggressive 
form, (Gu et al., 2000). Reduced levels of expression have been found in bladder, gastric 
and oesophageal cancer (Bahrenberg et al., 2000). There have only been a few reports 
investigating the PSCA gene and colorectal cancer which have not yielded any conclusive 
results.  
 
Although these genes were identified with the previous microarray study, it is generally 
accepted that validation of microarray findings is necessary. This is usually achieved by 
examining gene expression in a separate cohort of patients to the original set or utilising 
different experimental methods. 
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5.1.2 Aims and objectives  
The aim of this study was to  
i) Measure the gene expression level of MUC2, MUC5AC, GADD45B, PSCA, 
SLC46A1, CXCL2, S100P and FUT2 in colorectal tumour tissue, adjacent 
MNM, at the resection margin and in control subjects to elucidate if these genes 
have any role in field cancerisation 
ii) Validate the findings from the micro-array study (discussed in chapter 4) by 
measuring mRNA expression of these genes and comparing it to levels 
identified using micro-array 
iii) Determine serum concentration of CXCL2 in control subjects and patients with 
cancer to determine if it could be used as a serum biomarker 
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5.2. Materials and Methods 
5.2.1 Setting and participants 
Ethical approval was sought as detailed in Chapter 2. In brief, after gaining informed 
consent from participants, mucosal tissue samples were taken from the tumour, adjacent to 
the tumour and at the most distant resection margin of the colectomy specimen from 
individuals undergoing surgery. These patients were age and sex matched to control subjects 
who were recruited at the time of colonoscopy. Mucosal pinch biopsies were taken from the 
caecal pole and rectum in these individuals. If a polyp was identified during the procedure, a 
biopsy adjacent to the polyp was also taken. The samples taken from these patients were 
used to examine field cancerisation around polyps. Only samples proven to be adenomatous 
on histology were included in this cohort. Right sided polyps and cancers (proximal to mid-
transverse) were matched with caecal samples from control subjects and left sided polyps 
and cancers were matched to rectal biopsies from control subjects. Patients with polyps also 
had additional biopsies taken from the caecum or rectum that were tested concurrently. No 
mucosal tissue was taken from the polyp itself as this is routinely analysed to exclude a 
malignant component. Thus, the results that are presented under the term ‘polyp’ are actually 
the gene expression levels of tissue found adjacent to the polyp.  
 
In total, 225 samples were included in the analysis from 30 cancer patients, 29 control 
patients and 23 patients with polyps. Due to the presence of synchronous lesions in some of 
these patients, 36 cancers and 32 polyps were assessed in total. Demographic data for the 
cancer and polyp patients are shown in table 5.2. In a subset of patients, serum CXCL2 
levels were measured as outlined in chapter 2.  
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Table 5.2. Clinical and pathological details of patients included in the analysis 
 Control Subjects 
(n=29) 
Polyp patients 
(n=23) 
Cancer patients 
(n=30) 
Median Age   
(IQR) 
69 (60-76) 71 (64-78) 66 (57-73) 
Male: Female 19:10 15:8 21:9 
 
Mean BMI (+/- S.D.) 25.9 (3.9) 26.3 (5.2) 26.1 (5.5) 
 
Smokers/Ex-
smokers (%) 
6 (21%) 10 (43%) 9 (30%) 
Diabetics (%) 4 (14%) 7 (30%) 3 (10 %) 
 
Aspirin use (%) 3 (10%) 7 (30%) 3 (10%) 
 
Statin use (%) 7 (24%) 5 (22%) 10 (33%) 
 
Cancers (n=36) 
 
Operation 
Right 
Hemicolectomy 
Extended R 
hemicolectomy 
Anterior Resection 
Sigmoid colectomy 
Left Hemicolectomy 
Other 
 
11 
 
5 
 
9 
1 
2 
3 
 
 
T staging 
T1-T2 
T3-T4 
N staging 
N0 
N1-N2 
Grade of tumour 
Well/Mod 
Poor 
 
8 
28 
 
19 
17 
 
21 
15 
 
Polyps (n=32) 
 
Type of polyp 
Sessile 
Pedunculated 
Villous 
Histology of polyp 
Tubular adenoma 
Tubulovillous 
adenoma 
Serrated adenoma 
Other 
 
24 
7 
1 
 
18 
7 
6 
1 
Size of polyp 
< 10 mm 
10-20 mm 
>20 mm 
Grade of dysplasia 
Low 
High 
Hyperplastic 
 
14 
10 
8 
 
29 
1 
2 
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5.2.2. Experimental methods 
The samples were stored in RNA later, kept at 4 oC overnight and subsequently stored at -20 
oC for future processing. mRNA was extracted using Qiagen RNeasy tissue mini-extraction 
kit and cDNA synthesis was performed with 250 ng cDNA as previously described (see 
chapter 2 for further details). Quantitative real time PCR (qRT-PCR) was performed with 
Taqman gene expression assays. The comparative 2-∆∆CT method was used to calculate 
mRNA expression level of the genes compared to expression levels of 18S which was the 
endogenous control. All values were log10 transformed prior to statistical analysis to 
normalise the data. Changes in gene expression of MUC2, MUC5AC, GADD45B, 
SLC46A1, FUT2, S100P and CXCL-2 were measured in all samples. To preserve the small 
quantities of samples available, PSCA was measured only in a subset of the patients as it 
was found to be expressed at very low levels, particularly in normal colonic tissue. Serum 
CXCL2 levels were measured using the MIP2 Human Simple Step Elisa Kit (Abcam, UK) 
as outlined in chapter 2. 
 
5.2.3. Statistical analysis 
Statistical analysis was performed using SPSS version 21 (SPSS Inc, Chicago, Illinois). 
Normally-distributed variables were described as mean and standard deviation and non-
normally distributed variables as median and interquartile range. Categorical variables were 
described as numbers and percentages. The test of significance to determine a difference 
between groups was assessed using chi-squared with categorical variables, t test or Mann-
Whitney U test for ordinal variables. A p value of <0.05 was considered significant. 
Multivariate linear regression analysis was used to identify patient and pathological factors 
that affected expression levels of the genes examined.  
The detailed analytical methods of the two types of analysis that were performed of the 
microarray data has been described in chapter 2. Genes that were chosen for validation in 
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analysis 1 were based upon statistical significance and biological plausibility with scientific 
reports linking the gene to field cancerisation. In the second analysis, genes were chosen 
based on their statistical significance across different comparisons between cancer, adenoma 
and control subjects. As alluded to previously, there was very little existing literature that 
linked these genes to field cancerisation.  
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5.3. Results 
5.3.1. Mucin expression is altered in CRC but GADD45B is no different 
MUC2 was significantly downregulated (0.4 fold) in tumour tissue compared to control 
subjects (∆∆CT (tumour) 11.41 versus ∆∆CT (controls) 10.04, p=0.003). However, expression 
levels in the adjacent MNM and at the resection margin were no different to control subjects 
(∆∆CT (adjacent MNM) 9.87 and ∆∆CT (margin) 10.09 versus ∆∆CT (controls) 10.04, p=0.467 
and p=0.826 respectively). 
 
In comparison, MUC5AC was significantly upregulated (12 fold) in tumour tissue compared 
to control subjects (∆∆CT (tumour) 13.45 versus ∆∆CT (controls) 17.12, p<0.0001). Again, the 
MUC5AC expression in the adjacent MNM and at the resection margin was similar to that 
found in control subjects (∆∆CT (adjacent MNM) 17.83 and ∆∆CT (margin) 17.25 versus ∆∆CT 
(controls) 17.12, p=0.408 and p=0.889 respectively).  
 
In control subjects, there was a significant increase in expression of MUC2 and MUC5AC 
along the colon with levels in the left colon being significantly higher than the right colon 
(p<0.001 for both). MUC2 was significantly down regulated in the tumour tissue for left 
sided tumours only (p=0.017) and MUC5AC was significantly upregulated for right sided 
tumours only (p<0.001).  
 
No significant differences in gene expression of GADD45B were found between the four 
groups examined (∆∆CT (tumour) 15.65 versus ∆∆CT (controls) 15.96, p=0.201).  
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Figure 5.1.1. MUC2 expression levels 
in control subjects compared to tumour 
samples, MNM adjacent to tumour and 
at the resection margin from the 
colectomy specimen.  
 
 
 
 
Figure 5.1.2 MUC5AC expression 
levels in control subjects compared to 
tumour samples, MNM adjacent to 
tumour and at the resection margin from 
the colectomy specimen.  
 
 
 
 
 
Figure 5.1.3 GADD45B expression 
levels in control subjects compared to 
tumour samples, MNM adjacent to 
tumour and at the resection margin 
from the colectomy specimen. 
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Based on paired analysis of samples taken from the colectomy specimen, MUC2 was 
significantly downregulated and MUC5AC was significantly upregulated in the tumour 
compared to the resection margin (p=0.004 and p<0.0001 respectively). No differences were 
found between the adjacent MNM and resection margin.   
Across all three genes, there were no differences in mRNA expression in the adjacent MNM 
around polyps compared to control subjects (MUC2 p=0.650, MUC5AC p=0.553 and 
GADD45B p=0.511). However, if the MNM adjacent to polyp was compared to that around 
cancers, MUC5AC was found to be significantly upregulated (∆∆CT (adjacent polyps) 15.73 
versus ∆∆CT (cancer) 17.83, p=0.017).  
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Fig 5.1.4. MUC2 expression levels 
in control subjects compared to 
right colonic, left colonic and 
adjacent MNM taken in patients 
with polyps.  
 
 
 
 
Fig 5.1.5. MUC5AC expression 
levels in control subjects compared 
to right colonic, left colonic and 
adjacent MNM taken in patients 
with polyps.  
 
 
 
Fig 5.1.6. GADD45B expression 
levels in control subjects compared 
to right colonic, left colonic and 
adjacent MNM taken in patients 
with polyps.  
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5.3.2. CXCL2, S100P and FUT2 are dysregulated in CRC 
PSCA was expressed at very low levels in colonic tissues (CT > 39 in 60 % samples tested). 
Hence, only a small proportion of the cohort were included in the analysis. PSCA was 
expressed in 10/12 tumours and there was no significant difference in expression levels in 
control subjects compared to the cancer patients (p=0.121). 
 
The expression levels of the other 4 genes are given in figure 5.3.1.6. Both CXCL2 and 
S100P were significantly upregulated in tumour tissue compared to control subjects 
(CXCL2: 60-fold difference, p<0.0001; S100P: 6-fold difference, p<0.001), FUT2 was 
significantly downregulated (1.6-fold difference, p=0.002) and no differences were found 
with SLC46A1 (p=0.115). 
 
CXCL2 was significantly upregulated in the adjacent MNM and resection margin mucosa of 
cancer patients compared to controls (4-fold difference and 5-fold difference respectively, 
p<0.001 for both). SLC46 A1 was only upregulated in the adjacent mucosa and not at the 
resection margin compared to control subjects. There were no differences in gene expression 
of S100P and FUT2 in the adjacent mucosa or at the resection margin.  
 
Using paired t tests, gene expression levels were also compared at the three sites of sampling 
undertaken in patients with CRC. CXCL2 and S100P were significantly upregulated in the 
tumour compared to the resection margin (p<0.0001 and p=0.009 respectively) and FUT2 
was significantly downregulated (P<0.0001). No differences were found with SLC46A1 
(p=0.666). The gene expression level of all four genes in the adjacent MNM was no different 
to that at the resection margin. 
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Fig 5.2.1. Expression levels of CXCL2, FUT2, S100P and SLC46A1 in control subjects 
compared to patients with cancer (samples taken from the tumour, adjacent MNM and at the 
resection margin). 
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With regards to patients who had polyps (see figure 5.3.1.7), CXCL2 was the only gene that 
was found to be significantly upregulated (2.4 fold) in the mucosa adjacent to a polyp 
compared to MNM taken from control subjects (∆∆CT (adjacent to polyp) 24.23 versus ∆∆CT 
(controls) 25.52, p=0.013). The level of CXCL2 gene expression in paired samples taken at 
distant points in the colon of patients with polyps did not differ from the level recorded in 
MNM of control subjects. No differences in gene expression were recorded for FUT2, 
S100P and SLC46A1 amongst the polyp patients.  
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Fig 5.2.2. Expression levels of CXCL2, FUT2, S100P and SLC46A1 in control subjects 
compared to patients with polyps (samples taken from adjacent MNM around polyps 
(labelled polyp), right colonic and left colonic biopsies).  
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5.3.3. There is a gradient in gene expression along the colon comparing caecum to 
rectum 
However, paired analysis using samples taken at caecum and rectum from patients with 
polyps revealed that CXCL2, S100P and SLC46A1 were significantly upregulated adjacent 
to the polyp compared to expression levels in the caecum (p<0.001, p<0.001 and p=0.03 
respectively) whereas FUT2 was significantly downregulated (p=0.003). No differences in 
gene expression were seen if expressions levels adjacent to the polyp were compared to 
rectal samples taken from control subjects (p=0.124, p=0.295. p=0.342 and p=0.352 
respectively). S100P expression was significantly higher in the adjacent MNM of left sided 
polyps compared to right sided polyps (p<0.001) and decreased with increasing number of 
polyps (p=0.006). FUT2 expression in the adjacent MNM of polyps correlated with number 
of polyps in the colon (p=0.006, r=0.422), size (p=0.034, r=-0.375) and morphology of the 
polyps (p=0.035, r=-0.373).  
 
If expression levels of the genes are compared in the caecum and rectum in controls 
subjects, there are significant differences along the colon for all four genes (CXCL2 
p<0.001, FUT2 p=0.003, S100P p<0.001 and SLC46A1 p=0.01). Due to this gradient in 
gene expression, if right sided tumours are compared to caecal samples from control 
subjects, all four genes are significantly different in the tumour compared to control subjects, 
including SLC46A1 (p=0.006). If left sided tumours are compared to rectal samples from 
control subjects, SLC46A1 is no longer upregulated in tumours (p=0.894). Despite this 
gradient in gene expression, there are no differences in gene expression of right sided 
tumours versus left sided tumours for all genes except FUT2. FUT2 is significantly 
upregulated in right sided tumours compared to left sided tumours (p=0.02).  
 
 
181 | P a g e  
 
5.3.4. Serum CXCL2 levels do not differ between the three groups 
Serum CXCL2 concentration was measured in 25 patients with cancer, 20 patients with 
polyps and 29 control subjects. There was no difference in serum CXCL2 concentration in 
patients with cancer compared to control subjects (mean concentration 401.7 +/- 46.8 pg/mL 
versus 376.0 +/- 54.6 pg/mL, p=0.73). Similarly, no statistical difference was noted between 
patients with polyps and control subjects (mean concentration 402.5 +/- 70.0 pg/mL versus 
376.0 +/- 54.6 pg/mL, p=0.77).  
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5.4 Discussion 
This study has identified significant differences in CXCL2 gene expression in the MNM 
around a cancer and adenoma highlighting its potential role in field cancerisation in CRC. In 
agreement with previous reports, it has also demonstrated differential gene expression of 
mucin in tumour tissue.  
 
Based on the qRT-PCR experiments, CXCL2 was significantly upregulated in the adjacent 
MNM of both cancer and polyp patients, with slightly lower levels being observed in the 
polyp patients. Previous studies have shown that CXCL2 gene expression increases in 
colonic tumour tissue and adenomas (Doll et al., 2010; McLean et al., 2011), however, this 
is the first study to demonstrate a difference in gene expression in the adjacent MNM of both 
pre-neoplastic and neoplastic colorectal lesions suggesting a potential role in field 
cancerisation. Inflammatory activity in CRC tumour tissue is a known predictor of prognosis 
(Galon et al., 2006) and in vitro studies have shown that colonic tumour cells both secrete 
cytokines and possess the receptors required to respond to them directly (Schimanski et al., 
2005; Sturm et al., 2005; Zipin-Roitman et al., 2007; Li et al., 2004). However, the point at 
which an inflammatory environment promotes tumour formation is not known. The finding 
that CXCL2 gene expression is increased in adenomatous lesions and this is accompanied by 
increased numbers of macrophages, neutrophils and T cells in the stroma (McLean et al., 
2011) suggests that inflammatory changes are important early on in carcinogenesis. The 
findings of this study, however, suggest that these changes may even predate the formation 
of adenomas. CXCL2 has been shown to have both angiogenic and proliferative activity 
(Wang et al., 2006a; Bruyère et al., 2011), hence, it is conceivable that changes in its levels 
could contribute to the early processes that are necessary for malignant transformation. 
However, there have been reports where no differences in gene expression of CXCL2 have 
been found when comparing tumour tissue to control tissue (Cuenca et al., 1992; Li et al., 
2004; Wen et al., 2006) leading authors to propose that it may be the balance between pro-
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angiogenic and anti-angiogenic cytokines that contributes to tumour formation rather than 
levels of a single cytokine (Strieter et al., 1999). Nevertheless, this study has demonstrated 
that CXCL2 gene expression at a distant site from the tumour could be utilised to identify 
patients with cancer. However, these differences in expression were not detected in serum 
samples taken from the three groups. This contradicts the findings of a recent study which 
demonstrated higher serum CXCL2 concentration in cancer patients compared to control 
subjects (Zheng et al., 2015) highlighting the potential role of CXCL2 as a serum biomarker 
of CRC. Although this study demonstrated a statistical difference between cancer patients 
and control subjects, there was wide variation in the serum CXCL2 concentration, 
particularly in the cancer patients. This is similar to the findings of the present study where 
wide variation was observed in all three groups. There are many factors that can contribute 
to raised serum CXCL2 concentration (Bauer et al., 2006; Tsai et al., 2014) which may 
explain the high levels detected in control subjects. Despite the recent report of its potential 
role as a serum biomarker, given the wide variation observed across individuals, it would be 
difficult to determine an appropriate cut-off for it to be used as a screening or diagnostic test.  
 
In agreement with several previous reports (Blank et al., 1994; Ajioka et al., 1996; Weiss et 
al., 1996; Perez et al., 2008; Sylvester et al., 2001; Börger et al., 2007), MUC2 was found to 
be downregulated in tumour tissue and MUC5AC was upregulated (Losi et al., 2004; Walsh 
et al., 2013; Arai et al., 2007; Park et al., 2006). In vitro studies have shown that loss of 
MUC2 results in increased cell proliferation, reduced apoptosis and increased cell migration 
(Velcich et al., 2002). Similarly, MUC2 knockout leads to a 65 % increased incidence of 
tumours of the small intestine, colon and rectum within 1 year of birth in murine models 
(Velcich et al., 2002). This study therefore suggests that MUC2 functions as a tumour 
suppressor, hence, inactivation promotes tumour growth. However, several studies have also 
shown that MUC2 and MUC5AC are more likely to be expressed in mucinous cancers with 
microsatellite instability (MSI) (Bu et al., 2010; Biemer-Hüttmann et al., 2000), BRAF 
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mutation and cancers that are poorly differentiated, proximal or have a high lymphocytic 
response (Walsh et al., 2013). Generally it is accepted that MUC2 is usually downregulated 
in CRC (Aziz MA et al., 2014) except in a proportion of mucinous cancers where it can be 
upregulated (Walsh et al., 2013). In the present study, MUC2 and MUC5AC gene 
expression were not related to tumour characteristics such as differentiation grade, mucinous 
histology or lymphocytic response. However, MUC2 was only downregulated in left sided 
tumours rather than right sided tumours suggesting preserved function with more proximal 
tumours as suggested in the literature. In contrast, MUC5AC gene expression was 
significantly upregulated in proximal tumours only and there were no differences in gene 
expression in left sided tumours compared to control subjects. A recent study which 
evaluated MUC2 and MUC5AC expression using immunohistochemistry also showed that 
MUC5AC expression was associated with proximal tumours and mismatch repair deficiency 
(Imai et al., 2013). This supports the hypothesis that these mucins are more likely to be 
expressed in proximal tumours which tend to develop along the MSI pathway rather than the 
conventional CIN pathway. As the differences in gene expression of MUC2 and MUC5AC 
were only observed at the tumour site and not in the adjacent MNM, these mucins are 
unlikely to play a role in field cancerisation. On the other hand, in this study, the mucosa 
adjacent to polyps demonstrated higher MUC5AC expression compared to adjacent MNM 
around cancers. Previous reports where MUC5AC protein expression has been examined 
along the colon have shown that there is variable staining of normal goblet cells in the MNM 
in close proximity to the tumour but no staining of these cells at more distant sites from the 
tumour (Walsh et al., 2013). This raises the possibility that MUC5AC may be indicative of 
an early field defect particularly around pre-neoplastic polyps. However, in an earlier study 
which was designed to evaluate the role of MUC5AC in field cancerisation around polyps, 
MUC5AC was not detected in any of the samples taken adjacent to polyps which led the 
authors to conclude that MUC5AC gene expression does not represent a ‘field change’ 
around polyps (Longman et al., 2000).  
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Similar to previous reports, this study also demonstrated that S100P is upregulated in 
colorectal tumour tissue compared to control tissue (Birkenkamp-Demtroder et al., 2005; 
Fuentes et al., 2007; Parkkila et al., 2008; Wang et al., 2012). S100P has been found to be 
overexpressed in several other cancers suggesting that it may play a more generic role in 
cancer formation by contributing to cell proliferation and migration (Dowen et al., 2005; 
Guerreiro Da Silva et al., 2000; Wang et al., 2007; Rehbein et al., 2008). In vitro studies 
have shown that S100P induces anchorage independence of tumour cells (Dowen et al., 
2005), increases proliferation (Fuentes et al., 2007), promotes migration, invasion and 
decreases chemosensitivity to conventional agents such as 5-fluoruracil (Dong et al., 2014). 
Conversely, blocking its action results in reduced cell growth, migration and invasion in 
vitro and smaller tumours with fewer liver metastases in vivo. Interestingly, in the present 
study S100P gene expression levels in the adjacent MNM around cancer were significantly 
lower than that in adjacent MNM around adenomatous lesions. As the majority of the 
downstream targets of S100P are cytoskeletal regulators, changes in cell anchorage and 
migration in the adjacent MNM may be more important in the field around adenoma 
formation compared to a neoplastic lesion as suggested by the findings of the microarray 
study described in chapter 4. 
 
In this study, FUT2 was upregulated in tumour tissue, however, no differences were found in 
the adjacent MNM around polyp or cancer compared to control subjects. Previous reports 
have shown altered gene expression of fucosyltransferases in colorectal cancer compared to 
control subjects (Petretti et al., 2000). Aberrant fucosylation can lead to expression of 
altered antigens on the cell surface which results in dysregulation of key cellular processes 
and altered cell adhesion. Bacteria in the GI tract often utilise host cell surface molecules, 
hence, genetic variation in the FUT2 gene has been implicated in susceptibility to several 
bacterial infections such as Norovirus (Marionneau et al., 2005; Carlsson et al., 2009) and 
Helicobacter Pylori (Ikehara et al., 2001). Loss of the FUT2 gene has also been linked to 
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increased incidence of Crohn’s disease suggesting that it plays a role in the host-microbial 
interface (McGovern et al., 2010). Given the link between colonic microflora and CRC, it is 
conceivable that disordered fucosylation could contribute to the malignant process. 
Furthermore, in the present study, FUT2 gene expression was significantly different in right 
sided lesions compared to left sided lesions. This may explain the differences observed in 
expression of H antigens along the colon and in neoplastic tissues that have been reported in 
a previous study (Fujitani et al., 2000).  
 
There are some limitations to the present study that require consideration. Firstly, there has 
been no attempt to subgroup the patients with cancer according to MSI status. Previous 
reports on field cancerisation in CRC have shown that the most consistent changes at the 
molecular level reported at distant sites along the colon include changes in methylation and 
DNA repair (Shen et al., 2005; Worthley et al., 2010; Facista et al., 2012). This suggests that 
cancers that develop along the conventional pathway with chromosomal instability are 
potentially less likely to harbour a field defect. However, there is no conclusive evidence in 
the literature to support this hypothesis. Given that the aim of the study was to identify 
potential genes that could contribute to field cancerisation, it was felt that excluding patients 
based on MSI status would mean that field cancerisation in conventional CRCs would not be 
explored which form the majority of patients.  
 
Secondly, this study has highlighted discrepancies in levels of expression measured using 
micro-array technology compared to qRT-PCR demonstrating some of the limitations of 
micro-array. The fact that no differences in gene expression were observed for the gene that 
was found with the highest fold change on micro-array, PSCA, suggests that validation of 
micro-array is necessary. Although there is general agreement amongst researchers that 
micro-array data needs validation (Chuaqui et al., 2002; Firestein & Pisetsky, 2002; Benes 
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& Muckenthaler, 2003), few attempts have been made to describe the precise methods and 
selection criteria for testing of individual genes (Brazma et al., 2001; Miron et al., 2006). 
These protocols are poorly adhered to resulting in considerable variability of reported 
outcomes across the literature (Cardoso et al., 2007) leading some authors to propose that 
the focus of enquiry should be based on biological pathways rather than individual genes 
(Chen et al., 2013b). Others have focussed on selecting genes with the largest effect, either 
determined by fold change value or statistical significance (Chuaqui et al., 2002; Irizarry et 
al., 2005; Larkin et al., 2005). However, this may not be the most optimal approach as 
highlighted in a study which demonstrated that a random stratified sampling approach is 
more effective at identifying genes for validation with qRT-PCR (Miron et al., 2006). 
Furthermore, wide ranging correlations between microarray and qRT-PCR data have been 
described in the literature (Beckman et al., 2004; Etienne et al., 2004; Larkin et al., 2005; 
Dallas et al., 2005), particularly with genes that are expressed at low levels in the tissue 
being examined (Czechowski et al., 2004). Other reasons for poor correlation include very 
high expression levels, at the limits of detection (Etienne et al., 2004) or alternative 
transcripts of the gene being detected by the two methods (Dallas et al., 2005). Despite these 
shortcomings, the present study was successful at identifying CXCL2 as a biomarker 
indicative of field cancerisation in colorectal cancer. As there have been no previous reports 
linking CXCL2 to field cancerisation, these findings highlight the importance of adopting a 
candidate free approach to evaluate global gene expression profiles in an exploratory study 
of this kind. 
 
5.5. Summary and conclusions  
 CXCL2 is upregulated in the adjacent MNM around both CRC and adenomas 
compared to MNM in control subjects therefore it could be an indicative marker of 
field defect 
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 MUC2 is downregulated and MUC5AC is upregulated in the tumour tissue 
compared to MNM in control subjects 
 There are no differences in expression of MUC2 or MUC5AC in the adjacent MNM 
or resection margin of colectomy specimens compared to MNM from control 
subjects 
 The findings highlight the importance of the inflammatory micro-environment in 
supporting cell growth, invasion and metastasis, possibly at an earlier stage than 
previously reported. 
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Chapter 6: The role of 
fibroblast growth factors 
in field cancerisation in 
colorectal cancer 
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6.1. Introduction, aims and objectives  
6.1. Introduction 
There is emerging evidence to support the concept that the tumour microenvironment plays a 
fundamental role in supporting tumour growth facilitating both invasion and metastasis 
(O'Toole et al., 2014; Chen et al., 2015). Previous reports have demonstrated that there are 
alterations in cell proliferation and apoptosis in the macroscopically normal colonic field 
around colorectal cancer supporting the field cancerisation concept (Anti et al., 2001; 
Badvie et al., 2006; Hanna-Morris et al., 2009). However, few have investigated how the 
stromal compartment changes in the macroscopically normal mucosa (MNM) around 
colorectal cancer (CRC) and adenomas (Despotović et al., 2014). The microarray study 
described in chapter 4 (page 144) identified fibroblast growth factor 7 (FGF7) as being 
dysregulated in the MNM adjacent to polyps compared to MNM taken from control 
subjects. FGF7 is also known as keratinocyte growth factor and is a mitogen that is produced 
by cells of mesenchymal origin (Finch et al., 1989; Rubin et al., 1989). It acts upon a 
particular subtype of fibroblast growth factor receptor (FGFR) called FGFR2b which is 
usually expressed by epithelial cells (Miki et al., 1991). There are 20 alternative splicing 
variants of FGFR2 that have been identified (Katoh, 2008). The major splicing event occurs 
in the carboxyl terminal half of the third Ig-like domain (D3) which results in two variants of 
receptor (Eswarakumar et al., 2005) –  
i) FGFR2IIIb which binds FGF 1, 3,7,10 and 22 
ii) FGFR2IIIc which binds FGF 1,2,4,6,9,17,18. 
The distribution of FGF7 and its receptor supports the proposal that it acts as a paracrine 
signal and plays a role in epithelial-mesenchymal transition (EMT) (Finch & Rubin, 2004). 
The downstream signalling pathways that are activated upon FGF7 binding to its receptor 
involve mitogen-activated protein kinases (MAPK) including ERK-1 and ERK-2 (Katoh & 
Nakagama, 2014).  
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FGF7 plays a role in epithelial repair in response to a toxic insult (Chen et al., 2004a; Farrell 
et al., 1998; Ulich et al., 1997; Yi et al., 1998) by stimulating cell proliferation, migration, 
differentiation,  DNA repair and induction of enzymes that are involved in eradication of 
reactive oxygen species (Finch & Rubin, 2004). FGF7 has been shown to be a mitogen that 
increases epithelial cell proliferation in many different organs and therefore may augment 
tumour cell growth (Housley et al., 1994; Nguyen et al., 1996; Ulich et al., 1994). It may 
also protect malignant cells from the toxic effects of chemotherapy by enhancing cell 
proliferation and increasing cell survival thus contribute to drug resistance.  
 
In CRC, conflicting results have been observed amongst studies measuring expression levels 
of FGF7 and FGFR2 with some investigators proposing that expression is higher in CRC 
(Watanabe et al., 2000) and others finding it to be no different (Otte et al., 2000). Some 
investigators have shown that expression of FGFR2IIIb confers a well differentiated 
phenotype of CRC (Yoshino et al., 2005; Otte et al., 2000). Stronger FGFR2 expression was 
detected in the invasive front of CRC cells compared to the surface or central area of 
cancerous cells (Matsuda et al., 2011). If FGFR2 expression was blocked in CRC cell lines, 
there was a reduction in cell migration, invasion and tumour growth highlighting the 
potential role of FGF7 in augmenting CRC growth. 
 
Several other fibroblast growth factors (FGFs) have also been implicated in CRC (Brooks et 
al., 2012), most notably, fibroblast growth factor 1 (FGF1) (Dirix et al., 1996; Wang et al., 
2010). All four fibroblast growth factor receptors have been linked to cancer formation (Sato 
et al., 2009; Jayson et al., 1999; Spinola et al., 2005; Jang et al., 2001). However, recent 
reports have proposed that fibroblast growth factor 19 (FGF19) may also play a role in CRC 
formation through interaction with the Wnt signalling cascade (Pai et al., 2008; Desnoyers et 
al., 2008; Katoh, 2006; Liu et al., 2013b). FGF19 belongs to the endocrine family of 
fibroblast growth factors (Kurosu & Kuro-O, 2009) and regulates bile acid (Holt et al., 
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2003), glucose (Kir et al., 2011; Potthoff et al., 2011), lipid (Tomlinson et al., 2002) and 
carbohydrate metabolism (Potthoff et al., 2012). FGF15/19 interacts with FGFR complexed 
with a membrane bound protein called β-klotho (Goetz et al., 2007; Lin et al., 2007; 
Tomiyama et al., 2010). If β-klotho is present, FGF19 can activate FGFR1c-3c and FGFR4 
(Kurosu et al., 2007), however, most of its biological activities are mediated through FGFR4 
as FGFR4 knockout mice show altered bile acid metabolism (Yu et al., 2000). Although 
FGFR4 plays a role in hepatocyte proliferation and suppression of bile acid synthesis, 
FGF19 is able to exert its effects on glucose and lipid metabolism independent of FGFR4 
(Wu et al., 2011) suggesting that there are multiple pathways through which FGF19 can act 
independent of the FGFR4 receptor. Several possible roles of FGF19 in driving CRC 
formation have been proposed in the literature (Nicholes et al., 2002; Sawey et al., 2011; 
Huang et al., 2009b). Several previous proteomic studies have identified FGFR4 as a 
potential predictive serum biomarker of CRC (Babel et al., 2009; Barderas et al., 2012). 
More recently it has emerged that FGFR4 activity drives epithelial-mesenchymal transition 
in CRC (Peláez-García et al., 2013; Liu et al., 2013b). However, its role in field 
cancerisation in CRC has previously not been investigated.  
 
6.1.2 Aims and objectives 
The aims of the study were as follows - 
i) To determine if gene expression levels of FGF7/FGF19 and its receptors 
FGFR2/FGFR4 differ between MNM adjacent to tumour, MNM adjacent to 
polyps and MNM taken from control subjects. 
ii) To ascertain if these changes in gene expression translate into discernible 
differences in serum concentration  
iii) To investigate which downstream pathways are affected by dysregulation of 
FGF signalling 
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6.2 Materials and Methods 
6.2.1. Setting and participants 
This study was approved by the Coventry and Warwick Local Research Ethics Committee 
(ref MREC ref no 09/H1211/38) and University Hospital Coventry & Warwickshire 
Research & Development division. Informed consent was gained from all participants. 
Mucosal tissue samples, serum, whole blood and plasma were collected from 117 
participants as outlined in section 2.2. There were 37 CRC patients, 23 patients with 
adenomas and 57 control subjects. The clinical and pathological details of these patients are 
given in table 6.1. 
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Table 6.1: Clinical and pathological details of all participants in the study. Due to the 
presence of synchronous lesions, 39 cancers and 32 adenomas were included in the analysis.   
 
 Control Subjects 
(n=57) 
Polyp patients 
(n=23) 
Cancer patients 
(n=37) 
Median Age  
(IQR) 
69 (60-76) 71 (64-78) 66 (57-73) 
Male: Female 31:26 15:8 20:17 
 
Mean BMI (+/- S.D.) 26.8 (6.6) 26.3 (5.2) 26.2 (6.7) 
 
Smokers/Ex-
smokers (%) 
17 (30%) 10 (43%) 10 (27%) 
Diabetics (%) 8 (15%) 7 (30%) 2 (5 %) 
 
Aspirin use (%) 11 (19%) 7 (30%) 2 (6%) 
 
Statin use (%) 9 (16%) 5 (22%) 10 (28%) 
 
Cancers (n=39) 
 
Operation 
Right 
Hemicolectomy 
Extended R 
hemicolectomy 
Anterior Resection 
Sigmoid colectomy 
En-bloc resection 
Other 
 
10 
4 
 
17 
3 
1 
2 
T staging 
T1-T2 
T3-T4 
N staging 
N0 
N1-N2 
Grade of tumour 
Well/Mod 
Poor 
 
11 
28 
 
22 
17 
 
26 
12 
 
Polyps (n=32) 
 
Type of polyp 
Sessile 
Pedunculated 
Villous 
Histology of polyp 
Tubular adenoma 
Tubulovillous 
adenoma 
Serrated adenoma 
Other 
 
24 
7 
1 
 
18 
7 
6 
1 
Size of polyp 
< 10 mm 
10-20 mm 
>20 mm 
Grade of dysplasia 
Low 
High 
Hyperplastic 
 
14 
10 
8 
 
29 
1 
2 
 
 
 
 
 
 
 
 
195 | P a g e  
 
6.2.2. Experimental methods 
Three different types of analysis were performed. Serum concentrations of proteins were 
measured using standard ELISA kits (see chapter 2) in 77 participants for FGF19 and 36 
participants for FGF7. As FGF19 is an endocrine FGF and is secreted into the bloodstream, 
the aim of the study was to determine how it differs in CRC and whether it could be used to 
identify patients with CRC. In comparison, FGF7 is not an endocrine FGF, thus, the aim of 
the study was to ascertain if there were sufficient protein levels in the bloodstream for it to 
be detected. If the results from this initial investigation were positive, then, further samples 
would be analysed to determine if it could also be utilised as a diagnostic biomarker.  
 
In a subset of patients, quantitative real time polymerase chain reaction (qRT-PCR) was 
used to measure changes in gene expression of FGF7/FGF19 and its receptors, 
FGFR2/FGFR4 respectively.  
 
The first downstream target along the FGF7 signalling cascade is fibroblast receptor 
substrate 2α (FRS2α) which is phosphorylated upon binding of FGF7 to its receptor FGFR2. 
The other downstream targets of FRS2α involve Erk 1/2 and Akt, both of which are 
phosphorylated upon activation (Eswarakumar et al., 2005). The protein expression levels of 
FRS2α, phospho-FRS2α, Erk 1/2, phospho-Erk 1/2, Akt and phospho-Akt were measured 
using Western blot analysis. Please see chapter 2 for detailed information regarding the 
methodology used.  
 
In total, 199 samples were analysed from 17 patients with CRC, 23 patients with polyps and 
34 control subjects. The control subjects were age and sex matched to the CRC patients with 
a 2:1 ratio. mRNA and protein expression were evaluated in the tumour tissue, MNM 
adjacent to tumour and MNM at the resection margin. In patients with adenomas, caecal and 
rectal samples were compared to MNM adjacent to the adenoma. There were no samples of 
the actual adenoma available for analysis as they were utilised for routine histological 
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analysis to exclude a malignant component. Hence, the results that are presented under the 
term ‘adenoma’ actually represent the expression levels detected in the MNM adjacent to the 
adenoma and not the adenoma itself. Right sided cancers or polyps were matched with 
caecal samples taken from control subjects and left sided lesions were matched with rectal 
samples from control subjects.  
 
6.2.3. Statistical analysis 
All qRT-PCR data was log10 transformed prior to statistical analysis with SPSS version 21.0. 
Mean expression levels between control subjects and cancer/polyp patients were compared 
using the unpaired t test. The paired t test was utilised to determine differences in gene or 
protein expression between samples taken at different sites from cancer patients. 
Multivariate linear regression was used to ascertain how different variables relate to serum 
FGF19 concentration. Statistical significance was based on p<0.05. 
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6.3. Results 
6.3.1. FGF7 is upregulated in the colonic field 
FGF7 was significantly upregulated in the tumour tissue itself (∆∆CT 21.4), its adjacent 
MNM (∆∆CT  20.9) and the resection margin (∆∆CT  21.1) in patients with cancer compared 
with control subjects (∆∆CT  22.6) (see figure 6.3.1). In comparison, there was significant 
down regulation of its receptor, FGFR2 in the tumour tissue itself (∆∆CT  21.2 in tumour 
versus 19.4 in controls, p <0.001). However, FGFR2 gene expression in the adjacent MNM 
(∆∆CT  19.6) and resection margin (∆∆CT 19.4) of CRC patients was no different from that 
found in control subjects.  
 
With paired analysis of samples taken from CRC patients, FGF7 and FGFR2 were both 
downregulated in the tumour tissue compared to the resection margin (p=0.036 for FGF7 
and p=0.013 for FGFR2). 
 
FGF7      FGFR2   
 
 
Figure 6.1: Mean gene expression level of FGF7 and FGFR2 in caecal or rectal samples 
taken from control subjects compared to samples taken from tumour tissue, adjacent MNM 
and resection margin of colectomy specimen from CRC patients. Statistical analysis using 
unpaired t test - P value < 0.05=*, <0.01= ** and <0.001= *** and NS=non-significant. 
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6.3.2. The FGF7-FGFR2 signalling axis is dysregulated in tumour tissue 
FGF7 gene expression was negatively correlated with FGFR2 gene expression in samples 
taken from control subjects. However, this relationship was lost in tumour tissue and no 
correlation was detected between expression levels of the genes.   
 
 
 
Control samples    Tumour samples 
    
   
Figure 6.2: FGF7 and FGFR2 correlation. Mean gene expression level of FGF7 and 
FGFR2 plotted against each other for control samples (n=71) and tumour samples (n=19). 
Pearson correlation coefficient and p value are displayed.  
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6.3.3. FGF7 and FGFR2 gene expression are no different in patients with polyps 
FGF7 gene expression in the right colon was no different to the left colon, both in control 
subjects and in patients with polyps. However, there was a significant difference in FGFR2 
gene expression between right and left colon (∆∆CT 16.2 in right colon versus ∆∆CT  17.4 in 
left colon, p=0.009).  
There was no difference in gene expression of FGF7 adjacent to the polyp (∆∆CT 21.0) 
compared to gene expression from samples taken from control subjects (∆∆CT 21.4) 
(p=0.386) (see figure 6.3.). Similarly, there was no difference in FGFR2 gene expression 
between the two groups (p=0.216). 
      
 
 
Figure 6.3: FGF7 and FGFR2 gene expression in patients with polyps. Mean gene 
expression level of FGF7 and FGFR2 in biopsies taken proximal, adjacent and distal to 
polyp compared to matched samples taken from control subjects. Statistical analysis using 
unpaired t test - P value < 0.05=*, <0.01= ** and <0.001= *** and NS=non-significant. 
 
 
 
 
0.042
0.044
0.046
0.048
0.05
0.052
0.054
0.056
control proximal
to polyp
polyp distal to
polyp
NS
0.052
0.054
0.056
0.058
0.06
0.062
0.064
control proximal
to polyp
polyp distal to
polyp
NS 
NS 
NS 
* 
NS 
FGF7      FGFR2 
200 | P a g e  
 
6.3.4. The FGF7-FGFR2 signalling axis is dampened in CRC tissue 
Protein expression of both FRS2 and phospho-FRS2 was reduced in the tumour tissue 
compared to the mucosa at the margin suggesting that the FGF7 signalling cascade was 
dampened in the tumour tissue itself. This was accompanied by a reduction in Akt signalling 
but no changes were observed in Erk 1/2 protein expression.  
There was no significant difference in protein expression between the adjacent mucosa and 
the resection margin.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Protein expression of FRS2α and pFRS2α measured using Western blot 
analysis (n=6). Paired t test used to determine statistical difference between expression at 
tumour site and adjacent to tumour compared to expression at resection margin. The ratio of 
pFRS2/FRS2 comparing tumour and resection margin is displayed.  
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Figure 6.5: Protein expression of phospho-Erk (pErk), Erk, phospho-Akt (pAkt) and 
Akt measured using Western blot analysis (n=6). Paired t test used to determine statistical 
difference between expression at tumour site and adjacent to tumour compared to expression 
at resection margin. The ratio of the phosphorylated form to unphosphorylated form was 
used in the analysis. The p value comparing expression at the tumour site compared to the 
resection margin is shown.  
 
 
6.3.5. FGF7 serum concentration does not differ between cancer and control 
No significant differences in FGF7 serum concentration were found between patients with 
CRC compared to control subjects (mean concentration 33.16 (+/- 5.67) pg/mL versus 33.81 
(+/- 5.43) pg/mL respectively, p= 0.72).  
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
tumour adjacent margin
A
U
pAkt Akt
0
0.2
0.4
0.6
0.8
1
1.2
1.4
tumour adjacent margin
A
U
pErk 1/2 Erk 1/2
pErk 
 
Erk 
 
Beta-actin 
pAkt 
 
Akt 
 
Beta-actin 
P=0.017* 
P=0.017* P=0.170 
202 | P a g e  
 
6.3.6. FGF19 is expressed at low levels in colonic tissue 
Based on the results obtained with qRT-PCR, FGF19 was only expressed in 9/17 tumours at 
a very low level (CT 30-38 cycles). Analysis of samples taken from control subjects did not 
give reliable values for expression level across triplicates. Therefore, tissue samples taken 
from control subjects were not analysed further for FGF19 gene expression due to limited 
biopsy material available. However, FGFR4 was detected across all samples that were 
examined. There were no differences in gene expression of FGFR4 in cancer tissue itself 
(∆∆CT 20.3), its adjacent MNM (∆∆CT 20.6) and the tissue at the resection margin (∆∆CT 20.5) 
compared to the expression levels in healthy colonic mucosa (∆∆CT 20.8) (p=0.175 for cancer 
versus control). When patients with cancer were divided into two groups based on those 
whose tumours expressed FGF19 (denoted FGF19 positive) and those that did not (denoted 
FGF19 negative), there was no significant difference in expression of the receptor, FGFR4 
(p=0.222).  
 
6.3.7. FGF19 serum levels are lower in CRC patients with right sided tumours 
Amongst the 77 patients whose serum FGF19 concentration was measured, there was no 
significant difference between cancer patients and healthy controls (mean concentration 
171.67 +/- 121.21 pg/mL versus 202.28+/- 113.46 pg/mL respectively, p=0.256). The only 
clinical parameter with which there was an association with serum FGF19 concentration was 
smoking (see table 6.3.7). There were 14 patients with right sided tumours and 25 patients 
with left sided tumours. The mean serum FGF19 concentration was significantly lower in 
patients with right sided tumours compared to left sided tumours (124.64+/-62.25 pg/mL 
versus 198.0+/-138.38 pg/mL respectively, p=0.029).  
 
There was no correlation between serum FGF19 concentration and gene expression of 
FGFR4 in the colonic tissue (Pearson’s correlation coefficient, r=0.053, p=0.841). However, 
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if the patients with synchronous cancers are excluded as they appear to have one tumour 
which expresses FGF19 and another that does not, serum FGF19 levels are lower in patients 
whose tumours express FGF19 compared to those whose tumours do not (p=0.041).  
 
 
 
 
 
Table 6.2: Serum FGF19 concentration and correlation with clinical factors. 
Relationship between clinical variables and serum FGF19 concentration determined using 
Pearson correlation in patients with cancer (n=37) and control subjects (n=57)  
 
Clinical variable Pearson’s correlation 
coefficient 
p value 
Age -0.172 0.134 
Sex -0.034 0.767 
BMI 0.040 0.730 
Smoker 0.304 0.007* 
Fasting sample -0.155 0.178 
T stage -0.214 0.191 
N stage -0.262 0.107 
Grade of tumour -0.068 0.683 
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6.4. Discussion 
Using a novel sampling strategy, this study has shown that FGF7 is significantly upregulated 
along the colon in patients with CRC and could potentially act as a biomarker of field 
cancerisation. This is accompanied by disruption of the FGF7-FGFR2 signalling axis in the 
tumour tissue itself with reduced protein expression of some of its downstream targets.  This 
suggests that loss of FGF7 activity may contribute to malignant transformation of the 
colonic mucosa. However, contrary to previous reports, there were no differences in gene 
expression of FGF19 or its receptor, FGFR4.  
 
FGF7 signalling was found to be disrupted in CRC patients with uncoupling of the negative 
reciprocal relationship seen between a ligand and its receptor. Under normal physiological 
conditions, when FGFRs are activated they undergo endocytosis which reduces the number 
of receptors found in the membrane. This negative feedback loop is important in regulation 
of FGFR activity and has recently emerged as a potential source of disruption in growth 
factor activity and may contribute to cancer (Haugsten et al., 2005; Mosesson et al., 2008; 
Haglund et al., 2007; Abella & Park, 2009). The authors of a recent study found that Src and 
its phosphorylation target, Eps8 facilitate clathrin mediated endocytosis of FGFRs (Auciello 
et al., 2013). FGFs increased the number of clathrin coated pits and events of clathrin 
mediated endocytosis suggesting that an increase in FGF7 expression would be expected to 
lead to downregulation of its receptor. Depletion of Eps8 inhibited FGFR trafficking with 
FGFR being retained in peripheral early endosomes and led to a reduction in burst of Erk 1/2 
activation suggesting that Eps8 is important for both FGFR trafficking and signalling. The 
uncoupling of FGF7 and FGFR2 gene expression found in this study could be explained by 
alterations in FGFR trafficking.  
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Previous studies have shown that FGF7 plays a role in the epithelial response to toxic injury. 
IL-7 is produced by intraepithelial lymphocytes in response to a toxic insult which acts upon 
the stromal cells to induce FGF7 release which drives epithelial cell proliferation. FGF7 
treatment of intestinal cells led to increased expression of epithelial cell derived IL-7 in vitro 
and in a mouse model (Cai et al., 2012). In a subsequent study, they showed that FGF7 also 
increased Lovo cell proliferation and increased intestinal wet weight, villus height, crypt 
depth and crypt cell proliferation in mice. With blockade of two further downstream targets 
of FGF7, IRF-1 and IRF-2 there was a reciprocal reduction in IL-7 expression suggesting a 
feedback loop where IL-7 induces epithelial cell growth through FGF7 (Cai et al., 2013).  
 
The reduction in protein expression of the downstream targets of FGF7 that was observed in 
this study could be explained by postulating that FGF7 protects against toxic injury and 
regulates cell differentiation. Loss of the FGF7 signal would thus disable the epithelium 
from responding appropriately to toxic/ inflammatory injury and could contribute to 
uncontrolled growth and tumour formation. A previous study found higher FGFR2 
expression in well differentiated tumours and those with shallow wall invasion (Yoshino et 
al., 2005) compared to poorly differentiated tumours suggesting that the FGFR2 signal is 
lost during malignant transformation into a more aggressive phenotype. Loss of FGFR2b 
expression has also been found in other tumours including cancer of the prostate, bladder 
and salivary gland (Diez de Medina et al., 1997; Naimi et al., 2002; Amann et al., 2010; 
Zhang et al., 2001).   Mutations where there is inactivation of the FGF7-FGFR2 axis have 
also been reported in melanomas (Gartside et al., 2009). Thus, it is plausible that in certain 
tumours, FGF7 protects against malignant transformation by contributing to cell 
differentiation and a less aggressive phenotype.  
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In a further study, FGF7 was found to be a strong mitogen only for normal epithelial cells 
and not tumour cells (Otte et al., 2000). Similarly, another study reported that recombinant 
FGF7 was only able to stimulate growth of primary, immortalised keratinocytes and not 
malignant head and neck squamous cancer cells (Hille et al., 2010). A neutralising antibody 
against FGF7 only abolished cell proliferation of the keratinocytes and again, had no effect 
on the malignant cells. FGFR2b was only expressed in the keratinocytes and not the 
malignant cells. Thus, they postulated that FGF7 acts in a paracrine manner in normal cells, 
however, it is unable to stimulate cell growth in malignant cells.  Similar findings were 
observed in the present study whereby there was loss of FGFR2 expression in the tumour 
cells despite high expression of FGF7. This was accompanied by a reduction in Akt protein 
expression and not Erk 1/2 expression. In a study using pancreatic duct cells, FGF7 
stimulated proliferation through MEK-Erk 1/2 pathway and cell differentiation through the 
Akt pathway (Uzan et al., 2009). Similarly, the Akt activity has been shown to be important 
in driving cell differentiation in embryonal carcinoma cells (Chen et al., 2013a). Hence, loss 
of Akt expression found in the tumour tissue in the present study could suggest that the 
ability of FGF7 to regulate cell differentiation via Akt has been lost whilst its ability to 
stimulate cell proliferation via Erk may have been retained. This may seem to contradict 
previous reports which have associated Akt activation with more aggressive forms of cancer 
(Agarwal et al., 2013) highlighting that Akt actually supports cell proliferation and tumour 
growth. This dual role of Akt can be explained by different effects depending upon the 
subcellular location of PI3K, its upstream activator. In sub confluent proliferating cells, the 
p85 regulatory subunit of PI3K was distributed in the cytoplasm whereas in confluent cells, 
it was found at cell-cell interfaces (Laprise et al., 2002). E-cadherin mediated cell-cell 
contact led to increased Akt activity and suppressed Erk activity. If PI3K was blocked, AKT 
activity was abolished and a sustained activation of Erk was observed in confluent 
differentiating cells but not in undifferentiated proliferating cells (Laprise et al., 2004). The 
authors proposed that PI3K-Akt activity supports proliferation in sub confluent dividing 
cells and once confluence is reached, it drives cell differentiation. Thus, PI3K-Akt plays an 
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important role in mediating the transition between proliferation and differentiation. It is 
therefore plausible that loss of its activity could render the cell in a permanent state of 
proliferation and prevent its ability to undergo differentiation contributing to malignant 
transformation.  
 
There have been reports of increased expression of FGFR2 in CRC that contradicts our 
findings. In one study, stronger FGFR2 expression was observed in the invasive front of 
CRC cells compared to the surface/central area of cancerous cells (Matsuda et al., 2011). 
Reduced expression of FGFR2 in CRC cells was met by a reduction in cell migration, 
invasion and tumour growth in vitro and in vivo. FGFR2 may also play a role in tumour 
angiogenesis by increasing VEGF-A production (Narita et al., 2009). Thus, it remains 
unclear whether FGF7 acts to regulate angiogenesis and in so doing augment tumour growth 
or restore regulated cell growth following inflammatory injury.  
 
Under normal physiological conditions, FGF7 has also been implicated in epithelial-
mesenchymal transition therefore defective cell signalling through this pathway could lead 
to altered cell-cell adhesion (Kudo et al., 2007). Using a FGF7 transfected CRC cell line, the 
authors demonstrated a higher degree of adhesion to ECMs (type IV collagen, fibronectin), 
enhanced ERK1/2 phosphorylation and increased focal adhesion kinase (FAK) expression. 
Therefore, FGFR2 could play a role in preventing malignant seeding by enabling CRC cells 
to adhere to underlying collagen. This may explain its association with less aggressive, well 
differentiated tumours that has previously been observed. However, in this study, there was 
no correlation between the histological differentiation grade of the tumour and FGF7 gene 
expression thus suggesting that the role of FGFR2 in preventing metastasis may be less 
likely.  
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Previous reports have demonstrated that FGF19 is overexpressed in human colon cancer 
tissue and in colon cancer cell lines (Desnoyers et al., 2008). When FGF19 activity is 
blocked with a neutralising antibody, the mouse tumour xenografts created using these cells 
are significantly smaller than those using wild type cells suggesting that FGF19 augments 
tumour growth. However, FGF19 was only expressed in 6/10 tumours tested suggesting that 
in some tumours, it did not drive carcinogenesis. This is similar to the present study which 
found that FGF19 was expressed in 9/17 tumours. As normal colonic tissue samples did not 
express FGF19, detection of FGF19 in the tumour tissue itself suggests that it was 
upregulated and therefore may contribute to malignant transformation. Similarly, no 
differences in FGFR4 gene expression in the tumour, adjacent MNM or resection margin 
were detected. This contradicts previous reports which have observed that FGFR4 is 
upregulated in CRC (Heinzle et al., 2012) and many other cancers including breast (Jaakkola 
et al., 1993), prostate (Sahadevan et al., 2007), gastric, rhabdomyosarcoma (Taylor et al., 
2009) and pituitary adenocarcinoma (Ezzat et al., 2002). However, FGFR4 was only 
upregulated in 20/71 cancers tested in the former study suggesting that in many of the 
colorectal tumours examined or investigated, FGFR4 was not upregulated. Similarly, in this 
study, FGFR4 was also only upregulated in a proportion of the tumours examined 
suggesting that it may not be a very good candidate for a clinical biomarker. This was 
further confirmed with no differences being detected in serum FGF19 between cancer 
patients and control subjects. Therefore, based on the findings of the present study, FGF19 
does not appear to be a candidate for a clinical CRC biomarker.  
 
There are some limitations to this study that require further consideration. The specific 
isoform of the FGFR2 receptor with which FGF7 interacts was not measured in the qRT-
PCR experiments. Recent evidence has emerged to support the concept that there may be a 
class switch from FGFR2IIIb isoform to FGFR2IIIc isoform in CRC which confers a more 
malignant phenotype and contributes to the neoplastic process (Matsuda et al., 2012). This 
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highlights that it may not be the total expression level of the FGFR2 gene that is important 
but the relative expression levels of its different isoforms. Despite this limitation, however, 
there were significant differences observed in gene expression of FGFR2 supporting its role 
in CRC.  
 
6.5. Summary and conclusions 
 Using a novel sampling strategy in a well characterised cohort of patients, FGF7 
was found to be upregulated throughout the resection specimen in cancer patients 
compared to healthy controls.  
 Dysregulation of the FGF7/FGFR2 signalling cascade was only observed in tumour 
tissue and not in the adjacent MNM suggesting that either decreased FGF7 activity 
contributes to malignant growth or the transformed cells found in tumours contain 
mutations that inactivate this pathway.  
 Reduced Akt signalling downstream of FGF7 suggests loss of cell differentiation 
with preserved Erk signalling which is usually responsible for cell proliferation 
 FGF7 could play a role in field cancerisation and help to elucidate in whom risk of 
neoplasia is greatest.  
 Pharmacotherapy aimed at restoring the FGF7 signal could be utilised in cancer 
patients to restore regulation of cell differentiation and antagonise malignant growth.  
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Section 7: Discussion 
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7.1. Introduction 
Colorectal cancer (CRC) remains a source of considerable health burden for most 
communities worldwide. Despite substantial advances in our understanding of the molecular 
biology that underpins CRC formation, patients are still diagnosed at a late stage with wide 
heterogeneity in response to available chemotherapeutic agents (Ferlay et al., 2013; 
Coleman et al., 2011). The field cancerisation concept (SLAUGHTER et al., 1953) offers an 
alternative approach to solving some of the clinical challenges that remain in the modern 
treatment of CRC. Improvements in our knowledge about the changes that occur in the 
colonic field prior to development of histological abnormalities may aid earlier diagnosis of 
CRC and could pave the way to unravelling some of the complexities that underlie this 
disease. Better risk stratification of both screened and symptomatic patients can help to 
develop more accurate screening and diagnostic tests. Assessment of risk in this manner may 
also aid design of surveillance schedules for those already deemed at high risk, that is, those 
with a genetic predisposition or CRC survivors. Furthermore, changes in the colonic field 
could serve as a surrogate endpoint for chemoprevention trials where CRC risk is modulated 
by various pharmacological interventions. With such wide application, it is important that 
the field cancerisation concept in CRC is investigated further.  
 
7.2. Field cancerisation in CRC – parallels between IBD and sporadic CRC 
Field effects have readily been accepted in CRC associated with inflammatory bowel disease 
(IBD-CRC) (Leedham et al., 2009; Risques et al., 2011; Katsurano et al., 2012), the reason 
being that inflammation is believed to be the primary cause for the increased predisposition 
to malignant transformation. In IBD-CRC, the presence of DALMs (dysplasia associated 
lesion or mass) has been associated with malignant risk supporting this hypothesis 
(Bernstein et al., 1994; Thomas et al., 2007). Studies using animal models corroborate this 
observation by demonstrating molecular changes in the mucosa at distant sites to tumour 
formation (Katsurano et al., 2012). In humans, mutations in KRAS, CDKN2A (p16) and 
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TP53 were observed in non-tumour, non-dysplastic and dysplastic epithelium of patients 
with Crohn’s disease (Galandiuk et al., 2012). However, field cancerisation in sporadic CRC 
is generally not as well accepted. The difference highlighted by investigators is that sporadic 
CRCs occur in otherwise biologically normal colon. As there is no histological abnormality 
in the mucosa, the assumption is made that this mucosa is ‘healthy’ and not biologically 
altered. However, in a similar manner to IBD, pre-neoplastic lesions such as aberrant crypt 
foci and adenomas are detected at multiple sites along the colon in patients who go onto 
develop CRC (Morson, 1974; Bird, 1987). The findings presented in the first chapter of this 
thesis demonstrated that there is a higher risk of developing metachronous lesions in the 
residual bowel after cancer surgery if synchronous adenomas are present at time of 
presentation. This implies that the colonic mucosa at sites distant to the tumour is also 
preconditioned to tumour formation and this predilection does not disappear after the 
primary tumour is removed. This has two implications; firstly, it supports the concept of 
field cancerisation in CRC and secondly, it suggests that field changes in the colonic mucosa 
are not a consequence of the presence of tumour itself and persist after curative resection 
implying that they predate tumour development. Earlier antagonists of field cancerisation 
had proposed that it was the presence of tumour which was inducing biological changes in 
the surrounding mucosa (Kuniyasu et al., 2000). This contention is not supported by the 
findings in the present study.  It also suggests that a proportion of CRC patients may not 
exhibit a field defect along their colon or that polyps are poor markers of field cancerisation 
and different molecular changes should be sought.  
 
7.3. Existing scientific evidence to support field cancerisation in CRC 
There have been several reports that have demonstrated cellular, genetic and epigenetic 
differences in the normal colonic mucosa at distant sites to the tumour supporting the field 
cancerisation concept in CRC. Earlier studies that were conducted provided evidence that 
the colonic field distant to the tumour exhibited differences in cell structure with altered 
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karyometry (Bibbo et al., 1990; Verhest et al., 1990; Alberts et al., 2007; Cherkezyan et al., 
2014), changes in crypt morphology (Dawson & Filipe, 1976; Riddell & Levin, 1977) and 
altered cell kinetics (Terpstra et al., 1987; Anti et al., 2001; Badvie et al., 2006; Hanna-
Morris et al., 2009). Subsequent studies have sought to clarify how the genetic and protein 
milieu of the cells in the colonic field around cancer differ from those found at distant sites 
(Chen et al., 2004b; Hao et al., 2005; Polley et al., 2006). Most of the genetic alterations 
proposed have been in DNA repair and methylation (Facista et al., 2012; Nguyen et al., 
2010; Shen et al., 2005; Ramírez et al., 2008). A recent study measured transcript expression 
and chromosomal changes along the colon (Hawthorn et al., 2014). The authors showed that 
although there were chromosomal abnormalities in the colonic field, these were much 
smaller in number than those observed in the tumour and were not consistently seen at 
distant sites from the tumour. There was variation in the abnormalities detected at 3,5 and 10 
cm from the tumour in the same individual. The authors proposed that the findings supported 
field cancerisation and could be explained by the mutator phenotype model for cancer 
whereby cells within a tumour are heterogeneous and do not always share the same 
mutations. Others have shown that that epigenetic makeup of cells in the colonic field 
mirrors the epigenetic changes that have occurred in the tumour itself (Worthley et al., 2010) 
suggesting that the tumour may have arisen within a field of biologically altered cells.  
 
7.4. A candidate free approach to identify novel genes 
The aim of this thesis was to investigate the concept of field cancerisation in CRC to 
determine which cellular processes and genes are dysregulated in the colonic field around 
cancer and adenomas. Although there have been reports identifying different epigenetic and 
genetic changes that could play a role in field cancerisation, there have been no previous 
studies which have taken a candidate free approach. It was felt that this would be the most 
appropriate way to identify novel genes or signalling pathways that had not previously been 
described. It would also enable a more general interrogation of the cellular machinery that 
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becomes altered in field cancerisation.  Microarray technology was utilised to identify 
differences in the global genomic expression profile of macroscopically normal mucosa 
(MNM) taken from patients with cancer or polyps compared with control subjects. This 
identified a number of different biological processes that were dysregulated including 
immune response, metabolism and epithelial-mesenchymal transition. Interestingly, genes 
that would be conventionally considered to contribute to tumourigenesis by regulating cell 
proliferation or apoptosis were not identified. Amongst the genes that were further validated, 
CXCL2 and FGF7 were both found to be significantly upregulated in the adjacent MNM to 
cancer compared to the MNM taken from control subjects. In contrast to previous studies 
which have shown that these field changes are limited to the immediate vicinity of the 
tumour (Shen et al., 2005; Facista et al., 2012), both these genes were found to be 
significantly upregulated at the resection margin compared to control subjects. This 
highlights that field changes can occur at considerable distances along the colon from the 
primary tumour indicating a wide field of biological change. With the use of protein 
expression studies, FGF7 was upregulated along the colon, its receptor, FGFR2 was locally 
downregulated at only the tumour site. This implied that disruption of this signalling axis 
could contribute to malignant transformation and in response, FGF7 could be upregulated 
along the colon. Protein expression studies confirmed down regulation of downstream 
targets, pFRS2α and pAkt only in the tumour and not at the resection margin site nor in the 
adjacent MNM. Based on these findings, FGF7 could play a role in contributing to CRC 
formation. Moreover, its widespread upregulation only in the colonic mucosa of cancer 
patients supports a potential role in field cancerisation. 
 
7.5. Implications of the findings of this thesis 
The findings of this thesis contribute to the existing body of scientific literature that 
proposes field cancerisation in CRC. It highlights that there are multiple biological processes 
that are dysregulated in the colonic field around a cancer or polyp. Although no field effect 
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around a polyp could be demonstrated with FGF7, the difference in CXCL2 expression 
found adjacent to polyp was intermediate to that observed in the MNM adjacent to the 
tumour and MNM in control subjects. This implies that there may be a field of altered 
mucosa around polyps, however, the differences in expression are small suggesting that it is 
closer to the mucosa in control subjects than the MNM found in cancer patients. Previous 
studies which have investigated field cancerisation around polyps have also yielded 
conflicting conclusions. In one study, an upward shift in the crypts’ replicative compartment 
of rectal mucosa in patients with adenomas heralded a higher risk of adenoma recurrence 
(Anti et al., 1993). However, in a subsequent study (Anti et al., 2001), no global changes in 
cell proliferation and apoptosis were observed in individuals with adenomas compared to 
those without. However, more recent studies where optical spectroscopy and light scattering 
technology have been used to evaluate changes in microvasculature and cell ultrastructure 
have highlighted important biological changes in the colonic field of patients with polyps. In 
a study with 222 subjects, an endoscopically compatible polarisation gated spectroscopic 
probe was used to measure changes in microvasculature around polyps. A gradient in the 
measure of blood supply was observed up to 30 cm from the polyp suggesting that there was 
a local increase around the polyp to support adenoma growth (Roy et al., 2008). In a 
subsequent study, however, this measure of microvasculature was found in be increased by 
50 % in the rectal mucosa of patients with adenomas compared to those without irrespective 
of the adenoma site (Gomes et al., 2009). The authors proposed that rectal measurement of 
microvasculature could be utilised to screen for patients with advanced adenomas without 
having to perform complete colonic investigation. Findings from this thesis, however, would 
suggest that the changes that take place in the field around polyps (as measured by CXCL2) 
are a local phenomenon and are not found at distant sites along the colon. In contrast, 
patients with CRC show evidence of upregulated FGF7 and CXCL2 at distant sites. Any 
clinical application based on these findings could enable discrimination between cancer and 
polyp patients using the gene expression of either FGF7 or CXCL2 taken from the distant 
rectal mucosa.  
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Studies utilising light scattering technology have shown that there are ultrastructural changes 
in the cells around polyps. The maximal difference between subjects with and without 
adenoma was observed at 100 µm which correlates with changes in epithelial cells or the 
extracellular matrix of the lamina propria (Radosevich et al., 2011; Radosevich et al., 
2012).. In the fourth chapter of this thesis, a large quantity of the genes identified to be 
differentially expressed in the adjacent MNM around polyps were involved in the 
extracellular matrix and lamina propria supporting the findings of these earlier reports.  
The main biological processes that were identified to be dysregulated in the colonic field 
around CRC were concerned with supporting epithelial cell growth rather than being 
responsible for driving it. Similarly, FGF7 facilitates epithelial proliferation and CXCL2 
attracts neutrophils which are pro-tumorigenic and angiogenic. Both of these genes represent 
changes in stromal elements that interact with epithelial cells. Hence, changes in the stroma 
maybe required earlier on in the carcinogenesis process than previously thought. Changes 
may occur in the stroma in preparation for malignant growth with mutations arising in 
conventional oncogenes and tumour suppressor genes later on. At present, most investigators 
propose that changes in vasculature and metabolism occur after tumour formation has been 
initiated to support increased cell proliferation (Hanahan & Folkman, 1996). Based on the 
findings from this thesis, however, these supportive growth signals may actually be 
important much earlier along the cancer pathway as they were detected in the colonic field 
which harbours no evidence of tumour formation macroscopically. 
 
7.6. Limitations 
The findings from this thesis demonstrate that field cancerisation exists around CRC and can 
be identified using FGF7 and CXCL2 at considerable distances from the tumour along the 
resection specimen. However, there are some limitations that require further consideration. 
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Firstly, no causal relationship between the observed changes in gene expression and 
subsequent tumour formation has been investigated. Previous studies utilising animal models 
have shown that there are changes in the histologically normal mucosa that predates the 
development of aberrant crypt foci (ACF) (Roy et al., 2004). Changes in light scattering 
parameters of MNM were found 2 weeks prior to the development of ACF with changes 
correlating both spatially and temporally with sites of subsequent development of ACF. 
Investigation to prove a temporal, causal relationship in humans with sporadic CRC is 
difficult to achieve, however, it has been described in a study on IBD-CRC. Mutations in 
KRAS, TP53 and CDKN2A were observed in the histologically normal mucosa of patients 
with Crohn’s disease up to 4 years before development of cancer suggesting that they 
predated the formation of malignancy (Galandiuk et al., 2012).  
Secondly, the focus has been on genomic profiling, however, it is important to realise that 
post translational modification of proteins will play a significant role in governing which 
signalling cascade is active in the cell. The studies on FGF7-FGFR2 interaction with protein 
analysis were therefore helpful in elucidating how this signalling axis is disrupted in CRC. 
Further investigation of CXCL2 would require similar evaluation with protein analysis.  
The other aspect of gene modulation that should be considered is plasticity whereby a single 
genotype can result in different phenotypes depending upon the local environment (Nieto, 
2013). This is particularly important in cancer where the cells acquire the ability to survive 
in hostile conditions and travel to distant organs, adopting a different phenotype to normal 
cells.  
 
7.7. Future directions 
The findings in this thesis have provided the foundation for future work into field 
cancerisation in CRC by highlighting two potential signalling pathways that could play a 
role in contributing to a field defect. FGF7 shows promise as a marker of field cancerisation 
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whose function appears to be important for regulation of cell differentiation. Thus, loss of its 
signal activity results in malignant transformation. CXCL2 is very significantly upregulated 
in tumour tissue but also upregulated in the adjacent MNM around both cancer and polyp. 
This implies that its expression could become altered much earlier on in the carcinogenesis 
process and thus, it may translate into an earlier biomarker of cancer. 
Whilst this thesis has been effective at highlighting the biological changes that occur in the 
colonic field and provides a novel way of interrogating genes implicated in CRC 
carcinogenesis, it does not elucidate the clinical implications of these findings. A 
prospective observational clinical study in which the tissue expression levels of these genes 
are correlated with clinical findings would help to characterise the clinical importance of a 
field defect. The mRNA expression level determined using a rectal biopsy could be utilised 
to cluster individuals with and without CRC. With longer follow up, the expression levels 
could be correlated with future neoplastic risk in terms of development of adenomas or 
cancer thereby elucidating if those with a field defect are at higher risk of recurrence. A 
further study assessing field changes before and after surgery may help to discriminate if 
these field changes are dependent upon tumour presence and could help identify its role as a 
prognostic indicator. The relationship between colonic field changes and presence of polyps 
is particularly interesting in this regard as polyps, at present, are the only means of risk 
stratification of CRC risk in symptomatic individuals at present.  
 
7.8. Final conclusion 
Since the molecular characterisation of the adenoma-carcinoma sequence, there have been 
considerable advances in our understanding of how CRC forms. However, there has been 
little translation into effective diagnostic and therapeutic modalities. Researchers need to 
address the cancer process in a different manner if we are to be successful at halting the 
process. Field cancerisation offers promise of providing clues into the origins of CRC by 
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providing a means of investigating what happened before the onset of carcinogenesis. Future 
investigation will not only need to demonstrate that field changes exist but provide ways in 
which to link these changes in a causative manner to the cancer process. Several studies 
have successfully shown that CRC is a heterogeneous cancer with several different pathways 
and different phenotypes. Instead of addressing the very many different types of CRC, a 
unified approach where the cancer is interrogated as a single disease may yield more 
positive results for development of screening tests. The cellular and structural changes that 
underpin cancer formation in several organs are similar in nature, hence, field cancerisation 
offers such a united approach. Based on the field cancerisation concept, it would be possible 
to discriminate between cancer patients and control subjects using distal rectal biopsies 
obtained through a limited endoscopic examination. Such biopsies could be utilised to risk 
stratify individuals with CRC or familial risk to inform surveillance schedules. If these genes 
form the targets for pharmacological therapy, field cancerisation offers the opportunity to 
not only identify high risk individuals but potentially enable modification of their neoplastic 
risk prior to the development of any histological abnormality. If used in this clinical setting, 
it would be possible to achieve prevention of CRC formation before any macroscopic 
changes occur in the mucosa.  
This thesis has demonstrated alterations in several biological processes in the colonic field 
around CRC which support tumour formation providing evidence for the field cancerisation 
concept in CRC. Growth signals (FGF7) and a pro-inflammatory environment (CXCL2) 
appear to contribute to field cancerisation rather than alteration in known oncogenes and 
tumour suppressors highlighting the importance of the stromal compartment in supporting 
tumour growth. Future studies will need to establish a mechanistic relationship with in vitro 
cell culture models and investigate the clinical implications of this field defect in 
longitudinal observational cohort studies. 
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Appendix I: DAVID analysis  
Table showing pathways that were found to be enriched using DAVID software. 
Cancer versus control 
LIMMA Robust Regression 
Function Enrichment 
ratio 
Number of 
genes 
Function Enrichment 
ratio 
Number of 
genes 
Transmembrane 
signalling 
2.05 29 No enriched 
functions 
  
Glycosylation 1.34 23    
 
Polyp versus control 
LIMMA Robust Regression 
Function Enrichment 
ratio 
Number of 
genes 
Function Enrichment 
ratio 
Number of 
genes 
Extracellular 
signalling 
4.27 16 Extracellular 
signalling 
3.95 26 
Glycosylation 1.88 7 Coagulation 2.46 3 
   Eye 
morphogenesis 
1.68 4 
   Signalling 1.47 6 
   Cytoskeleton 1.38 5 
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Cancer versus polyp 
LIMMA Robust Regression 
Function Enrichment 
ratio 
Number of 
genes 
Function Enrichment 
ratio 
Number of 
genes 
Response to 
DNA 
damage 
2.71 8 Nucleoplasm 6.35 184 
Cell cycle 2.65 23 DNA packaging 6.06 65 
DNA 
packaging 
2.41 17 Protein 
assembly 
4.58 57 
Metal ion 
binding 
2.20 3 Cell cycle 4.34 90 
Regulation 
of cell cycle 
1.76 16 Histone 
assembly 
3.93 18 
DNA repair 1.51 16 RNA 
processing 
3.60 68 
Cytoskeleton 1.43 31 Cytoskeleton 3.51 217 
Lysosome 1.40 8 Microtubule 3.09 29 
GTP binding 1.53 36 Chromosome 2.64 19 
Protein 
maintenance 
1.49 10 Mitochondria 2.62 102 
Cell cycle 
regulation 
1.46 39 Nucleotide 2.60 169 
ATP 
dependent 
activity 
1.46 31 Protein 
localisation 
2.58 86 
Tissue 
homeostasis 
1.40 12 Monosaccharide 
metabolic 
process 
2.53 29 
Helicase 
activity 
1.36 6 DNA repair 2.33 58 
Response to 
nutrients 
1.34 22 Nuclear 
transport 
2.21 15 
   Heat shock 
protein 
2.06 16 
   DNA damage 2.05 16 
   Biological 
regulation 
1.70 30 
   Transcription 1.66 48 
   Microtubule 
cytoskeleton 
1.64 67 
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Appendix II: Patient information sheet 
 
Department of Gastroenterology 
 
University Hospital 
Clifford Bridge Road 
Walsgrave 
Coventry 
CV2 2DX 
 
Tel: 024 7696 6087(sec) 
Fax 024 7696 6090 
www.uhcw.nhs.uk 
 
A study to look at how bowel fermentation and 
diet affect other diseases 
 
PATIENT INFORMATION SHEET 
 
1. Invitation  
 
You are being invited to take part in a research study.  Before you decide if 
you want to take part, you may wish to consider two things: firstly, why the 
research is being done and secondly what you would have to do. Please 
take time to read the information below and talk it over with someone else if 
you want to. If anything is not clear or you would like to know more, please 
ask.  
 
Please also note that some aspects of this information sheet may not be 
relevant to yourself. It would largely depend on the specific condition in which 
you are consulting your specialist. The reason is that this is a large study that 
covers several different areas of medicine. 
 
Version 6 (RPA) 
Dec 2014 
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Thank you for reading this. 
 
2. What is the reason for the study? 
 
Bowel problems are common and diet is known to be important in certain 
diseases of the large bowel (colon). Within the bowel there are large number 
of bacteria which help in the process of fermentation. Changes in diet may 
result in changes in fermentation which is thought to be contributory not only 
to certain bowel diseases but other metabolic diseases such as diabetes and 
obesity and even kidney, bladder, joint and heart disease. We hope that this 
study will give us a better understanding of the relationship between diet and 
bowel fermentation and its effects on other diseases. Food is digested by 
bacteria within our bowels and produces certain gasses (fermentation). 
These gasses are unique to certain diseases and we detect these using 
specialised instruments (electronic nose). It is hoped that this study will lead 
to early diagnosis and avoid invasive tests in the future. 
 
3. Why have I been chosen? 
 
Due to the specific nature of your illness, which is the subject of study in this 
research, your consultant has invited you to participate in this research.  
 
4. Do I have to take part? 
 
It is for you to decide whether you wish to take part.  If you do decide to take 
part, you will be given this information sheet to keep. You will be asked to 
sign a consent form. Even if you decide to take part you can withdraw at any 
time. If you decide to withdraw, you do not need to tell us why and it will not 
change your treatment in any way. 
 
5. What will happen to me if I take part? 
If you agree to take part, we will invite you to sign a consent form to allow us 
to take samples of tissue. Depending on your medical condition we will 
collect certain tissue sample types e.g. urine, blood, breath or bowel tissue. 
However, not all may be relevant to yourself. We also seek permission to 
look at your medical records. Information sought from your medical records 
will be your medical history and medication.  
 
For those attending Endoscopy 
To obtain bowel tissue, an Endoscopic procedure is required 
(sigmoidoscopy/colonoscopy). This may already be a pre-requisite as part of 
your routine clinical investigation. At the time of examination, the doctor 
doing the test will take pieces of tissue for examination under a microscope 
(this is known as taking a biopsy). An extra 3 to 4 small pieces of tissue will 
be taken (each being the size of a grain of rice). Taking these extra biopsies 
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will not affect your care or add any significant risk. Your flexible 
sigmoidoscopy/colonoscopy will be the same whether or not you take part in 
the study. The doctor will discuss the results of your test either during or after 
the examination. 
 
After the examination, a doctor who is part of the research team, will take a 
sample of blood and urine as well as a breath sample. We will also ask that 
you complete a food and lifestyle questionnaire which should take about 20 
min. This can often be completed when you attend for your clinic visit or for 
an endoscopic examination. If this is not possible, the form can be completed 
at home and posted back to us. Recordings of your height, weight, hip and 
waist circumference will also be made (if not already done on your clinic 
visit). 
After this, you may go home with follow up, if necessary, as planned by your 
consultant. We will also provide you with a stool pot to provide a stool 
specimen. A member of the research team will contact you 7 days after your 
test to arrange a suitable time and place (of your convenience) to collect the 
stool specimen. If you attend follow-up clinic, we may ask you again for 
further samples (e.g. urine, stool or blood). You will not be required to make 
an additional visit to the hospital for this purpose. Below is a chart of what will 
happen. 
 
Blue text indicates what is additional as a result of this study. 
 
If you agree to participate, 
Sign CONSENT form 
 
 
Clinic visit – sampling of blood, urine, breath & completion of questionnaire as well 
as height/weight measurements 
 
 
Endoscopy – biopsy tissue sampling (depending on clinical condition). 
[ PN: If you attend directly for your endoscopic examination then we will collect the 
above samples and take measurements during this visit. You will not be required to 
attend a separate visit for this purpose to minimise inconvenience to yourself]  
 
 
 
 
 
 
 
A pot will be provided for stool 
specimen collection. After 7 days we 
will contact you to arrange a 
convenient time and place to 
yourself to collect the stool 
specimen. Further sampling may  be 
required at clinic visit.  
For those with stomach/gastric 
symptoms, you will be invited to a 
breath test after your endoscopy 
(whilst in recovery). A special sugary 
drink will be provided and breath 
sampled 15 -30 min later. 
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6. What do I have to do? 
 
You need do nothing until you attend for your test. At this point, if you agree 
to participate, one of the doctors from the research team will discuss this with 
you and obtain your consent.  If you have any questions beforehand, please 
see no 14.  
 
 
7. What are the possible disadvantages and risks of taking part? 
 
a) Bleeding very rarely occurs following biopsies and the risk of bleeding is 
small. (In one study [1], there was one case of bleeding noted after 5000 
consecutive biopsies i.e. 0.02% risk). Our own experience in a previous 
study had no immediate complications following 4500 consecutive 
biopsies in 500 individuals (Arasaradnam et al PhD Thesis 2007; University of 
Newcastle)  
b) Taking a blood sample can be a little uncomfortable and occasionally for 
some there is a little bruising.  
c) The additional biopsies required will add only 3-5 minutes to the 
procedure.  
d) It is hoped that all necessary information can be obtained during the clinic 
or endoscopic visit and if not this will add no more than 10-15 min to your 
overall visit.  
 
8. What happens to the samples taken? 
 
Samples of stool will be analysed for changes in fermentation within the 
bowel and analysis of type of bacteria. The blood, urine and breath will be 
analysed in a similar manner to look for similarities in pattern compared with 
stool. The blood and urine samples give us more information about your diet. 
Samples from bowel tissue will be used to analyse gene, cell and protein 
changes and compared with the fermentation changes. Specifically, these 
gene changes include molecular changes such as ‘methylation’, ‘acetylation’ 
and markers of ‘mitochondrial’ damage. We will then try to link these 
changes with your diet from the information you gave us in the questionnaire. 
We value your anonymity hence all samples will be anonymised which 
means that in the event of any research related findings that come to light 
from this research study, the results cannot be traced to yourself. However 
significant clinical findings which relate directly to your care will be fed back 
to your overseeing consultant and to your GP.  
We will also request permission to store some of the bowel tissue, blood 
urine and breath samples indefinitely. This is because in the future, newer 
techniques may become available which will allow us to perform more up to 
date testing. As mentioned above, these samples will be anonymised and 
therefore cannot be traced back to you. 
 
9. What are the possible benefits of taking part? 
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We hope that the information we get from this study will help us understand 
more about how diet affects certain genes and proteins in the normal bowel. 
In the future this may help us understand more about how certain diseases 
develop and perhaps even how to better prevent this through alteration in 
diet.  
 
10.   Will my taking part in this study be kept confidential? 
 
All the information we have about you from this study is strictly confidential.  
This information will be kept securely while the study is taking place.  Only 
the research doctors will be able to see it. Any information about you that 
leaves the hospital as part of a research report will have your name, address 
and any other personal information removed so that you cannot be identified 
from it. Your GP and your hospital consultant will be told that you are taking 
part in the study if you wish.  
 
 
11.  What if something goes wrong? 
 
In the unlikely event that something goes wrong, there are no special 
compensation arrangements.  If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have 
to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service (NHS) 
complaints mechanisms will be available to you. 
 
12. Who is organising and funding the research? 
 
This study has been organised and will be done at UHCW in conjunction with 
the University of Warwick. The chief investigator is Dr R P Arasaradnam. 
None of the researchers will be paid in person nor will they receive any 
financial gain for doing this study. Sponsorship in the form of a Research 
Grants have been obtained from local charities, research networks and 
collaborative bids (commercial and non-commercial). 
 
13. Who has reviewed the study? 
 
The Warwickshire Research Ethics Committee has reviewed and approved the 
study  
 
14. Contact for Further Information or Complaints 
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Dr R P Arasaradnam 
Assoc. Prof of Gastroenterology, 
Department of Gastroenterology, 
University Hospital Coventry & Warwickshire, 
Clifford Bridge Rd, 
Coventry CV2 2DX 
 
Tel: 02476 966087 
 
E mail: ramesh.arasaradnam@uhcw.nhs.uk or Nicola.O’Connell@uhcw.nhs.uk 
 
 
Thank you for taking part in the above study. 
 
A copy of the information sheet and signed consent form is available for your 
records. 
 
 
 
Reference: 
1. Macrae FA, Tan KG, Williams CB. Towards safer colonoscopy: a report on 
the complications of diagnostic or therapeutic colonoscopies. Gut 1983 
May;24(5):376-83 
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Appendix III: Consent form 
    
Department of Gastroenterology  
University Hospital  
Clifford Bridge Road  
Walsgrave  
Coventry  
CV2 2DX  
  
  
RPA  
Version 5 August 2015  
  
Consent for removal and storage of Human Tissue, Blood, 
Urine, Faeces and breath for Research  
  
Thank you for reading the information about our research project.  If you 
would like to take part, please read and sign this form.  
  
  
Study number:  
Patient identification number for 
this study:   
  
Food and fermentation using metagenomics in 
health and disease (FaMIsHED study) 
Title of 
project:…………………………………………………………………………………………………….  
            Dr R P Arasaradnam, Dr M Pharaoh, Dr G Williams, Prof. C Nwokolo,  
        Prof.  K D Bardhan and Prof S Kumar  
Name of researcher 
(s):…………………………………………………………………………………………    
    02476 966087 or e mail: ramesh.arasaradnam@uhcw.nhs.uk   
Contact details for research team:…………………………………………………………………………..  
Please initial boxes   
  
1. I have read the attached information sheet on this project, dated…December 
2014… (Version 6) and have been given a copy to keep if I wish.  I have been able to ask 
questions about the project and I understand why the research is being done and any risks 
involved.  
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2. I agree to give samples of tissue including bowel, blood, urine, faeces and breath 
for this research project. I understand how the samples will be collected, that giving 
samples for this research is voluntary and that I am free to withdraw my approval up to 
the point of anonymisation, for the use of the sample at any time without giving a reason 
and without my medical treatment or legal rights being affected. I am aware that the 
samples given will be analysed for gaseous products, gene and protein changes. I 
understand that the samples given for research purposes will be anonymised and 
therefore cannot be traced back to myself. Clinical findings will be fed back to my 
consultant and GP.  
  
  
3. I give permission for someone from the research team to review my medical 
records. I understand the information will be kept confidential. I do/do not wish for the 
research team to inform my GP of my participation in this study.                   
 
     
 
4.  I understand that I will not benefit financially if this research leads to the development 
of a new treatment or medical test.  
  
  
  
  
  
  
Thank you for agreeing to participate in this research     
  
  
  
 
 
  
RPA  
Version 5  
August 2015  
  
  
  
…………………………………………  ………………………  ……………………………………  
Name of patient       
(BLOCK CAPITALS)  
  
  
Date      Signature  
……………………………………….   ……………………  ……………………………………  
Name of person taking consent   
(if different from researcher)  
  
  
Date      Signature  
……………………………………..    ……………………  ………………………………….  
Name of researcher      Date      Signature  
